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Abstract 
Despite a growing armamentarium of therapies available to treat rheumatoid arthritis (RA), 
predicting response to therapy remains a clinical challenge.  Witnessed variability in 
treatment outcomes translates to a large unmet clinical need; with significant risk of disease 
progression, exposure to side effects and health economic burden.  Clinical heterogeneity in 
RA is reflected at the tissue level as diseased synovium displays variation in both degree and 
organisation of immune cell infiltration. Transcriptomic analysis suggests that synovial cellular 
heterogeneity is mirrored by a diversification of molecular profiles which may affect response 
to therapy.  B-cells play a critical role in the pathogenesis and propagation of RA.  Treatment 
response to the B-cell depleting agent rituximab in RA is varied and clear predictors of 
response are yet to be elucidated.   
 
The first aim of this work was to develop a pathological scoring system for the rheumatoid 
synovium to determine ‘B-cell rich’ and ‘B-cell poor’ pathotypes and investigate whether 
these subgroups can predict clinical response.  I establish that despite the degree of reduction 
in synovial B-cells following rituximab therapy, clinical response remains indeterminate.  
 
The second aim was to investigate whether a molecular signature associated with response 
to rituximab therapy.  Critically, I demonstrate that an upregulation of genes associated with 
ectopic lymphoid structures (ELS) and those which orchestrate Th17/interleukin 17 (IL-17) 
pathways are associated with diminished response to rituximab.  Furthermore, these genes 
can be utilised to create a model which has high sensitivity to predict response to rituximab.  
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 Finally, I investigate whether changes in synovial cellular infiltration and gene expression are 
associated with changes in ultrasound (US) synovial thickening (ST) and power doppler (PD) 
signal, demonstrating a key role of fibroblast and IL-17 associated genes.  Synovium remains 
the site of insult in RA; this work enhances the notion that synovial biopsies may be pivotal 
stratification tools of the future. 
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1.0 Rheumatoid Arthritis: an overview 
Rheumatoid arthritis (RA) is an autoimmune, progressive, multisystem inflammatory disease 
that primarily affects the synovial lining of diarthrodial joints.   It is associated with significant 
and progressive morbidity, increased mortality and high socioeconomic costs [1].  Despite 
recent advances in the understanding of disease pathogenesis, early diagnostic accuracy, 
changes in classification, improved clinical assessment scores and the continued development 
of novel therapeutics, the true aetiology of the disease has not yet been fully elucidated.  The 
complex interplay between genetics, the environment and immune system lead to a diversity 
of clinical phenotypes, which, despite a growing wealth of new therapies, continue to provide 
treatment challenges for those who suffer from the disease and for the physicians of today.   
 
1.1 Epidemiology of RA 
RA affects approximately 0.5-1% of the world’s population, with an estimated annual 
incidence of 3 per 10000 adults [2].  The disease has a prevalence of 0.02-0.05%, with the 
peak incidence in the fifth to sixth decades of life [3, 4]. Geographic variations have been 
reported, however, with a prevalence of 0.02-0.07% in Southern European countries [5-7] 
and lower rates in developing countries  [8] [9, 10]. Interestingly, some particular ethnic 
subgroups show higher rates of the disease, such as Pima Indians and other native American 
Indian populations [11, 12].  Other studies have suggested that such observations may, in part 
be attributable to methodological differences in survey methods and reflect changes between 
classification criteria between 1958, 1987 and 2010 [4, 10, 13, 14].  Even accounting for this, 
there appears to be a distinguishable difference between population groups worldwide. 
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In the United Kingdom, the prevalence of RA is estimated at 1.16% in women and 0.44% in 
men [15] using the 1987 American College of Rheumatology (ACR) classification criteria. The 
incidence of the disease has been reviewed more recently using the more recent 2010 
ACR/European League of Action against Rheumatism (EULAR) criteria using data from the 
Norfolk Arthritis Register, with rates of 54/100,000 for women and 25/100,000 for men [13].  
This was higher than if using the 1987 criteria; however, similar rates were achieved if 
individuals were followed up to five years suggesting the new criteria has increased sensitivity 
for early disease detection [13].  
Some studies have shown a decrease in the incidence of RA over time, particularly in females 
[16-20]. There are several plausible explanations for this observation.  Firstly, there may be a 
true decline in the incidence of the disease.  This has been attributed to changes in 
environmental factors.  Secondly, as discussed by both Silman [10] and Ulhig and Kvien [21], 
methodological variations in data collection may affect results, as repeated surveys differ 
from prospective notifications, with varying levels of reporting or classification bias.  The 
findings from these studies and perceived general decline may indicate that a shift in 
environment or infectious agents may play an important role in the pathogenesis of the 
disease. 
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1.2 RA: Clinical Features, Disease Activity and Treatment Modalities 
1.2.1 Articular signs and symptoms 
RA is the most common form of inflammatory joint disease.  It is characterised by articular 
stiffness, pain and swelling which is usually symmetrical.  Clinical onset is usually insidious and 
gradual but although less frequent, some individuals can present with a more acute onset 
with systemic symptoms over days  [22, 23].  Other forms of onset include predominant 
tendon and bursa involvement and palindromic RA, where there is spontaneous remission of 
symptoms after a few hours or days of pain and swelling.  A polymyalgic onset of RA has also 
been described more commonly in the elderly, where systemic symptoms predominate and 
are associated with proximal myalgia [24, 25].   
 Joints typically involved at the onset of disease are the metacarpophalangeal (MCP) or 
proximal interphalangeal joints (PIP), wrists or metatarsophalangeal joints (MTP) which are 
affected in a polyarticular manner, although occasionally the disease starts as an oligo- or 
pauciarticular disease and develops over time.  The temporomandibular joint and cervical 
spine may also be involved, with relative sparing of the lumbosacral joints [22, 26, 27]. Tendon 
sheath and bursal inflammation can cause distension or rupture of structures and entrapment 
neuropathies. Ongoing inflammation within the synovium can result in a loss of joint space, 
degradation of cartilage and bone erosions.  Left untreated, this leads to a reduction in the 
range of movement, subluxation and deformity of the joints which results in physical 
disability. 
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1.2.2 Extra-articular manifestations 
RA is a multisystem disorder with varying levels of systemic involvement.  Extra-articular 
manifestations are thought to associate with the severity of the disease and excess mortality 
[28, 29]. Systemic findings are summarized in table 1.1, with some more details of specific 
organs provided below. 
Previously, rheumatoid nodulosis occurred in up to 25% of patients with RA who had 
detectable autoantibodies were thought to be pathognomonic of  disease [27].  More recent 
data suggests the figure is somewhat lower, with 7% presenting with nodules at the time of 
diagnosis [30].   They occur typically over areas of pressure such as the Achilles tendon and 
olecranon bursa, however have been described in several other areas including the larynx, 
lungs, eyes and heart.  The size of the nodules may increase or wane over time through the 
course of the disease, sometimes paradoxically worsening with treatment. 
Lung involvement is another common finding in RA and can include airway, parenchymal, 
pleural or vascular disease. Airway involvement manifests in the form of bronchiectasis [31] 
or bronchiolitis.  Arthritis of the cricoaytenoid joints can result in hoarsenes or stridor. 
Bronchiectasis or interstitial lung disease are usually associated with a gradual onset of 
dyspnea and cough and detected on high resolution computed topography scanning.  
Patterns in RA include usual interstitial pneumonia (UIP), non-specific interstitial pneumonia 
(NSIP) and organising pneumonia, with some other rare forms described in the literature [32]. 
Rheumatoid nodules may also be present within the lung and also may change in size over 
time.  Inflammation of medium sized blood vessels can result in a pulmonary vasculitis, 
although this is a rare finding.  Pleuritis and pleural effusions are also frequently encountered, 
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characterised by exudative fluid with multinucleated giant cells and elongated or ‘tadpole’ 
macrophages [33]. 
Cardiovascular risk in RA has been studied in detail in the last decade.  Studies show that 
patients with RA have an increased mortality of up to 50% when compared with the general 
population [34-38]. The increased risk has been shown to be directly linked to high levels of 
circulating cytokines and subsequent inflammation, promoting endothelial dysfunction, 
vessel abnormalities, a shift in lipid levels and oxidative stress [39-41]. In light of these 
findings, specific recommendations have been made for tight disease control in order to 
reduce the burden of cardiovascular disease. The European League of Action against 
Rheumatism (EULAR) guidelines recommend an annual cardiovascular risk assessment in all 
patients with rheumatoid arthritis and to apply a multiplier to certain subsets of patients 
when using traditional risk scores such as the Framingham or Systemic Coronary Risk 
Evaluation model [42]. 
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Table 1.1 Extra-articular and drug associated manifestations of RA 
Organ Involvement Features 
Cardiovascular Increased Cardiovascular risk, pericarditis, pericardial 
effusion, myocarditis 
Constitutional Symptoms Weight loss, fever, asthenia 
Dermatological Nodules, leucocytoclastic vasculitis, ulceration 
Gastroenterological Gastroduodenal ulceration, usually drug related 
Haematological Anaemia, thrombocytocytosis, thrombocytopenias, 
other blood dyscrasias, Felty’s syndrome, 
hyperviscosity, cryglobulinaemia 
Malignancy and Infection Increased risk of malignancy and infection 
Muscle, bursae and bones Muscle weakness and atrophy, Osteoporosis 
Neurological Entrapment neuropathy, mononeuritis multiplex, 
cervical myelopathy 
Ocular Keratoconjunctivitis sicca, scleritis, episcleritis, corneal 
perforation 
Pulmonary Pleuritis, interstitial pneumonitis, nodular lung disease 
Renal Glomerulonephritis, Tubular interstitial nephritis 
(usually drug related), secondary amyloidosis 
Vasculitis Skin, lung, renal, peripheral neuropathy 
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1.2.3 Classification criteria 
To date, there have been three clearly defined criteria for RA.  The first were adopted by the 
American Rheumatism Association (ARA) in 1958 and divided patients into possible, probable 
and definite RA  [43]. These guidelines were revised in 1987 in an attempt to streamline the 
diagnosis and build a platform for evidence based medicine within the field and are presented 
in Table 1.2 [44].  
Table 1.2 1987 ARA Classification Criteria for RA [44] 
Morning Stiffness* 
Arthritis of 3 or more areas* 
Arthritis affecting hand joints* 
Symmetrical Arthritis* 
Rheumatoid Nodules 
Positive Rheumatoid Factor (RF) 
Radiographic changes 
At least 4 out of 7 criteria must be satisfied for RA, * must be present for at least 6 weeks 
Although these criteria performed better than their 1958 predecessors, a shift towards early 
treatment of the disease indicated that the updated criteria were limited in both sensitivity 
and specificity, especially in early disease without radiographic changes  [18, 45, 46].  A large 
meta-analysis of 7438 patients by Banal et al showed a sensitivity and specificity of 77% in 
early RA vs 79% and 90% in established RA, which was deemed to be significant [46]. 
Furthermore, the discovery of anti-citrullinated peptide antibodies (ACPA), which are a 
prognostic marker for more erosive disease were not included in the 1987 criteria.  The 
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criteria were therefore reviewed and revised by the American College of Rheumatology (ACR) 
/ European League of Action against Rheumatism (EULAR) taskforce in 2010 and are 
summarized in Table 1.3 [47].  Several studies have since been performed to validate the 
sensitivity and specificity of the new criteria, summarized by Radner et al [48] which gave a 
pooled sensitivity of 0.81 in early disease.  
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Table 1.3 2010 ACR / EULAR Classification Criteria for RA[47]  
 
A score of ³6 fulfils the criteria for definite RA 
Abbreviations: RF = rheumatoid factor, ACPA = anti-citrullinated protein antibodies, ESR = 
erythrocyte sedimentation rate, CRP =  C-reactive protein 
 
 
Joint Involvement  
1 large joint 
2-10 large joints 
1-3 small joints (with or without involvement of large joints) 
4-10 small joints (with or without involvement of large joints) 
>10 small joints 
0 
1 
2 
3 
5 
Serology 
Negative RF and ACPA 
Low positive RF or low positive ACPA 
High positive RF or high positive ACPA 
0 
1 
2 
Acute phase reactants  
Normal ESR or CRP 
Abnormal ESR or CRP 
0 
1 
Symptom Duration  
< 6 weeks 
³ 6 weeks 
0 
1 
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1.2.4 Assessment of disease activity 
Alongside early recognition and prompt treatment of RA, there has been a move towards a 
“treat to target” approach [49]. In order to define a clear ‘target’ however, well defined 
models of disease activity are required, which incorporate both clinical findings and overall 
patient well-being and that can be used as a measure in clinical trials and routine practice.  To 
this end, a multitude of disease assessment criteria have been developed and validated, those 
used commonly in clinical trials are briefly described below.  More extensive information is 
provided in a comprehensive review by Anderson et al [50]. 
Disease Activity Score: 28 joints (DAS-28 Score) 
The DAS-28 score is the most frequently used disease activity index in routine clinical practice.  
It was developed by EULAR and is endorsed for disease activity measures in clinical trials [51]. 
The original DAS score incorporated 44 joints, however this was reduced to 28 to facilitate 
feasibility and ease of use within the clinical setting following studies that the two scores were 
comparable[52, 53]. It consists of four different domains: a tender joint count (TJ) , swollen 
joint count (SJ), patient assessment of global activity (PtGA) by the means of a visual analogue 
score (VAS) and a biological marker of inflammation through the ESR or CRP.  The formula is 
calculated as follows: 0.56 × V (28TJC) + 0.28 × V (28SJC) + 0.70 × ln(ESR) + 0.014 × PtGA and 
modified according to which acute phase reactant is used [54].  A high score reflects high 
disease activity.  Pre-defined values give an indication of remission, moderate or high disease 
activity and changes after treatment can be utilised to select ‘responders’ and ‘non-
responders’, summarised in Table 1.4[55]. 
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Table 1.4 The EULAR response criteria using the DAS-28 score [55] 
 
 
  
 
 
 
 
Abbreviations: DAS-28 = Disease Activity Score using 28 joints 
Simplified Disease Activity Index (SDAI) 
The simplified disease activity index is similar to the DAS-28 score, varying in that it includes 
a provider assessment of global activity (PrGA) and utilises the CRP value. It correlates well 
with the DAS-28 score and the score is the sum of the included domains 28SJC + 28TJC + PrGA 
+ PtGA + CRP[56]. 
The clinical disease activity index differs from the SDAI in that the laboratory values are not 
included: 28SJC + 28TJC + PrGA + PtGA.   It is useful due to its simplicity and in trials involving 
biologic agents where acute phase reactants are suppressed due to the pharmaceutical agent 
and not necessarily a reduction in disease activity[57]. 
 
 
   Improvement in DAS-28 from Baseline 
 
DAS-28 at 
Endpoint  
     >1.2 <0.6 and £1.2          £ 5.1 
£ 3.2 Good 
 
 
 
 
        None 
>3.2 and £5.1                             Moderate 
>5.1   
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ACR Core Set measures 
The ACR core dataset was first proposed in the 1993 in order to facilitate standard 
measurements across clinical trials.  It consists of seven domains: tender joint count, swollen 
joint count, patients’ assessment of pain, PtGA, PrGA, patient’s assessment of physical 
function and evaluation of one acute phase reactant.  Measurements are described as 
percentage improvements, with ACR 20, 50 and 70 responses equating to 20%, 50% and 70% 
improvement in the core set data, respectively [58].  Although this measure is commonly used 
in the reporting of clinical trials, it is often difficult to incorporate into routine clinical practice. 
Boolean Remission 
Despite varying indices for low disease activity, it was felt that several of the disease measures 
did not encompass the true definition of remission in RA.  For this reason, Felson and 
colleagues attempted to redefine this in the context of clinical trials [59]. The Boolean based 
remission criteria therefore were defined as follows: TJC ≤1, SJC ≤1, patient global assessment 
≤ 1 and CRP ≤1. 
The role of imaging in RA treatment and prognosis 
Structural damage can occur early in RA.  Imaging modalities include plain radiographs, high 
sensitivity doppler ultrasound (US) and magnetic resonance imaging (MRI).  Recent 
recommendations by the EULAR task force consisting of rheumatologists, radiologists, 
methodologists and rheumatology practitioners recommended the use of MRI or US in order 
to confirm disease in case of clinical uncertainty, and to aid the diagnosis of early RA from 
undifferentiated arthritis [60]. Imaging is better at detecting residual synovitis than 
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examination alone, figures of 2.21-fold and 2.18-fold differences in synovitis detection have 
been reported for MRI and US, respectively [60]. 
 
US is more readily available, quicker and easier to perform than MRI. Several studies have 
shown that US is more sensitive at detecting subclinical synovitis than clinical examination 
alone [61-64] which formulates an argument to include imaging in disease activity scores and 
indeed to define remission. Recently, however, two large trials have concluded that targeted 
US remission is not associated with significant improvements in clinical or patient reported 
functional outcomes[65, 66].  A further randomised controlled study (Targeted Ultrasound in 
Rheumatoid Arthritis) which is expected to complete this year aims to address whether 
clinical outcomes will vary based upon treatment guided by clinical or US remission (clinical 
trials identifier: NCT02056184). 
 
1.2.5 Treatment Strategies in RA 
The “window of opportunity” or the need for early treatment has been well recognised for 
several decades [47].  Untreated, RA results in both functional and economical disability.  
Early control of inflammation is crucial to try and prevent clinical and radiographic 
progression.  A ‘treat-to-target’ or ‘tight control’ strategy has been recommended by EULAR 
[67], defined as clinical remission or low disease activity.  A recent systematic literature review 
incorporating trials where a treat-to-target approach was used, demonstrated that all trials 
brought more patients into remission or low disease activity quickly, with improvements in 
pain scores and functional abilities [68].  An important message here is that the 
methodologies employed focus on the intensity of treatment without specifically 
commenting on any particular disease modifying anti-rheumatic drug (DMARD), with the 
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exception of methotrexate.  I have outlined the treatment modalities below and will go on to 
describe B-cell depletion therapy in more detail. 
Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids 
NSAIDS inhibitors have been ubiquitously used for several decades.  Despite ameliorating 
symptoms, they do not affect disease progression and are often limited by their side effects, 
particularly the risk of gastrointestinal bleeding and cardiovascular disease [69].   
Corticosteroids are still a cornerstone of treatment in RA, particularly during ‘flares’ of 
disease.  Current EULAR recommendations consider low dose glucocorticoids as initial 
treatment in combination with conventional synthetic DMARDs (csDMARD) [70] but with a 
view to taper them as quickly as possible.  This is largely supported by the COBRA trial, which 
demonstrated sustained radiographic progression when steroids were incorporated into a 
combination regimen with csDMARDs [71] and the observation that low dose steroids may 
decrease radiographic progression when given in early RA [72]. 
Conventional synthetic disease modifying antirheumatic drugs (csDMARDs) 
Current EULAR recommendations suggest that patients should initially be commenced on 
conventional synthetic disease-modifying anti-rheumatic drugs, which include methotrexate, 
sulfasalazine, leflunomide or hydroxychloroquine.  Methotrexate (MTX) should be 
preferentially used, except in the advent of intolerance or reaction [70].  Utilisation of 
combination therapy in early disease remains under debate. 
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Biologic DMARDs 
Failure to achieve a low disease activity or remission should prompt treatment with a biologic 
DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD), as non-response to 2 or more 
cDMARDs is likely to result in disease progression [73]. If possible, methotrexate should be 
continued, as greater efficacy is achieved in combination [74].  bDMARDs include the tumour 
necrosis factor (TNF) inhibitors (infliximab, etanercept, adalimumab, certolizumab and 
golimumab), anti-CD20 monoclonal antibody (rituximab), inhibitors of interleukin 6 (IL-6) 
(tocilizumab and sarilumab) and CD80/CD86 blockade through abatacept.  Since the advent 
of biosimilars, further nomenclature changes have been made, with the terms bio-originator 
and biosimilar to distinguish between the parent drug and those which have the same protein 
structure and biologic functions.   
Targeted synthetic DMARDs 
TsDMARDs modulate specific targets within the immune cascade.  Currently, inhibitors of 
janus kinase (JAK), tofacitinib and baracitinib are licensed for the treatment of RA [74].  Their 
placement in the treatment algorithm is alongside bDMARDs.  Baricitinib has been shown to 
be superior to adalimumab[75] in combination with methotrexate, although this was not 
demonstrated with tofacitinib [76]. 
They key to optimal treatment lies in early recognition of disease and flares.  The number and 
choice of drugs available to rheumatologists continues to grow – yet efficacy rates between 
drugs remain similar [74], once again highlighting the need for biomarkers or predictors of 
response. 
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1.3 The aetiology of RA: genetic and environmental factors 
RA is a complex autoimmune condition that appears to rely on the interplay on both 
endogenous and exogenous factors, outlined in figure 1.1. The presence of circulating 
autoantibodies years before any clinical manifestations and not always associated with 
subsequent disease development suggests that environment factors play a critical role in RA 
pathogenesis.  This includes exposure to pathogens, lifestyle factors and in the case of 
females, differences in levels of circulating hormones.  Factors influencing this transition from 
being ‘at risk’ to disease manifestation are yet to be fully understood and may in the future 
lead to a shift in focus from disease treatment to prevention.  
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Figure 1.1 Pathways to RA 
In a genetically predisposed host with susceptibility genes, environmental insults, epigenetic modifications, and 
post-translational modifications can lead to loss of tolerance with subsequent asymptomatic synovitis, 
ultimately leading to clinically overt arthritis. ACPA = autoantibodies against citrullinated peptides. 
RF=rheumatoid factor.  
From [77], with permission from Elsevier. 
1.3.1 Genetic factors  
The notion of genetic susceptibility in RA is well established. This was first noticed through 
familial clustering and increased concordance between monozygotic twins [78].  Overall 
predisposition to RA through genetic factors is thought to range from 20-65% with a 
discernible variation between ACPA positive and negative disease [79-81]. These can largely 
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be grouped into genes which directly involve the major histocompatibility complex (MHC) and 
those outside this region.  In recent times, genome-wide association studies (GWAS) have 
identified >100 loci which may be associated with RA susceptibility [82].  Furthermore, several 
susceptibility genes have been also been associated with severity of disease [77]. 
Human Leucocyte Antigen (HLA) DRB-1 locus and the shared epitope hypothesis 
An association between MHC genes and RA has been known for approximately 40 years [83]. 
Human leucocyte antigens (HLA) are a group of proteins expressed on cell surfaces which 
allow the immune system to differentiate between ‘self’ and external antigens.  Six genes, 
including HLA-DRB1, encode the MHC class II genes, which influence interactions with 
proteins found on certain cells of the immune system.   Studies identified multiple RA risk 
alleles found within the same HLA-DRB1 region on chromosome 6(6p21.3) displaying 
common, conserved amino acid sequences.  These sequences are found at positions 70-74 in 
the third hypervariable region of the HLA-DRb1 chain and associate with the HLA DRB1*01 
and *04 alleles [84, 85].   This led to the development of the ‘shared epitope hypothesis which 
confers that these polymorphisms, which occur at the antigen binding site of the MHC 
molecule, are directly involved in T-cell activation and the initiation of the immune response  
[84].   Different combinations of alleles confer varying susceptibility to disease across 
populations and may also result in higher disease severity [85-87].  Du Montcel and colleagues 
proposed a further classification for HLA-DRB alleles, by which the amino acid at positions 70 
or 71 can further subdivide the shared epitope alleles into S1, S2 S3P and S3D subsets [88]. 
The presence of these alleles confers, to varying degrees, susceptibility to the development 
of ACPA and therefore may contribute directly to disease pathogenesis [89]. 
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The contribution of non-HLA genes to RA    
The contribution of the HLA complex to the disease is approximately 37% [84, 90].  This leaves 
approximately two thirds of the genetic component of RA to be due to non-HLA genes.  The 
last two decades have seen unprecedented advances in whole genome screening and 
subsequent single nucleotide polymorphism (SNP) analysis.  Recent GWAS studies have 
confirmed multiple loci conferring susceptibility to disease in individuals with European 
ancestry; common ones are discussed herein [91].   
Protein tyrosine phosphatase non receptor type 22 (PTPN 22)    
PTPN22 resides on chromosome 1. (1p13.2) and confers the second strongest risk association 
with RA [92]. Several studies and metanalysis have shown a positive association between 
polymorphisms and RA [93-95]. The gene encodes for a tyrosine phosphatase LYP that binds 
to c-terminal src tyrosine kinase (CSK) and acts as a negative regulator of T-cell activation.  
The 1858 C/T polymorphism has been widely observed, changing an arginine residue to a 
tryptophan and subsequently disrupting interactions between LYP and CSK, leading to an 
increased T cell response [92].  Furthermore, variant PTPN22 expression can further promote 
autoimmunity through alterations in B-cell tolerance and receptor signalling.  Data from both 
murine models and human studies suggest that risk variants can result in an increased 
number and positive selection of transitional B-cells, with a subsequent increased proportion 
and range of autoreactive B-cells found at critical checkpoints[96-98].  Furthermore, Menard 
and colleagues demonstrate an upregulation of genes CD40, TRAF1 and IR5, involved in B-cell 
receptor (BCR) signalling [96]. 
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Cytotoxic T lymphocyte associate antigen 4 (CTLA4) 
Cytotoxic T lymphocyte associated antigen 4 (CTLA-4) is a member of the immunoglobulin 
superfamily and found at location 2q33.2.  It is homologous to CD28, which binds to CD80 on 
antigen presenting cells and maintains the T-cell response [93]. The interaction of CTLA-4 and 
CD80 inhibits T-cell activation.  Associations have been observed with polymorphisms, 
particularly 49 A/G and CT 60 G/A, which decreased the inhibitory function of CTLA-4 and 
therefore may have a role in the reduction of peripheral tolerance [93]. The putative role of 
this gene is also further defined by good therapeutic response to Abatacept therapy, a CTLA4/ 
Ig fusion protein licensed for the treatment of RA [29]. 
Pepitdylarginine deaminase (PAD) 
The discovery of ACPA in RA suggested involvement of a family of citrullinating enzymes 
known as peptidylarginine deaminases (PAD).  The PAD4 enzyme is responsible for the post 
translational conversion of arginine to citrulline, which can result in the production of 
pathogenic autoantibodies.  The gene encoding this enzyme was found by linkage 
disequilibrium methods to reside at 1p36.13.[99] and later confirmed by GWAS [100]. Some 
meta-analyses suggest that pathogenic polymorphisms may be more common in the Asian 
population than those of European descent [101, 102].   
Signal Transducer and Activator of Transcription 4 (STAT4) 
Inflammation in RA is driven by immune cell interactions and the production of systemic 
cytokines.  The STAT4 gene encodes a transcription factor that mediates intracellular 
interactions by type 1 interferons and several cytokines, namely interleukin (IL)-12, IL-23 and 
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IL-27.  Of these, STAT 4 plays a crucial role in IL-12 dependent Th1 helper cell differentiation 
and interferon dependent natural killer (NK) cell proliferation [93]. STAT4 also plays a role in 
systemic lupus erythematosus (SLE) and has been shown to confer increased risk in RA [103]. 
Tumour necrosis factor (TNF) receptor associated factor 1 (TRAF1) 
TRAF 1 is an adapter protein that links the TNF to downstream signalling networks, inducing 
cell survival[92].  Polymorphisms have been linked to alteration in toll-like receptor (TLR) 
signalling, changes in messenger RNA (mRNA) levels and an overall increased risk of RA [104-
106]. 
Tumour necrosis factor alpha-inducible protein 3 (TNFAIP3)  
Tumour necrosis factor alpha-inducible protein 3 is a gene responsible for the production of 
a ubiquitin editing protein A20. This protein regulates and inhibits nuclear factor kappa B 
(NFkB).  Polymorphisms in this gene have been associated with RA in studies and subsequent 
meta-analyses [107, 108]. 
1.3.2 Epigenetics in RA 
The discordance rates for monozygotic twins in RA suggest environmental differences may 
play a role in development of the disease.   Epigenetics relates to changes outside encoded 
genes which directly affect gene expression, such as deoxyribonucleic acid (DNA) methylation 
and post translational histone modifications [78]. Such changes may be related to 
environmental or metabolic factors.  In unrelated individuals, nine differential clusters of 
methylation in the HLA region have been identified [109]. Hypomethylation of both T-cells 
and fibroblast like synoviocytes (FLS) has been observed in individuals with RA when 
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compared with controls [110] [111].  Genome wide evaluation of FLS revealed nearly 2000 
differentially methylated loci [112] between individuals with RA and osteoarthritis (OA), many 
relating to cell trafficking and adhesion.  Whitaker and colleagues furthered these findings by 
investigating the stability of DNA methylation, concluding that persistent alterations within 
the genome could lead to diversity of FLS phenotypes that contribute to disease pathogenesis 
[112].  Effective targeting of epigenetic modifications in disease remains challenging due to 
wide variations at the individual level. 
1.3.3 The role of micro-RNAs 
Micro-ribonucleic acids (miRNAs) are short single stranded non-coding RNA’s that have been 
implicated in both autoimmunity and cancer.  These post transcriptional regulators pair with 
the 3’end of a target mRNA resulting in degradation or inhibition of translation and have roles 
in both physiological and pathological processes [78].  In RA, some examples include the 
upregulation of miRNA-115 and miRNA 203 in FLS, which lead to increased production of 
matrix metalloproteinase-1 (MMP1) and IL-6 [113].   miRNA-14a has also been found to be 
higher in peripheral blood monocytes in patients with RA than OA and may play an important 
role in IL-17 expression [114].  A summary of other miRNA’s identified in RA is presented in 
an extensive review by Miao et al [115]. 
Despite extensive genome-wide studies attributing causality to specific findings remains 
difficult due to the number of patients required to adequately power studies.  Nevertheless, 
miRNAs remain a potential target for therapy in an era where genomic platforms and 
computational analysis continue to expand. 
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1.3.4 Environmental factors in RA 
The role of smoking 
The link between smoking and RA was first described by Vessey and colleagues approximately 
30 years ago [116]. There is a strong association between cigarette smoking and RA, although 
this finding is more established in seropositive disease and in males.  A meta-analysis of 16 
studies showed that the odds ratio for developing RA in males who had ever smoked was 1.89 
and 1.27 for females.  This ratio increased to 3.2 in males who were positive for rheumatoid 
factor [117].  A further meta-analysis suggested that this risk may be dose dependent up to 
20 pack years [118].  
The combination of certain shared epitopes and smoking confers a higher risk for developing 
RA with both increased production and heterogeneity of ACPA proteins, particularly 
citrullinated-a enolase 1 and anti-vimentin antibodies[119].  The presence of ACPA is highly 
predictive of disease, with PADI enzymes required for the post-translational change from 
arginine to citrulline.  Higher levels of PAD2 enzymes and subsequently citrullinated proteins 
have been found in bronchoalveolar lavage fluid from smokers, indicating that this may be an 
important explanation for the higher incidence of RA [120].  This is also the case for lung 
tissue, where investigators found higher levels of citrullinated proteins than in other tissues 
[121], although in this study levels were similar in smokers and non-smokers leading the 
authors to propose a “two-hit hypothesis”, where molecular mimicry is followed closely by 
antibody production and epitope spreading. 
Cigarette smoke also contains a multitude of toxic substances, many of which have the ability 
to modulate the immune system.  There is data to suggest that smoking results in a shift from 
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Th1 to Th2 type 2 immune responses, blunts immune reaction to foreign antigens and results 
in the formation of mutated tumorigenic cells [118]. Additionally, macrophage responses in 
the alveoli are also diminished, demonstrated through both animal models and in cultured 
human cells in vitro [122, 123].  Tobacco found in cigarettes has also been implicated in 
dysregulation of apoptosis and sequestration of intracellular antigens, which may also induce 
a break in tolerance.  Direct release of free radicals increases rates of DNA mutagenesis, which 
again may lower the threshold for developing autoimmune disease.   
The role of cigarette smoking is both complex and multifactorial with links to infection, 
inflammation and DNA methylation and mutagenesis.  Direct and indirect modulation of the 
immune system through smoke and chemical exposure modulates the host response to 
microbes, local inflammation and the citrullination of proteins which when combined are 
likely to cumulatively increase the risk of developing RA. 
The role of microbes  
The possibility of a link between bacteria and the development of RA has been discussed for 
many years, with a particular focus in recent times on periodontal disease and the gut 
microbiome.   Bacteria thought to be involved include escheria coli, proteus mirabilis, 
mycoplasma, porphyromonas gingivalis (p.gingivalis); important viruses include the human 
immunodeficiency virus, Epstein barr virus, parvovirus B19, hepatitis B and C and chikungunya 
[124, 125].  The ‘molecular mimicry’ hypothesis arises from the notion that bacteria have 
similar epitopes to the host with a resultant loss in tolerance as self-antigens are no longer 
recognised.  This theory, however has never been completely proven in RA, and previous 
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authors have postulated that a “double hit” or prior susceptibility is still necessary for 
development of the disease [125, 126]. 
The role of periodontal disease 
The postulation that oral sepsis plays a role in the pathogenesis of several different diseases, 
including RA, dates back several centuries.  Periodontitis is a condition that is caused by 
bacteria which progressively destruct structures surrounding the tooth.  The key pathogen in 
this process is porphyromonas gingivalis (p.ginigivalis); others thought to play an important 
role are trepnoma denticola and tanerella forsythia which together, are also known as the 
red complex [127] .   
Recent epidemiological studies have shown that despite accounting for common risk factors 
such as smoking, HLA status and other environmental factors, individuals with periodontitis 
are at an increased risk of developing RA  [128-131]. By the same vein, periodontal disease is 
more common within the RA population.  There are several lines of evidence to suggest a 
pathogenic role for periodontal disease in RA; for example levels of antibodies to p. ginigivalis 
correlate with ACPA and RF in humans [132] and in animal models, infection with the 
organism results in increased severity of collagen induced arthritis [133]. The question arises 
as to the mechanisms by which the presence of bacteria can result in a break of immune 
tolerance.   Infection by the organisms described above results in gingival inflammation and 
the recruitment of neutrophils, activation of the complement cascade and cell death, 
promoting the release of human PADI and citrullination of local proteins within the gum.  P 
gingivalis is unique in that also expresses PAD.  Release of the bacterial enzyme may result in 
further changes in protein conformation and the formation of a neo-epitope [129]. This 
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hypothesis is supported by findings that bacterial DNA is present in the sera and synovium of 
patients with RA [134] and that human PAD, PPAD and citrullinated proteins are also found 
in the oral mucosa [135].   
The role of the gut microbiome 
Intestinal flora may also play a role in the development of RA.  Murine models of arthritis can 
be improved or exacerbated by alterations in the levels of gut bacteria [136, 137].  In humans, 
dysbiosis of gut bacteria has been implicated in several diseases and are being increasingly 
investigated following the advent of sequencing initiative such as the National Institutes of 
Health human microbiome project [138]. Analysis of the faecal microbiota of patients with 
newly diagnosed RA showed lower diversity and overall counts than patients with 
fibromyalgia.  [139]  A higher prevalence of prevotella capri and lower numbers of bacteroides 
species within the gut has also been described in patients with early RA [140].  The link was 
further investigated in mice that exhibited a more severe phenotype when exposed to 
prevotella.  Association is further supported by the clinical response to pharmaceuticals 
directly modulating microbial action such as sulfasalazine and tetracyclines [141]. The 
mechanisms by which gut flora may induce arthritis are likely to involve dysregulation of TH17 
and T cell balance [136, 142]. Toll like receptors (TLR) are also likely to be implicated in shaping 
the T-cell repertoire in the intestine, possibly resulting in self-reactive cells. Migration of these 
cells to the joint may promote inflammation and destruction, resulting in the overall clinical 
phenotype of RA [141]. Further work is, however, needed to establish a definitive pathogenic 
link and dissociate causality from chance co-existence. 
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1.3.5 Sex hormones and gender  
It is well recognised that there is female preponderance in autoimmune conditions and RA is 
no exception.  Observation that the disease improves in pregnancy also suggests a role for 
hormonal factors.  Sex hormones are involved in the immune response and there are several 
putative mechanisms by which they may influence the course of disease.  
Androgen and oestrogen receptors are found on synovial macrophages and monocytes [143, 
144] indicating that these cells are sensitive to circulating sex hormones.  Oestrogen 
stimulates the Th2/humoral response and increases levels of interferon gamma (IFN-g)  and 
interleukin (IL) -10, which are found in high levels in the sera of patients with RA [145].  
Progesterone also results in a shift from Th1 to Th2 responses which may decrease levels of 
circulating Th17 cells, which may account for the improvements in the prepartum period 
[146]. Oestrogens can also modulate B-cell function.  Oestradiol is involved in antigen 
presentation and results in an increase in the survival of autoreactive B cell and release of 
pro-inflammatory cytokines such as IL-1, IL-6 and TNF-a, leading to a shift towards 
autoimmunity [147, 148]. 
Androgens may play an anti-inflammatory role in RA.  Serum testosterone levels are inversely 
correlated with disease activity [149]. Their potential protective effect is further showcased 
by the observation that administration of anti-TNF agents downregulate the conversion of 
androgens to oestrogens [150].  Lower levels of testosterone have been found in the joints of 
patients with RA, leading to studies investigating the role of androgen replacement therapy 
in males with RA, although this avenue was not followed commercially [151].  
 52 
Demarcating the influence of individual roles of genetic, environmental and endogenous 
hormonal factors in the pathogenesis of RA is an arguably difficult, perhaps even impossible, 
task.  The current model of RA suggests that in a genetically susceptible individual, 
environmental or bacterial triggers can cause alteration of self-proteins that lead to 
autoantibody formation, dysregulation of the immune system and the activation of the 
inflammatory cascade resulting in the clinical phenotype that is RA. 
1.4 The Aetiology of RA: the role of the immune system 
1.4.1 The role of the innate immune system in RA 
 The role of Toll like receptors in RA   
The innate immune system provides the first line of defence against pathogens.  Following 
exposure to an antigen, the immune response is mediated by TLRs which activate other innate 
immune cells, including macrophages, monocytes and dendritic cells.  TLR activation results 
in the release of pro-inflammatory cytokines that act to recruit and retain macrophages and 
monocytes which take up the pathogen and travel in circulation until components of the 
adaptive immune system are met.  The pathogen is then cleared, with a resolution of 
inflammation.  In RA this process is defective, resulting in high levels of ongoing inflammatory 
responses which lead to joint swelling and destruction. 
TLR’s are a family of receptors found in a number of cells that recognise pathogen associated 
molecular patterns (PAMPs) found on microbes or danger associated molecular patterns 
(DAMPs) which are expressed when cells are under stress.  TLR 1, -2, -4, -5 and-6 are 
expressed extracellularly, whereas -3,-7,-8 and -9 are intracellular and require ligand binding 
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and endocytosis in order to activate downstream cells.  The adaptor-ligand complex results 
in the activation of two pathways[152]. The first, the MyD88 dependent pathway activates 
NFkB and results in cytokine expression and mitogen activated protein kinases whereas the 
second, which is MyD88 independent, results in interferon release [152].  Additionally, 
binding of endogenous ligands such as heat shock proteins (HSP), fibronectin, fibrinogen and 
endoplasmic reticulum stress protein (gp96) may also result in TLR activation.   
Patients with RA show an increased expression of TLR 2 and TLR 4 in both peripheral blood 
and synovial macrophages, as well as being present on synovial fibroblasts [152-154].  Within 
the synovium, there is expression of TLR 3, 7, 8 and 9 which have been found to be elevated 
when compare with patients who have OA – stimulation can result in the production of 
cytokines and matrix metalloproteinases (MMPs) [155] and furthermore result in 
osteoclastogenesis.  There are numerous other reports of expressed TLR and examples of 
putative pathogenic roles in RA reviewed in [152].   
Neutrophils: the role of NETosis   Recently it has emerged that polymorphonuclear cells have 
the propensity to generate neutrophil extracellular traps (NETs), a process in which 
autoantigens and immune modulators are externalized.  These have been recognised in 
several autoimmune diseases and are thought to play an important role in the citrullination 
of protein.  Citrullination of histones is an important step in NETosis and these are displayed 
externally on the NETs.   Levels of NETosis have been found to correlate with ACPA and 
inflammatory markers, and are induced potently by anti-citrullinated vimentin antibodies. 
[156, 157] It is therefore suggested that presence of these traps has the propensity to result 
in a cycle of chronic citrullinated autoantibody formation and subsequent inflammation, 
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potentially making NETosis a target in pre-clinical disease or to break the cycle of ACPA 
production in early RA. 
Monocytes and Macrophages  
 Macrophages are key orchestrators of the immune system.  They play a key role in RA, 
evidenced by the success of conventional therapies which act to decrease levels of cytokines 
produced by this subset of cells, such as TNFa blockade.  Additionally, it has been shown by 
several groups that a reduction of the number of residing macrophages in the synovial 
sublining layer correlates with treatment response [158-160].  They also, through the 
production of cytokines, play a chemotactic role for other cells of the immune system.  
Targeting macrophages specifically in RA is difficult as they form one of the first and most 
important lines of host defence; therapy would need to preferentially target activated 
macrophages. 
Dendritic Cells    
Dendritic cells play an important role in the rheumatoid synovium, particularly in the 
formation of ectopic lymphoid structures (ELS).  Following an antigenic stimulus, they migrate 
and act as mature antigen presenting cells in lymphoid organs.  In RA they have been shown 
to be resident in the perivascular infiltrate [161].  They have also demonstrated to produce 
cytokines including IL-23, IL-12, BAFF and IL-18 [162].  Dendritic cells are therefore able to 
activate naïve T-cells to recognise self-epitopes and differentiate into activated T-cells, thus 
initiating the immune cascade[163]. 
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Fibroblast like synoviocytes (FLS) 
Inflamed hyperplastic synovium contains a high number of activated FLS which normally 
reside in and are crucial to the normal architecture of the joint[164].  FLS respond to a pro-
inflammatory environment through the production of cytokines, proteases and alterations in 
metabolic pathways through cellular crosstalk, leading to progressive joint destruction[165]. 
Activated FLS are also thought to display an inflammation independent pattern of 
destruction, demonstrated through ongoing cartilage degradation when RA fibroblasts were 
implanted in mice homozygous for the severe combined immune deficiency spontaneous 
mutation (SCID)[166, 167].  Targeting FLS in conjunction with alterations to circulating 
immune cells may therefore be an option in a subset of patients with RA. 
 
Mast cells 
The role of mast cells in RA has been debated, with potentially pro and anti-inflammatory 
functions[168].  Recent work from our laboratory suggests that high numbers of mast cells 
were associated with disease activity and local inflammation, particularly in patients with 
lymphoid aggregates.  Furthermore, they were able to demonstrate that mast cells promote 
the activation and differentiation of B-cells in vitro and in vivo through an antigen induced 
mouse model of arthritis [169]. This is in line with previous studies that have demonstrated 
expansion of mast cells in early disease[170, 171]. Mast cells may exert their effects by a 
number of different mechanisms through the production of  IL-10, a pleitropic cytokine with 
both anti and pro-inflammatory effects, and IL-33 and as regulators of cellular recruitment 
and tissue permeability [172].  Whether their increased presence in RA is causal or effectual 
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remains to be clearly established and therefore we remain some way from these cells 
becoming potential disease modifying targets. 
1.4.2 The role of the Adaptive Immune System in RA 
The adaptive immune response consists of cellular and humoral responses by T and B 
lymphocytes.  Since the focus of this work is on B-cell pathways, I will describe the role of T 
cells and key cytokines first, with further dedicated emphasis on B-cells and subsequent B-
cell depletion therapy in the next section.  
1.4.2.1 The role of autoantibodies in disease pathogenesis 
Autoantibodies in RA can be identified years before the disease manifests.  Studies have 
suggested that this time is usually 3 to 5 years, although up to 15 years prior to onset has 
been observed.  [173] To date, a number of autoantibodies have been described, the most 
important and common of which are RF and ACPA, and which are included in the new ACR 
classification criteria. 
Rheumatoid Factor 
RF was first described by Waaler in 1940 [174].  These are a family of antibodies directed 
again the crystallised fragment (Fc) portion of immunoglobulin (Ig) subclass G, detected in 60-
80% of patients with RA.  They can also be found in disease-free individuals, ranging from 4% 
in Caucasians to higher levels of 30% in certain ethnic groups such as Pima Indians [175]. They 
also co-exist in other diseases such as SLE , Sjogren’s syndrome and tuberculosis and therefore 
are sensitive, but lack specificity [176]. They exist in different isoforms, IgE, IgM, IgG and IgA, 
but IgM is the isoform routinely detected in clinical practice. A difference has been reported 
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between RF’s from RA patients and from healthy individuals, as the former bind with a much 
higher affinity, having undergone T-cell driven affinity maturation with more sense mutations.  
The latter bind to antigens weakly and tend to be polyreactive [177]. 
Circulating antibodies can be pathogenic by their ability to form immune complexes and 
activate the complement cascade, enhancing joint destruction.  A recent study has also shown 
that IgM-RF increases cytokine production by macrophages, dependent on the number of 
engaged FcgR [178].  Furthermore, RF is a prognostic marker in RA, as patients with higher 
circulating levels are more prone to develop erosions and extraarticular manifestations of 
disease [176, 179].  
Anti-Citrullinated Protein Antibodies (ACPA)  
In 1964, Nienhuis and Mandema identified a new class of autoantibodies in the sera of 
patients with RA  [180] which reacted to anti-perinuclear granules in the buccal mucosa.  
Several years later it was reported that these antibodies co-localised with filaggrin [181].  
Serre and colleagues noted that filaggrin in buccal mucosa and fully differentiated epithelial 
was different to profillagrin found in cultured cells.  The main modification of the protein was 
found to be the presence of citrulline.  This was subsequently shown to be essential for 
antigenicity of these antibodies in RA [182] and led to the identification of cyclic citrullinated 
antibodies (CCP), which showed better specificity than the original linear enzyme linked 
absorbent assays (ELISAs).  This was further refined in 2002 with the advent of the CCP2 assay 
which was derived from screening approximately 12 million synthetic peptide libraries with 
sera of patients with RA [183, 184].   
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In normal physiology, citrullination occurs in the presence of high calcium and usually 
accompanies cell death.  Apoptotic cells are then usually cleared by the innate immune 
system [184].  If these are ineffectively cleared, active PAD enzymes and citrullinated proteins 
are exposed to the immune system, with the ability to citrullinate more local proteins within 
joints, such as collagen or fibrillin.  As discussed earlier, the presence of the HLA DRB1 epitope 
greatly increases the risk of developing RA when the immune system is exposed to 
citrullinated proteins.  This “spreading” of the ACPA  pool is a step recognised prior to the 
onset of disease  [185].  Like RF, the presence of circulating ACPA can result in immune 
complex formation and the release of pro-inflammatory cytokines to stimulate the 
inflammatory cascade and result in joint  damage. 
ACPA positivity is associated with more erosive disease and presence of circulating antibodies 
is a strong predictor of erosions, shown by a recent meta-analysis of 25 studies [186]. 
Positivity is also associated with worse clinical phenotypes and cardiovascular disease[184, 
187] indicating a direct pathogenic role in the disease.  How this is achieved is yet to be fully 
elucidated, but animal models of the disease show that transfer of synthetic antibodies 
enhances collagen induced arthritis in mice and citrullinated collagen or fibrinogen can induce 
joint symptoms in the animals. [187-190]  In vitro, similar to changes induced by RF, 
macrophages produce more cytokines, particularly TNF-a, propagating a pro-inflammatory 
environment[191].  Additionally, activation of the complement cascade is responsible for 
recruitment and retention of inflammatory cells to the synovium. 
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Anti carbamylated antibodies (Anti-CarP antibodies) 
Akin to citrullination, carbamylation is another post-translational modification process that 
results in the generation of a different amino acid, in this case, homocitrulline, which differs 
from citrulline in the length of its side chain, resulting in a conformational change [192].  The 
physiological role of carbamylation has not yet been fully ascertained, but it has been 
described in kidney disease, uraemia, atherosclerosis and inflammation  [193].  These 
antibodies have recently been recognised as a separate entity in RA, although approximately 
20% do overlap with ACPA positive patients [192]. 
Protein 14-3-3   
14-3-3 are a seven-isoform family of proteins that act as chaperons and have the capacity to 
interact with over 200 intracellular proteins, thus regulating several processes including 
cellular signalling, protein trafficking and cytoskeletal transport[194, 195].  14-3-3h has been 
shown to be present in higher levels in the sera of patients with RA, and up to five times 
normal levels in synovial fluid.  Levels correlate strongly with MMP-1 and MMP-3, suggesting 
that they may play a role in joint damage. [196]  A study of 619 patients with RA showed that 
identification of the protein was associated with a diagnosis of RA with an associated 
sensitivity and specificity of  77% and 92.6% respectively [197, 198]; adding this test to ACPA 
antibodies alone increased disease identification rates to 72% compared with 59%, and 
addition to both RF and ACPA increased the detection rate from 72% to 78%. There are 
currently studies underway to enhance the knowledge of this protein and its potential as a 
disease biomarker. 
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Nuclear ribonucleprotein complex  Anti A2/ anti-RA 33 antibodies are directed to the 
heterogenous ribonuclearprotein A2 (hnRNP-A2), a protein found in nuclei that is involved in 
mRNA splicing and transport[199].   These occur in approximately 33% of patients with RA 
but can also be found in connective tissue diseases such as lupus and mixed connective tissue 
disease.  If these diseases, however are ruled out, clinically and through the exclusion of other 
lupus associated antibodies, specificity for RA may rise to 96%[200].   
Anti-Bip antibodies   
Anti-stress protein immunoglobulin heavy-chain binding protein (Bip) antibodies have been 
demonstrated to be present in approximately two-thirds of RA patients with a specificity of 
96%.  They have been reported to be overexpressed in the synovium and may form a target 
for  autoreactive T-cells [201].   
Anti-SA antibodies Anti-SA antibodies are directed against a protein of unknown function and 
are found more frequently in patients with established disease.  A study investigating 
antibodies in early arthritis found that these were associated with more destructive disease 
in males, indicating that they may be of prognostic benefit [202]. 
1.4.2.2 The role of T-cells in RA 
T-cells comprise of two major subsets: CD4+ T-helper cells and CD8+ cytotoxic T- cells.  CD4+ 
T-cells are activated by engaging with a complex of (possibly arithritogenic) antigen fragments 
presented by professional antigen presenting cells (APC’s) and MHC class II molecules.  
Additionally, a co-stimulatory molecule of CD80/CD86 expressed on the APC is required to 
interact with CD28 found on T cells for activation to take place  [203]. Once activated, T cell 
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clones proliferate to become effector T cells and secrete cytokines that initiate the 
inflammatory cascade. 
CD4+ T-helper (Th) cells were traditionally divided into Th1 and Th2 subtypes, however in 
recent years evidence has emerged that Th17 cells also play a critical role in RA. Th1 cells, 
associated with the transcription factor STAT1, STAT4, Tbet (TBX1) and IL-12, secrete 
interferon-g (IFN-g) and tend to protect against intracellular bacteria; Th2 cells appear to 
combat extracellular organisms such as parasites through the production of Il-4, -5 and -13 
and are associated with the expression of transcription factor GATA 3, and STAT 6 [204]. There 
is a further functional difference related to various target antigens, Th1 cells link to cellular 
immunity, largely provided by CD8+ cells, whereas the latter lead to activation of B-cells and 
humoral immunity[205].  Initial ideas regarding the role of T-cells hypothesized that  a shift 
towards a preponderance of Th1 cells resulted in an abnormal release of associated cytokines 
resulting in disease; however this was challenged by a paucity of IFNg and IL-2 in the 
synovium, resulting in a shift in focus yo the potential role of TH17 cells and CD4+CD25+ 
regulatory T-cells (Tregs) [203]. 
Th17 cells 
In the last decade, a new lineage of T effector cells has been described, known as Th17 cells 
based upon their ability to produce IL-17.  The importance of this cytokine and subsequently 
subset of cells was first described in models of autoimmune encephalitis and in experimental 
animal models. CD4+ effector T cells were shown to be pathogenic in a collagen-induced 
arthritis model, as IL-23 (required for production of IL-17) deficient mice did not develop 
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disease, whereas the same was not observed in mice deficient in IL-12, which is required for 
Th1 IFNg producing cells, who developed arthritis[206, 207].  
Th17 cells require specific cytokines for proliferation, including IL-1, IL-6 and IL-23 and 
transforming growth factor (TGF)-b [208].  In normal physiology, several naïve Th cells dwell 
at mucocutaneous barriers such as the skin, gut and respiratory tract, differentiating to TH17 
after encountering bacterial and fungal infections [209]. The differentiated cells express IL-
17A and IL-17F, IL-21, IL-22, IFNg and granulocyte colony stimulating factor (G-CSF) [209]. IL-
17 binds to its receptor to trigger an intracellular signal that leads to the production of IL-6, 
CXC chemokines, resulting in synovial inflammation, cartilage damage and bone resorption 
[210].   
The role of T regulatory cells (Tregs) 
Regulatory T-cells, akin to their name, dampen and regulate inflammatory responses towards 
self-antigens through cell to cell interactions and cytokine production.   Tregs express the 
regulatory transcription factor Foxp3, CD25, CTLA 3 and glucocorticoid induced tumour 
necrosis factor receptor family-related protein (GITR). Although CD4+ an CD8+ are the prime 
targets of Tregs, they can also have suppressive effects on B-cells, natural killer cells, dendritic 
cells and other APCs [211].  They are also responsible for the production of IL-10 and TGFb 
[212] and have been found in both the peripheral blood and synovium. 
There is currently debate over the numbers of T-cells found in RA sera compared with healthy 
controls, as studies have shown conflicting results of increased, decreased and normal 
circulating Tregs [213-217].  Less conflicting, however, is the notion that Tregs are 
dysregulated in the presence of abnormal levels of cytokines, as in the rheumatoid joint.  
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TNFa and 1L-17 diminish the suppressive effects of Tregs [217], which can be reversed to 
normal levels by anti-TNF therapy [215].  It has also been suggested that Tregs are less able 
to regulate CD4+ effector cells within the synovium which appear to be more resistant to 
suppressor effects, particularly TH17 cells.  These cells are in balance with Treg cells and 
depending on cellular signals can be derived from the same precursor[217, 218]. A change in 
this delicate ratio can therefore lead to inflammation and has been implicated in the 
development of certain tumours and in acute lung injuries [219, 220]. 
 
1.4.3 Mechanisms of inflammation: the roles of cytokines and chemokines 
TNF-a superfamily 
TNF-a plays a critical role in inflammation and a pivotal role in RA.  It is a multifunctional 
cytokine with downstream pro-inflammatory effects on several cells of the immune system, 
including macrophages, synoviocytes, chondrocytes and osteoclasts, promoting synovial 
immune cell proliferation and tissue damage.   It is produced by activated macropahges and 
T-cells, and exerts function after binding to p55 (TNF-R1) or p75 (TNFRII.)  Both receptors have 
an intracellular portion for signal transduction; cleavage of the extracellular domain results in 
soluble TNF receptors which are capable of sequestering anti-TNF [221].  High levels of TNF 
have been found within the rheumatoid joint.  It is a potent inducer of several other 
inflammatory cytokines, including IL-1, IL-6, IL-8 and GM-CSF.  Additionally, within the joint it 
stimulates fibroblasts to produce cell adhesion molecules, thus regulating critical pathways in 
immune cell recruitment and pannus formation.  It also regulates the receptor activator of 
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nuclear factor kappa-B ligand (RANKL) and affects the RANKL / osteoprotegerin balance, 
favouring osteoclast formation, leading to the increased presence of erosions.   
Interleukin -1 (IL-1) 
Another important interleukin that forms part of the inflammatory milieu is IL-1.  IL-1 is a 17 
kd protein produced by monocytes and macrophages, but also endothelial cells, B cells and 
activated T-cells [222]. It promotes leucocyte activation, endothelial cells, osteoclasts and 
chondrocytes and release of circulating MMPs, resulting in joint damage. IL-1 is bound by two 
types of cell surface receptors, of which only type 1 are capable of intracellular signalling.  
Type 2 receptors bind IL-1 in the circulation but do not have any downstream intracellular 
affects.  Like TNF, levels of IL-1 are high in the synovial fluid of patients [223]. Despite its 
potent pro-inflammatory actions, IL-1 blockade through Anakinra has only proved to be of 
modest value in RA [224]. 
Interleukin-6 (IL-6) 
IL-6 is a key mediator of inflammation in RA, with both local and systemic effects.  IL-6 signals 
via a protein complex that has a membrane bound receptor unit and two signal transducing 
gp130 subunits.  IL-6 trans signalling utilises a soluble receptor which binds to membrane 
bound gp130 subunits.  Gp130 is found on a wide range of cells, such as endothelial cells and 
synoviocytes, broadening the repertoire of cells that will respond to IL-6  [225].  Local effects 
of IL-6 include neutrophil recruitment, Vascular endothelial growth factor (VEGF) production, 
osteoclast activation, B-cell proliferation and antibody production.  It also plays a role in T –
cell proliferation and differentiation.  In addition, systemic effects include the production of 
acute phase proteins, acceleration of cardiovascular disease through alterations in oxidative 
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stress and lipid dysregulation, anaemia  and changes in the hypothalamic pituitary axis 
resulting in fatigue and depression, commonly found in patients with RA [225]. Clinically, 
inhibition of the IL6 pathway with biologic therapies such as Tocilizumab and Sarilumab, 
which competitively bind to the IL6 receptor, is an effective therapeutic approach for RA 
patients [226, 227]. 
Interleukin-17 (IL-17) 
IL-17 is produced by Th17 cells and has, in recent years been shown to have a key role in 
inflammation.  IL-17A is similar to IL-17F, and these two isoforms appear to be predominant 
in human peripheral blood monocytes (PBMCs) [228]. They bind to a receptor complex 
composed of at least two subunits, IL-17RA and IL-17RC. IL-17 cytokines activate pathways 
linked to the innate immune system, hence acting as a potential link between the primary 
host defenses and the adaptive immune system.  IL-17 stimulates the expression of multiple 
genes involved in inflammation, including IL-6, G-CSF, IL-32 and chemokines CXCL1, CXCL2, 
CXCL5 and CCL20.  IL-17 also has the ability to upregulate receptors for TNF in synoviocytes 
and therefore in the presence of TNF is a potent pro-inflammatory mediator[229].  This 
synergy is also displayed with IL-1 and IFN-g via a positive feedback mechanism which 
perpetuates inflammation. Trials utilising secukinumab and ustekinumab, which block IL-17 
and the IL-12/IL-23 pathways respectively, have so far not conferred clinically significant 
benefits[230-232].  
Several other cytokines are known to play a role in RA including IL-15, IL-32, IL-33, GM-CSF, 
IL-12, macrophage inhibitory factors.  Many of these are being currently characterised and 
investigated for the utility of potential treatment targets. 
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Chemokines 
Chemokines are low molecular weight proteins that are required for chemotaxis and 
recruitment of immune cells such as leucocytes and angiogenesis.  They are expressed both 
constitutively and can be upregulated during inflammation or stress.  Chemokines have been 
divided into four supergene families: CXC, CC, C and CX3C with L denoting the ligand of each 
specific chemokine [233]. 
IL-8/CXCL8, epithelial-neutrophil activating protein 78 (ENA-78)/CXCL5 and gro-alpha/CXCL1 
are well characterised in RA and are found in high levels in the sera and synovium of patients 
with RA [234-236]. The main producers of these chemokines are synovial macrophages; 
however, they may also be found in fibroblasts and resident synovial cells.  A role in disease 
pathogenesis has been demonstrated through induction of synovitis following an 
intraarticular injection to rabbit knees [237]. 
Potentially some of the most important roles of chemokines in the immunopathogenesis of 
RA are witnessed as they orchestrate production of ELS within the synovium.  Stromal cell 
derived factor 1 (SDF-1)/CXCL12 is a ligand specific for CXCR4.  SDF-1/CXCL12 is involved in 
organization of the lymphoid compartment, it has been found to be expressed by synovial 
endothelial cells and therefore implicated in lymphoid neogenesis.  It affects T-cell migration 
and adhesion; in SCID mice transplanted with human synovial tissue, monocytes were 
preferentially recruited to transplanted human synovium injected with CXCL12, indicating a 
chemotaxis following exposure to the ligand complex [238]. Adhesion of T-cells to fibroblasts 
upregulates production, resulting in leucocyte migration, osteoclastogenesis and erosions 
[154, 234, 239]. 
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Formation of ELN within the joint also relies on the expression of CXCL13 and CCL21.  Manzo 
and colleagues provided direct evidence that CXCL13 and CCL21 were produced in the joint 
and this was associated with the formation of lymphoid aggregates within the synovium, 
mirroring the homeostatic structural and compartmental changes in secondary lymphoid 
organs [240].  A role for ELN in the pathogenesis of disease and resistance to treatment will 
be discussed further in this work. 
Over 50 chemokines have been described to date, many of which have homeostatic roles 
which change in the presence of inflammation or injury.  Only a few have been mentioned 
here.  Several chemokines are known to be upregulated in RA, the dynamics and subsequent 
cell movement models, however are limited to animal or cultured cells.  Ubiquitous 
expression of chemokines and their role in homeostasis also makes it difficult to target them 
as potential therapeutic agents, although efforts have been made to modulate the CCR2 
receptor with little clinical benefit  [241]. 
1.5 The role of B-cells in RA 
1.5.1 B-cell development and function  
Following the discovery of RF by Waaler, B-cells were initially postulated to be key players in 
the pathogenesis of RA.  The lack of RF specificity shifted attention towards alternate cells of 
the immune system, with increased focus on the dysregulation of T-cells and macrophages 
[242].  The clinical response seen to the anti-CD20 antibody, Rituximab reignited interest in 
B-cells and their critical role in the development and propagation of the disease process. 
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B-cells are part of the adaptive immune system.  They are produced continuously throughout 
life, arising first from the foetal liver and later from hematopoietic stem cells in the bone 
marrow.  Transgression from an immature B-cell to a fully functioning mature B-cell requires 
several tightly regulated checkpoints and transcription factors as well as factors contained in 
the stromal environment. 
 
Figure 1.2 details the stages of B-cell development and is described herein.  B-cell 
development is initiated when lymphoid progenitor cells receive the appropriate signal from 
bone marrow stromal cells, under the influence of Terminal deoxinucelotidyl transferase and 
recombinase activating genes (RAG-1 and RAG-2) [243].  Additionally, the presence of stem 
cell factor, kit and IL-7 are required for transition signalling.  
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Figure 1.2 Stages of B-cell development; used with permission [244] from the Journal of 
Allergy and Clinical Immunology 
Abbreviations:  HSC haematopoetic precursor cells, GL germline, BAFF-R B cell activating factor 
receptor,  
GC germinal centre, PC plasma cells, CSR class switch recombination 
 
 
 
Each change in the stage of development is dependent of the rearrangement of 
immunoglobulin gene segments that result in antibody formation, with variable 
recombination of the variable (V), diversity (D) and joining (J) regions.  Early pro-B cells are 
formed following a D-J recombination on the immunoglobulin heavy chain gene (IgH) and are 
characterised by the expression of CD45 and MHC class II molecules.  Late pro-B cells form 
following addition of an upstream V segment [244]. VDJ rearrangement and expression of a 
membrane bound surrogate light chain in the B-cell receptor defines the pre B-cell 
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population; early and late stages are differentiated by size (early pre-B cells are dividing and 
larger) and expression of the membrane chain in the cytoplasm and on the surface.  The cells 
now express CD45, CD19 and CD40 [245].  
Immature B-cells are formed following V-J recombination of light chain genes, a process which 
exhibits allelic exclusion.  If a functional light chain is produced and paired with a heavy µ 
chain this is expressed on the cell surface as IgM.  Alternative mRNA splicing will result in the 
formation of IgD (IgD+/ IgM+) and membrane bound IgG which completes the transition to a 
naïve mature B-cell.  At this stage it is ready to leave for the periphery.  VDJ recombination 
which occurs prior to antigen exposure is the first step towards developing an almost infinite 
repertoire of diverse antibodies [246].   
1.5.2 B-cell maturation and the germinal centre reaction 
Naïve mature B-lymphocytes migrate continually through the bloodstream and secondary 
lymphoid organs in search of potential antigens.  They circulate through primary lymphoid 
follicles and following antigen encounter undergo further expansion to form secondary 
follicles which contain germinal centres (GCs) [247]. GCs are found in the follicular B-cell zones 
of lymphoid organs such as the spleen and lymph nodes. GCs have been subdivided into 
‘zones’ based upon histological findings from tonsils and lymph nodes, named the dark and 
light zones which are surrounded by follicular mantle B-cells.  The organization and migration 
of cells is dependent on an array of tightly regulated cytokines and chemokines.  The 
formation of compartments relies on CXCL12, which is more abundant in the dark zone, and 
CXCL13 which is present in the light zones.  These differences depend on the expression of 
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CXCR4 by centroblasts in dark zones and CXCR5, the ligand for CXCL13 in light zones [248, 
249]. 
Dendritic cells present the antigen to Th cells followed by clonal expansion of these antigen 
specific cells.   Following encounter of a mature B-cell with a specific antigen, upregulation of 
the chemokine receptor CCR7 and migration to its ligands CCL19 and CCL21, results in the 
congregation of B-cells at the border of B-cell and T-cell rich areas in order to further engage 
Th-cells [250, 251].  These encounters are responsible for GC reactions, particularly through 
binding of CD40 to its ligand, CD40L, expressed on Th2 cells [252].  Rapid clonal expansion of 
these B cells results in the formation of the secondary follicle.  B-cells then undergo somatic 
hypermutation in order to increase affinity for the antigen.  This process is aided by the 
presence of antigen as immune complexes held by FDC’s.  Cells with high affinity undergo 
positive selection and continue to proliferate to recirculate and become B memory cells; 
those with low affinity return for a further cycle of SHM or if after several rounds low affinity 
persists, cells undergo apoptosis and are taken up by tingible body macrophages. 
1.5.3 Somatic hypermutation 
B-cell Receptor (BCR)  maturation and diversification is a [253] achieved through a process 
called somatic hypermutation (SHM).  As cells proliferate within GC’s they undergo high rates 
of mutations in the IgV genes, usually in the form of single nucleotide exchanges.  The enzyme 
activation induced cytidine deaminase (AID) is vital for this process and is found in the dark 
zone of germinal centres[254, 255].  Its action is to deaminate cytidine to uracil. Random 
changes are introduced by excision of deoxycytidine bases by uracil DNA glycosylase and 
subsequent addition of bases by a DNA sequence error prone polymerase.  Replacement 
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mutations are inserted in preference to silent changes. Most mutations occur at 
complementarity determining regions (CDRs) which will result in a conformational change at 
the binding site of the antigen. B-cell variants with high affinity and specificity are then 
selectively expanded through repeat cycles of GC selection. [249, 256, 257].   
1.5.4 Class-switch recombination (CSR) 
Antibodies are divided into five different classes determined by the heavy chain constant 
region, which determine their effector function. The process of CSR is an intra chromosomic 
deletional recombination event in switch (S) regions upstream of VH regions, resulting in a 
switch in immunoglobulin classes, defined as IgM, IgG, IgA , IgD and IgE isotypes.  IgG is further 
subdivided in four subclasses: IgG1, IgG2, IgG3 and IgG4; similarly IgA is subdivided into IgA1 
and IgA2 [258].  S regions are characterised by short, 20-80bp G-rich sequences which are 
unique to each isotype.  CSR can occur anywhere within or near these regions  [259]. 
There are several distinct steps in CSR. The first step required is CD40 ligation/ TLR stimulation 
which is required to initiate CSR and release cytokines and chemokines which will drive the 
process. Like SHM, AID is necessary for the steps that follow.  Deamination of cytosine to 
uracil in the S and variable Ig regions is the first to occur, followed by the formation of single 
stranded breaks in DNA by uracil DNA glycosylase (UNG).  The formation of double stranded 
breaks occurs by two mechanisms; the first occurs if another single stranded break (SSB) is 
sufficiently near, or if the SSB is more distal, then mismatch repair mechanism is employed 
[253].  The empty base sites are repaired by enzymes known as apurininc or apyrmidinic 
endoculeases [260].  Mismatch repair occurs if SSBs are not in close proximity to one another.  
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Any 5’ or 3’ overhangs are subsequently excised or completed using polymerases or 
endonucleases.  Following this S regions are joined by non-homologous end joining.   
1.5.5 Plasma Cell Development 
Plasma cells from mature B-cells and are capable of producing mature, high affinity 
antibodies.  B-cells which leave GCs acquire continue as memory B-cells or develop into short-
lived plamsa cells.  Plasma cells from mature B-cells and are capable of producing mature, 
high affinity antibodies.  Plasma cells can develop from either outside the follicle or within 
GCs [261]. 
First, they can develop from marginal zone B-cells and follicular cells.  These cells tend to be 
short lived and are required for the immediate immune response.  Within a few hours of 
exposure to antigen, marginal zone cells move to the red pulp and bridging channels within 
the spleen and undergo proliferation, resulting in IgM secreting plasmablasts  [262]. Secondly, 
circulating mature follicular cells can receive Th2 help after they have encountered an antigen 
and differentiate to plasmablasts and plasma cells.  These have not, however, undergone the 
process of SHM and therefore tend to be short-lived, undergoing cell-death in situ after a few 
days  [263].  Post GC plasma cells arise from B-cells who have undergone rounds of SHM and 
CSR are able to exit the germinal centre and produce antibodies.  Memory B-cells display high 
affinity BCR on their surface and following re-encounter with an antigen have the ability to 
rapidly proliferate to form antibody producing plasma cells.    
Long-lived plasma cells are formed in GCs and preferentially migrate to reside in the bone 
marrow and can produce ongoing antibodies for years, even in the absence on ongoing 
antigenic stimuli [264, 265].  They are also found in various organ-specific niches such as gut 
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mucosa and sites of ongoing inflammation [266, 267].  This is an important finding in 
autoimmune diseases, where autoantibodies are differentially reduced between patients and 
therapies, suggesting that there are niches of development and residence for these cells, 
including the bone marrow, lymphoid tissue and the synovium. 
1.5.6 The roles of BAFF and APRIL 
B-cell activation factor (BAFF) of the T-cell family (also called BLyS) and A-proliferation 
inducing ligand (APRIL) regulate lymphocyte activation and survival.  BAFF has three 
receptors, the BAFF-Receptor (BAFF-R), Transmembrane activator and CAML interactor (TACI) 
and with lower affinity to BCMA (B-cell maturation antigen).  APRIL also binds to the latter 
two receptors, but additionally interacts with proteoglycans.   These ligands play several roles 
in the modulation of lymphoid cells, with functions differing between receptors.  They play a 
role in the survival of peripheral B cell survival and in the induction of self-reactive B-cells 
[268]. 
BAFF is necessary for B-cell survival signals, however in the absence of B-cells, BAFF is 
continuously expressed by constitutive cells [269].  It is also a player in the expansion of 
autoreactive B-cells, as B–cells bound  to self-antigens can escape cell death in the presence 
of high levels of circulating BAFF, which has been postulated as a mechanism for ongoing 
autoimmunity  [270].  BAFF and APRIL also have varying roles in different B-population 
subsets, as responses in mice to a T-cell dependent antigen and a molecule blocking both TACI 
and BAFF was a reduction of circulating plasma cells  but long term immunity appeared to 
remain intact, suggesting that these cytokines may have little role on memory cells [271]. 
BAFF is responsible for the cell surface markers CD21 and 23.  BAFF and APRIL may also play 
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a role in antibody switching via T-cell independent mechanisms.  Lastly, BAFF also had the 
ability to stimulate T-cells through IFN-g and IL-2 production[268]. 
 
1.5.7 The pathogenic role of B-cells in the pathophysiology of RA 
B-cell tolerance checkpoints 
Autoreactive B-cells undergo negative selection at two distinct checkpoints.  The first is 
centrally, within the bone marrow, where the majority of naïve auto reactive B-cells are 
eliminated.  A further peripheral checkpoint in the spleen also counter selects against 
transitional B cells which display poly- or autoreactivity [246].  It has been suggested that 
these checkpoints are deficient in patients with RA, following a small study of six patients by 
Samuels and colleagues in 2005 [272]. The same group showed that these were not changed 
by administration of methotrexate, concluding that the break of tolerance occurs early in RA 
[273].  Peripheral checkpoints are also defective, and may be due to a combination of 
dysregulated Tregs and relative resistance to FAS-mediated apoptosis [274, 275]. 
Autoantibody production  
The importance and formation of autoantibodies in RA has already been discussed.  
Antibodies act against foreign and self-antigens in several ways including the formation of 
immune complexes and complement activation, subsequent recruitment of immune effector 
cells and a direct tissue or cytotoxic effect through binding of the Fcg receptors. 
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Antigen presentation 
B-cells can act as antigen presenting cells to stimulate the CD4+ T-cell population. Takemura 
and colleagues showed that in SCID mice, B-cells were necessary for the development of T-
cell responses after adoptive transfer of CD4 cells[276].  This finding is mirrored after the 
administration of Rituximab, a monoclonal antibody directed against CD20; treatment 
response was associated with a decrease in the number of activated CD4+ T-cells [277].  
Another study showed that this was particularly relevant for the Th17 subtype and did not 
affect other CD4+ cell numbers  [278].  These findings suggest a level of T-cell / B-cell immune 
crosstalk, indicating that B-cells are important mediators of the ongoing inflammatory 
process in roles other than just autoantibody production.   
Cytokine production 
B-cells secrete several cytokines.  One of the most important is the production of IL-6 which 
has an effect on the regulatory roles of suppressive Tregs and the balance with 
proinflammatory Th17 cells [274]. There is also evidence to suggest that B-cells play an 
important role in forming specific subunits required for the activation of certain cytokines, 
and are a source of RANK-L in the synovium.  More recently, the presence of RANK-L has also 
provided a putative mechanism by which B-cells play a direct role in bone destruction as 
patients who exhibit ACPA positivity have a higher erosive load, indicating a direct role in the 
disease process [279]. 
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1.6 B-Cell depletion therapy  
Several clinical trials have highlighted the efficacy of B-cell depletion therapy with Rituximab 
for patients with RA and are summarised in the next section.  Despite these findings, however, 
only 40-60% of patients exhibit a meaningful response to therapy.   Much work has been done 
to try and elucidate patterns of response to therapy and the factors that drive disease relapse, 
which will be further discussed in this section. 
1.6.1 Rituximab mechanism of action 
Rituximab is a chimeric mouse / human monoclonal antibody directed against B-cells 
expressing CD20.  CD20 is a 33-37 kilodalton (kDA) protein that is found on the surface of 
most B-cells (except precursors and plasma cells).  Binding of the drug causes internalization 
or shedding of CD20 at the membrane. Its mechanism of action is dependent on binding its 
Fc receptor which mediates antibody dependent cellular toxicity and complement mediated 
cytotoxicity.  Rituximab also results in direct apoptosis of CD20 cells [280, 281]. It does not 
display an effect on stem cells, pro-B cells and mature plasma cells.  It causes near complete 
depletion of circulating peripheral blood B cells, with variable depletion in the synovium, 
discussed later in this chapter. 
1.6.2 Clinical Trials of Rituximab: an overview 
Rituximab first came to light in RA after patients receiving the drug for haematological 
malignancy experienced alleviation in their joint symptoms [282]. Edwards and colleagues 
had also started using Rituximab in 1998 to treat patients with RA, resulting in the publication 
of the first open label trial [283]. Since then, efficacy has been proven through several 
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randomised controlled and observational studies.  A summary of randomised controlled trials 
is provided in Table 1.4. 
Edwards et al published initial Rituximab data in 2001 as a small, open label study of 5 patients 
showed a significant improvement in symptoms following a combination of 
cyclophosphamide, Rituximab and prednisolone[283]. This led to the development of the first 
randomised controlled trial where 161 patients with established RA who had failed 
methotrexate therapy were randomised to receive: Methotrexate monotherapy, Rituximab 
monotherapy, Rituximab and methotrexate or Rituximab and cyclophosphamide [284].  The 
dose of Rituximab was 1000mg administered intravenously 14 days apart.  The results showed 
that at week 24, ACR 50 responses in the arms that contained Rituximab with or methotrexate 
or cyclophosphamide were higher than controls (p =0.005).   A higher number of patients 
exhibited ACR 20 responses at 24 weeks in all rituximab groups and the a statistically 
significant proportion in the rituximab and methotrexate group reached an ACR 70 response 
(p=0.048). 
The DANCER trial was a phase IIB dosing study, where 465 DMARD refractory patients were 
randomised to receive placebo, or 500 mg or 1000 mg of Rituximab in combination with 
methotrexate.  Both Rituximab arms showed better clinical response than placebo [285].  The 
MIRROR trial was another dose related study of 346 RA patients on stable doses of 
concomitant methotrexate who received varying dosing regimens of Rituximab at baseline 
and again at 24 weeks: 2 x doses of 500 mg and 2 x 500 mg, 2x 500 mg and 2 x 1000mg and 
finally 2 x of 1000 mg and 2 x 1000mg.  There were no significant differences in ACR 20 
response at week 48.  The higher dose regimen however showed a significant improvement 
in EULAR response (p=0.0495).  Numerically, patients receiving the higher dose regimens 
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maintained or improved response at week 24 [286].  The SERENE trial was a similar study, 
where 511 patients resistant to methotrexate were randomised to receive two 500 mg doses 
or two 1000 mg doses or placebo, in combination with methotrexate.  Both doses showed 
superior efficacy to placebo but no significant differences were demonstrated between the 
two groups  [287]. 
An early randomised controlled trial of Rituximab therapy exploring radiographic damage was 
the IMAGE trial of 748 patients.  Patients were randomised to receive placebo, 2 doses of 
Rituximab at 500mg, 2 doses at 1000mg in combination with methotrexate.  At one year both 
Rituximab arms showed better ACR50 responses when compared to methotrexate alone, but 
the higher dose group showed significant limitation of joint damage, which continued for 
further 12 months [288].  The RA-SCORE trial randomised RA patients who had failed anti-
TNF therapy to placebo, 2x 500 mg and 2 x 1g Rituximab at days 0 and 14. It demonstrated a 
significant reduction in MRI erosions scores and cartilage loss in both rituximab groups 
compared with placebo[289]. 
Four trials have investigated Rituximab in patients with established RA who failed anti-TNF 
therapy.  The REFLEX trial randomised patients, in combination with methotrexate to receive 
rituxumab, two doses of 1000mg or placebo and showed better responses in all ACR core set 
measurements at 24 weeks.  Radiological outcomes were also better in the Rituximab group 
at 2 years, making it a pivotal phase III trial leading to drug approval  [290, 291]. The other 
three trials were open label observational studies.  559 patients who had failed anti-TNF 
therapy received Rituximab two doses of 1000mg with methotrexate in the SUNRISE study, 
with randomisation to a second course for those who failed to achieve a DAS-28 response at 
week 24[292]. At week 48, those who had received Rituximab had better outcomes than 
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methotrexate alone.  The MIRAR trial was a non-randomised study where 1124 patients were 
allocated to another anti-TNF therapy or Rituximab; clinical outcomes were better in those 
who switched therapy [293]. The RESET trial was an open label study where patients received 
Rituximab following failure to TNFi with an improvement in ACR responses at week 24 [294].  
In terms of further observational studies, Assous et al[295] retrospectively assessed 50 
patients who had failed or had a contraindication to TNF-alpha agents, demonstrating a 
EULAR good or moderate response of 82% following treatment with 1g of rituximab at days 
0 and 15 in conjunction with methotrexate.  A study where rituximab 375 mg was 
administered weekly for four weeks showed a clinical improvement in DAS-28 in 73% in 46 
patients who were had failed DMARD and TNF-alpha therapy[296]. Keystone and colleagues 
demonstrated in an open-label extension study that further cycles of rituximab in 1039 
patients resulted in sustained improvement in both ACR and EULAR outcomes with no added 
safety concerns[297].  The same group reported a reduction in progressive joint damage with 
rituximab treatment over five years[298]. 
Registry data from the CORRONA register showed in 296 patients who had failed anti-TNF 
therapy that administration of Rituximab resulted in favourable CDAI outcomes, but more so 
in patients who had only failed one-anti TNF therapy previously  [299]. Additionally, a recent 
Cochrane meta-analysis of Rituximab therapy recommended that 2 doses of 1000mg in 
combination with methotrexate therapy was more efficacious than methotrexate alone in RA 
[300].   
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Authors Study design Arms n Length Retreatment Primary outcome 
Cohen, 2006 
(REFLEX) 
Randomised, 
double-blind, 
placebo- 
controlled phase 
III 
PBO+MTX 
RTX 2x1000mg  
+MTX 
 
209 
308 
24 weeks Y(rescue 
therapy) 
ACR 20 response 
51%  vs 18% p<0.0001 
Edwards, 2004 Randomised, 
double-blind 
controlled 
Phase IIb 
PBO +MTX 
RTX  2x1000mg 
RTX  2x1000mg 
+CTX 
RTX 1000mg +MTX 
40 
40 
41 
 
40 
48 weeks Y ACR 20 
24 wk: 38% vs 65% 
(p=0.025), 76% 
(p=0.001) and 73% 
(p=0.003) respectively  
48 wk: 20% vs 33% 
(ns) vs 49% (p=0.01) vs 
65% (p<0.001), 
respectively 
Emery, 2006  
(DANCER) 
Randomised, 
double-blind, 
double-dummy, 
placebo-co 
ntrolled, dose- 
ranging  
Phase II B trial 
PBO+MTX 
RTX 1000mg+MTX 
RTX 500mg +MTX 
149 
192 
 
124 
24 weeks N ACR 20 
28% vs 55% (p<0.001) 
vs 54% (p<0.001) 
respectively 
Emery, 2010 
(SERENE) 
Randomised, 
placebo-
controlled, double 
blind, parallel 
group 
PBO+MTX 
RTX 1000mg +MTX 
RTX 500mg+MTX 
172 
170 
 
167 
48 weeks Y ACR 20 
24 weeks: 22.3% vs 
54.5% (p£0.0001) vs 
50.6% (p£0.0001) 
 
48 weeks: vs 55.7% 
and 57.6% (p£0.0001) 
 
Owczarczyk, 
2008 
Randomised, 
open-label trial 
RTX 1000mg 
RTX 1000mg + MTX 
20 
20 
24 weeks N DAS-28 
DAS-28 4.54 vs 4.43 
(ns) 
Robert Roth, 
2010 
(MIRROR) 
Randomised, 
double-blind 
phase III trial 
RTX 2 x 500mg, 
2x500 mg +MTX 
RTX 2 x 500 mg, 
2x1000mg +MTX 
RTX 2 x 1000mg, 
2x1000 mg +MTX 
134 
 
119 
93 
48 weeks Y ACR20 
64% vs 64% vs 72% 
(ns) 
Tak, 2010 
(IMAGE) 
 PBO+MTX 
RTX 2x 500 mg + 
MTX 
RTX 2x1000 mg 
+MTX 
249 
249 
 
250 
104 weeks Y Change in mtss from 
baseline to week 52 
Week 24: 
0.70 vs 0.58  vs 0.33 
(p<0.05) 
Sustained at week 52 
0.38 vs 0.06 vs 0.03 
(p<0.01) 
Peterfry, 
 2014 
(RA-SCORE) 
Randomised, 
double-blind, 
placebo controlled 
PBO + MTX 
RTX 2x500mg +MTX 
RTX 2x1000mg + 
MTX 
63 
62 
60 
24 weeks Y Change in RAMRIS 
score from baseline to 
week 24 
0.47 vs 0.18 (p=0.003) 
vs 0.16 (p=0.001) 
 
Table 1.5 Summary of controlled trials using rituximab with or without combination methotrexate 
Abbreviations: PBO =  placebo, MTX =  methotrexate, RTX =  rituximab, CTX =  cyclophosphamide, mg milligrams, 
ACR =  American college of rheumatology, mtss =  Mean total sharp score, RAMRIS =  RA MRI scoring system 
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1.6.3 Rituximab: dosing and retreatment considerations 
A full understanding of mechanisms driving the amelioration of symptoms following B-cell 
depletion is yet to be fully elucidated.   Rituximab may exert some effects by depletion of B-
cells in peripheral blood and more variably in the synovium. The initial concept driving B-cell 
depletion as potential treatment in RA was presumed to be the elimination of autoreactive 
B-cells and subsequent pathogenic plasma cells.  B-cell depletion appears to have wider 
effects, as clinical efficacy may perhaps also be achieved through a reduction in B-cell 
associated cytokines and a reduction in their function as antigen presenting cells [301].   
In most cases, rituximab treatment results in a reduction in circulating B-cells [302], however 
most patients will go on to relapse, with complete remission observed in only a minority of 
patients. The time to relapse, however varies and can be classed as concordant, where the 
return of clinical symptoms correlates with B-cell return in the periphery, or discordant where 
relapse is delayed [303, 304]. Despite these observations, two key questions remain 
unanswered when considering rituximab treatment: 1) the optimal dose and 2) the point in 
time at which patients should be retreated.  
Early trials demonstrated significant improvements in both the 2x 500 mg and the 2 x 1000 
mg dosing regimens [285-287, 290]. A recent systematic review concluded that 2 x 500 mg 
doses of rituximab was non-inferior to 2 x 1000 mg, although there is a statistically significant 
difference between doses and radiographic outcomes, measured through the mean total 
sharp score [305].  Mariette and colleagues randomised patients who had received an 
improvement in disease activity six months after one cycle of standard dose rituximab to 
receive either 1x1000mg rituximab infusion or 2x1000mg [306]. They demonstrate non-
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inferiority of the single-dose regimen with similar improvement in DAS-28 scores and time to 
retreatment.  They noted higher but non-significant levels of circulating IgG in the group 
receiving the lower dose, although there was no difference in the rates of serious infections, 
a trend further confirmed by the aforementioned systematic review. A further report of 
seventy patients who had achieved a EULAR response following three cycles of a standard 
dose regimen found no differences in disease activity if the subsequent dose was decreased 
to 2 x 500 mg [307].  There has been a small open-label study of low dose 1 x 100mg [308] 
and three reported case studies [309-311] of 1x 50 mg and 2 x 100 mg which have resulted in 
B-cell depletion and disease amelioration.  It should be noted, however, that all three case 
reports are from the same centre.  To address this further there is currently a randomised, 
double-blind controlled trial underway to assess ultra-low dose, 1x 500 mg, 1 x 200mg 
compared to standard low dose 1x 1000 mg rituximab [312].  These studies suggest that in a 
subset of patients, low dose B-cell depletion may be enough to establish a clinical response. 
Based upon previous studies and the reduction in radiological damage, however, the current 
recommended dose remains 2 x 1000 mg at fixed intervals [313]. 
 
The second question that remains largely debated is the time of retreatment. Options include 
a fixed treatment regimen (eg every six months), treatment at disease relapse or 
individualised treatment regimens to prevent relapse.  The mean time for retreatment in a 
prospective study was approximately 8.5 months [294], but for some individuals remission is 
achieved for longer [302], which suggests that perhaps retreatment intervals should be based 
on individual profiles in order to prevent full relapse of the disease.  The risk of disease relapse 
and radiographic progression is offset by the increased theoretical risks of infection and low 
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levels of circulating immunoglobulins witnessed with repeat cycles[297, 304, 314].   A 
retrospective study of 177 individuals, in the absence of previous steroid or 
cyclophosphamide therapy, repeat cycles were not associated with an increased risk of 
hypogammaglobulinaemia [315] and infections were not necessarily linked levels of 
immunoglobulins.  Serum immunoglobulin levels are therefore checked and monitored with 
each cycle and reviewed if levels are progressively lower, especially in high risk individuals 
[313]. 
B-cell reconstitution is characterised by newly generated immature B-cells and re-emergence 
of plasma cells.  Naïve B-cells increase and tend to predominate the peripheral compartment 
with a delayed repopulation of CD27+ memory cells, which can remain at low numbers for a 
significant period of time [316].   A concomitant decrease in autoantibodies has also been 
observed following rituximab, indicating that these are likely to be produced by short-lived 
plasma cells which are interrupted by B-cell depletion[317].  The degree of efficacy of 
rituximab has been linked to the degree of depletion[318] and disease relapse is associated 
with the return of memory B-cells [319, 320] as determined by flow cytometry analysis – serial 
measurements however are not feasible in routine clinical practice. 
1.6.4 Current markers of response / resistance to Rituximab  
Response or resistance to rituximab therapy may be modulated by several individual and 
drug-related factors.  Depletion depends on the total number of B-cells and perhaps the total 
dose of rituximab administered, which I have discussed above.  The immune effector 
mechanisms of rituximab are linked directly to endocytosis and binding on the number and 
type of Fcg receptors, which in turn can influence serum drug levels [321, 322].  Differences 
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in internalization between types of CD20 monoclonal antibodies have been described in vitro 
in cells from both SLE and RA patients [323].    Polymorphisms in the FcgR have been 
associated with a diminished response to rituximab [324] and in the development of side 
effects such as late-onset neutropenia[325].  The presence of certain complement regulatory 
proteins have been associated with faster B-cell repopulation[326] and may potentially vary 
depending on the type of monoclonal antibody used[327].   
B-cell apoptosis induced by crosslinking of CD20 molecules with rituximab is dependent on 
intact lipid rafts within the cell membrane [328], which are disrupted by statin therapy.  The 
link between response and statin use is yet to be clearly elucidated in RA – one small study 
suggested that statin use may result in diminished response[329], although others, included 
a pooled retrospective analysis have not demonstrated and differences in clinical 
response[330, 331]. 
 
Studies have shown that the presence of ACPA or RF increases the probability of achieving a 
favourable response to Rituximab therapy.  Early data from 10 European registries which 
included 2019 patients [332] showed that patients who were RF, ACPA or double positive 
achieved better DAS-28 responses than those who did were seronegative.  Further adjusted 
regression analysis confirmed that ACPA positivity and lower DAS-28 at baseline were 
significant predictors of response. Another Italian study in 110 patients showed that the 
number of prior anti-TNF agents, RF and ACPA positivity associated with an ACR 50 response 
by univariate analysis; further multivariate analysis confirmed that the number of TNF agents 
and RF positivity conferred a more positive response to therapy [333]. The SMART study, a 
Rituximab retreatment study involving 208 patients showed that high baseline ACPA 
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antibodies, RF, serum immunoglobulin levels, kappa and lambda light chains (all indicators of 
B-cell activity), were associated with a favourable response to therapy [334].   
 
Further retrospective work on RA patients showed that high ACPA titres resulted in a good 
response to Rituximab therapy with a significant association with a decrease in DAS-28, 
EULAR good response criteria and a EULAR remission criteria [335]. A meta-analysis 
conducted by Isaacs et al, which included 2177 patients from four placebo-controlled phase 
II or III trials showed that seropositive patients respond more favourably than seronegative 
patients to rituximab[336], although titres did not affect the change in DAS.    A meta-analysis 
which included 14 studies and 2103 patients treated with Rituximab showed more mixed 
results [337].  
 
Several other studies have investigated other clinical parameters and response. Couderc et al 
explored retrospective registry data in 1709 patients and found that although men appeared 
to display higher remission rates than women gender played no role in EULAR response.[338] 
One retrospective study has explored whether body mass index can predict response to 
Rituximab therapy.  Data analysed from 114 patients failed to show that BMI affected 
response to B-cell depleting therapy, contrary to results from anti-TNF data [339].   Other 
studies have looked at less commonly measured serological markers as predictors of response 
to Rituximab, including alternative autoantibodies and circulating protein levels.  Lindenberg 
et al demonstrate that a decline in antibodies against mutated citrullinated vimentin was 
predictive for response to Rituximab in 50 patients [340]. 
 
 87 
High sensitivity flow analysis has shown that residual peripheral blood B cells and the return 
of memory B cells are associated with a poorer response and relapse [319, 320]. Early studies 
showed that B cell depletion was variable [319, 320] at six months, and the presence of B cells 
resulted in less favourable outcomes than in those in whom B cells were undetectable. RA 
patients have increased circulating of activated memory B cell populations prior to treatment, 
which seem to persist even after therapy in patients who fail to respond adequately[341]. 
Additionally, RA patients with a lower baseline percentage of circulating CD27+ memory cells 
[342]  seem to have an enriched response to Rituximab therapy, as do those with a lower 
mRNA plasmablast signature[343].   This may be due, in part, to variable depletion in the 
synovium or lymph nodes.   
 
As alluded to previously, B-cell depletion in different compartments is variable [321].  A 
question that remains to be answered is whether migration of B cells from peripheral blood 
to sites of inflammation affects clinical response to rituximab therapy and indeed whether 
this is measurable.  Chemokines play a crucial role in the development and trafficking of B-
cells, in particular CXCL12, CXCL13 and CCL19.  Sellam and colleagues reported a subgroup of 
patients with a lower baseline level of memory B-cells and plasmablasts that showed a good 
clinical response to rituximab  [334, 342]. The group went on to explore whether levels of 
circulating chemokines could be used as predictors of response to B-cell depletion therapy 
[344].  Patients with RA had significantly higher level of B-cell chemokines and that these were 
inversely correlated with CD27+IgD- switched memory B-cells.  CXCL12 and CXCL13 levels 
were not associated with clinical response to Rituximab at baseline, whereas they observed 
an association between the log-transformed CCL19 level with a EULAR response.  This study 
however did not include matched synovial tissue or fluid, leading the authors to speculate 
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that the higher levels of circulating chemokines in the peripheral blood lead to an increased 
proportion of activated B cells being recruited to the site of inflammation. 
 
Lending support to this hypothesis is the presence of activated B-cells and ectopic lymphoid 
structures in the synovium.  Mononuclear cell aggregates at the interface of the synovium 
and bone marrow have been found to contain mature memory-switched B-cells and 
numerous plasma cells [345].  Tertiary lymphoid organs, or ectopic lymphoid structures are 
also found at sites of inflammation in both infection and autoimmune diseases and have been 
well characterised in RA synovium. Previous ex vivo data has supported a role for B-cell 
aggregates in disease pathogenesis via functioning as survival niches for autoreactive B cells 
[346]. Subsequent in vivo data supported this concept demonstrating that response to 
rituximab is associated not simply with degree of synovial B cell infiltration but suggesting 
that modulation of functionality is important.  Certainly synovial plasma cell depletion [347] 
and modulation of immunoglobulin synthesis [348] have been associated with clinical 
response whilst persistent circulating pre plasma cell precursors (presumably originating from 
solid tissue such as synovium) associated with treatment resistance [320, 349, 350].  Further 
analysis from the VC gene repertoire within the synovium also shows accumulate plasma cell 
clones suggesting that these are produced within locally generated niches [351].  
1.6.5 Synovial depletion of B-cells 
Several small, open label studies have been undertaken to ascertain the effects of Rituximab 
on the synovium.  A study of 17 patients with refractory RA treated with Rituximab showed 
that at 4 weeks, there was significant depletion of synovial B-cells. 3 biopsies demonstrated 
no B-cells prior to treatment.  3 patients showed complete B-cell depletion, whereas this was 
 89 
incomplete in 11.   The early timepoint of the biopsy precluded any correlation within clinical 
response and specifically the relationship of B-cell presence to clinical response was not 
assessed. [352] 
The same group extended this study to 24 patients (including those in the original study) 
[347], with biopsies taken at baseline, 4 weeks and 16 weeks post treatment.  They reported 
that baseline B-cell levels did not correlate with clinical response, although there was an 
association noted with progressive plasma cell depletion at the 6-month primary endpoint.  
Additionally, there was a decrease in T-cell numbers and lymphocyte aggregates that did not 
correlate with clinical response. 
In the ARISE study, 13 patients underwent biopsies at baseline and 8 weeks post treatment 
(without peri-infusional steroids).  This group demonstrated a non-significant trend 
associated with B-cell depletion and clinical response and a significant reduction in 
immunoglobulin synthesis in clinical responders [348]. 
A further study from Leiden with 25 patients who underwent biopsies at baseline and 12 
weeks post-treatment (with perinfusional corticosteroids) found no association with clinical 
response and the level of B-cell depletion (CD79a+ cells).  This group followed this with a study 
of 20 patients with biopsies at baseline, 12 weeks and 21 weeks post treatment.  They 
demonstrated a gene expression signature within the synovium that enriched for clinical 
response.  Of particular relevance, poor responders showed increased expression of 
interferon alpha and remodelling genes.   They also found that a low disease activity state 
correlated with low synovial levels of plasma cells  [353, 354]. 
All of these studies demonstrate that treatment with Rituximab, at least in the early phase, 
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does result in depletion of B-cells in the joints of RA patients.  To determine correlation with 
clinical response, however, proves more problematic.  This can be attributed to the small 
numbers of patients included within these studies, the variations in biopsy sampling time-
points and the differences in the use of peri-infusional medications which makes it difficult to 
extrapolate findings to the clinical setting.  No studies have directly assessed the question of 
the number of baseline B-cells and overall clinical response.  Finally, B-cell depletion within 
the synovium may not be the primary determinant of overall clinical response, although it 
may be associated with resistant disease or relapses within individual joints. 
1.7 Synovial histology: a new biomarker of response? 
1.7.1 Methods of synovial tissue acquisition 
Recent advances in the acquisition of synovial tissue have enhanced our understanding of 
disease pathogenesis and have allowed the identification of biomarkers of prognosis and 
response[355, 356]. Arthroscopy has been utilised heavily in clinical trials and has to date 
been the gold standard for synovial tissue sampling [357] but is limited by the specialist 
training that is required, high cost and complications [358].  Arthroscopy is limited to large 
joints, which preclude its use in the earliest phases of disease where often small joints are 
more likely to be affected.  Minimally invasive techniques include the blind needle biopsy, 
portal and forceps technique and US guided procedures, which are both cheap and require 
less technical expertise to perform.  Furthermore, they increase access to both large and small 
joints[359]. Following the insertion of a guidewire under US guidance, the portal and forceps 
technique utilises a Hartmann’s forceps for tissue extraction [360].  A minimally invasive 
technique using a 14- or 16-gauge QuickCore (Cook Medical) needle has been described as a 
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safe and tolerable procedure which results in sufficient tissue for both histopathological 
analysis and mRNA extraction [361, 362]. Of importance, the technique does not alter 
subsequent pain scores or power doppler scores [363] and can therefore be reliably used in 
serial biopsies to monitor disease progression before and after treatment.  Figure illustrates 
the different methods of synovial tissue acquisition. 
A recent multicentre study [364] has validated the use of US guided techniques using 159 
procedures from five different centres. 25 arthroscopic, 35 US guided portal and forceps, 11 
US needle biopsies and blind needle biopsies were performed on large joints; there were no 
significant differences in the amount of graded tissue samples or total gradeable tissue area 
between the different techniques, with the exception of the blind needle technique.  41 
procedures were carried out on small joints (11 US guided portal and forceps, 20 US-guided 
needle biopsies and 10 blind needle biopsies).  34 sequential biopsies were also included for 
evaluation.  Again, no significant differences were observed between the groups.  This 
supports the notion that US guided synovial biopsies can be incorporated into clinical trials to 
provide reliable synovial tissue for analysis and crucially, for sequential biopsies following 
therapeutic intervention.  The authors do note limitations, however, as only limited tissue is 
available for RNA extraction and therefore dependent on study design, arthroscopy may be 
preferential for several experiments which require tissue for molecular analysis.  
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Figure 1.3 Methods of synovial tissue acquisition, from [364] with permission from John 
Wiley    
A Arthroscopic sampling of the knee joint, inset depicts direct vision of synovial tissue, B Ultrasound guided 
portal and forceps technique, inset depicts the needle in the suprapatellar pouch, C Blind needle biopsy of the 
knee joint D US-guided synovial biopsy of the wrist joint, inset depicts the needle within the joint space 
 
1.7.2 The Normal Synovium 
The synovium is the primary site of insult in RA.  It is an ectoderm derived soft tissue lining 
which covers the surfaces of diarthrodial joints, tendons and bursae.  It consists of an intima, 
characterised by the presence of macrophage-like and fibroblast-like synoviocytes and a 
subintimal layer composed of fibroblasts, collagen-containing extracellular matrix and a 
supply of nerve fibres, blood and lymphatic vessels.   The presence of hyaluronic acid between 
intimal cells ensures fluidity of movement between tissues. [365] Normal synovium is only 1-
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2 cells (20-40mm) thick and is associated with a relatively acellular subintimal layer with few 
resident immune cells and vascular structures.  Thickness varies across different tissues, 
bursae and tendons, mirrored by varying amounts of synovial fluid. 
Three different patterns of synovial tissue have been described: fibrous, areolar and adipose, 
based upon the content of the subintimal layer.  [365]  CD163 and CD68 macrophages, 
derived from circulating monocytes are found in the normal intima, expressing a FcIIIg 
receptor.  These cells are also known as type A synoviocytes.  CD55 expressing fibroblasts, or 
type B synoviocytes, are also found in the intima and subintima, with interspersing dendritic 
cells that can act as antigen presenting cells.  These cells are usually derived locally.   The 
latter  cell population also express adhesion molecules such as vascular cell adhesion 
molecular-1 (VCAM-1), intracellular adhesion molecules (ICAM)-1, CD44 and integrins.  [365]  
Small numbers of CD3+ cells and occasional B lymphocytes may also be found within the joint  
[366].  The normal cytokine milieu in the joint favours suppression of inflammation and 
maintains joint homeostasis.  Low levels of IL-1, IL-5 and TNFa and receptor activator of 
NFKB/rank ligand are detectable within the joint; however appear to be countered by higher 
levels of inhibitory antagonists and osteoprotegerin  [365, 366].  The findings described are 
significantly altered in the presence of disease. 
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1.7.3 Changes in the diseased synovium 
So far, I have discussed risk factors, the break of tolerance and the critical roles of antigen 
processing, T and B cell differentiation in the disease.  The hallmark of RA, however, is synovial 
inflammation.  Innate immune cells and those from the adaptive immune system infiltrate 
the joint to create a pro-inflammatory environment, propagated by cross talk between cells 
and the influx of cytokines, chemokines and newly differentiated immune cells.   The result is 
hyperplasia of the synovium and conglomeration of immune and inflammatory cells, termed 
pannus formation.  The synovial lining thickens following macrophage and synovial fibroblast 
proliferation; predominantly infiltrating Type A fibroblasts.   Bone and cartilage destruction 
are mediated by the release of matrix metalloproteinases, serine proteases, aggrencases 
released by macrophages, further enhanced by osteoclast activation and subsequent bone 
and cartilage loss.  The synovium becomes hyperplastic, resulting in both pain and swelling. 
Influx of inflammatory cells is accompanied be neoangiogenesis within the sublining layer to 
allow transfer of oxygen and nutrients.  Numerous growth factors, chemokines and cytokines 
regulate vessel formation.  The presence of vascular growth endothelial factor (VGEF),  
platelet derived growth factor and hepatocyte growth factor has been demonstrated in 
synovial tissue and in fluid.  This is countered by inhibitors of angiogenesis such as endostatin 
and thrombospondin 1 and 2, indicating that there may be dysregulated balance between 
neovascular promotion and angiostasis.  [237, 367] 
1.7.4 Patterns of synovial infiltration 
Three distinct patterns of immune cell infiltrate have been described in the synovium. Of most 
critical relevance are highly organized tertiary lymphoid structure (30-40%), the second 
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pattern is a diffuse pattern of infiltrating cells and the third, most recent pattern that has 
been described is a pauci-immune synovitis  [368, 369].    These patterns are not mutually 
exclusive and it has not yet been ascertained whether they are dynamic at different stages of 
the disease or distinct subtypes of RA. 
What is of interest, however, is that these synovial pathotypes have been shown to segregate 
with specific transcriptomic signatures.  Three recent patterns have been described: 
Lymphoid, myeloid and fibroblast associated patters as determined by specific gene sets and 
appear to correlate with histomorphological subtypes [356]. Gene expression tends to 
associate with specific patterns or families; for example, B-cell associated genes segregate 
predominantly with the lymphoid phenotype.  Furthermore, there are some signals indicating 
that they may be predictive of response to treatment[356]. 
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Figure 1.4 Synovial heterogeneity in RA   
Examples of follicular, diffuse and pauci-immune synovitis.  RA synovial tissues stained by haemotoxylin and 
eosin (H&E), and by immunohistochemistry H&E for B cells (CD20), T cells (CD3) macrophages (CD68 and plasma 
cells (CD138). From [369] with permission from Wiley materials. 
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1.7.5 Ectopic Lymphoid Structures (ELS): pathogenic players or bystanders? 
The lymphoid pattern of synovitis is characterised by the presence of B and T cells which are 
found in up to 40% of individuals with RA.  ELS form at sites of chronic inflammation and have 
been described in several diseases, including RA and Sjogrens syndrome in synovium and 
salivary glands, respectively  [370].  Within the joint, they are characterised by aggregates of 
T and B cells, the presence of high endothelial venules and may or may not express CD21 
follicular dendritic cells and the expression of AID, when they are coined tertiary lymphoid 
organs.   
Within the synovium, B-cells have a crucial role in the regulation of lymphoid tissue 
architecture within lymphoid organs and at peripheral sites. Ectopic lymphoid structures (ELS) 
are present in approximately 5-25% of patients with RA within the synovium. Key cytokines 
and chemokines such as IL-7, IL-21, LTα, LTβ, TNFα, RANKL, CXCL13, CCL19 and CCL21 are 
known to be instrumental in their formation. It has been demonstrated that synovial ELS are 
functional, and support the self-sustaining differentiation/survival of B cells and 
plasmablasts/plasmacells (PB/PC) that continue to produce class switched IgG ACPA when 
ELS+ve synovial tissues are transplanted into Severe Combine Immunodeficent (SCID) mice, 
in the absence of new cells coming into the grafts [346]. It is therefore possible to postulate 
that one mechanism for resistance to Rituximab may be due to the “escaping” of auto-
reactive B cell PB/PC clones surviving in “protected” niches within the joint.  
The pathogenic role of ELS in disease has been debated.  However, there are now several lines 
of argument that exist to suggest functionality for lymphoid structures within the synovium.  
It has been shown that ELS within the joint express AID and are capable of ongoing SHM and 
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CSR, suggesting that the synovium could form a niche where there is ongoing activation and 
differentiation of autoreactive B-cells [346].  Furthermore, circular transcripts resulting from 
CSR continued to be expressed when engrafted into SCID mice, indicating that ongoing 
antibody production is possible even in the absence of new immune stimuli  [346]. This finding 
is also supported by the recognition that analysis of the V-gene repertoire displays expanded 
clonal subsets with highly mutated V regions, suggestive a local antibody mediated process. 
 
1.7.6 The synovial biopsy as a potential biomarker  
Whether distinct synovial pathotypes can predict outcome to treatments remains unknown. 
Interpretation of previous synovial biopsy-based studies is difficult, as studies have varied in 
methods of tissue acquisition and the timing of biopsies in relation to the disease process. 
Furthermore, there is no agreed method of grading lymphocytic infiltrates and infiltrating 
immune cells.  Finally, there are few published gene expression studies specifically addressing 
modulation of both imaging and the synovium following therapy.   
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1.8 Summary and hypotheses 
RA is a heterogenous disease, characterised by distinct synovial and molecular phenotypes.  
Despite an increase in imaging modalities, new technologies and a growing number of 
therapies, tailoring treatment at an individual level remains a desirable goal.  Treatment is 
still based on ‘trial and error’, resulting in progressive damage until the right therapeutic 
target is met.  Although a successful treatment for some, a sizeable proportion of patients fail 
to respond to Rituximab therapy.   
The aim of this thesis is to examine the hypothesis that distinct histological and molecular 
pathoypes, i.e. B-cell or lymphoid rich within the synovium can segregate responders and 
non-responders following B-cell depletion.   
The specific aims are to identify whether: 
1. A specific B-cell rich synovial pathotype can predict response to Rituximab therapy 
and whether response is associated with changes in immune cell infiltration following 
treatment 
2. The molecular signature of the synovium can predict response to Rituximab therapy 
and to explore the immunomodulatory effects of Rituximab on the synovium 
3. Treatment with Rituximab correlates to changes in synovial thickening and power 
doppler graded using ultrasound and whether this associates with histological and 
molecular changes  
4. The synovium can be used as a predictive tool to predict response to Rituximab 
therapy by combining clinical, transcriptomic and imaging data 
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Methods 
General protocols are described within this chapter, more detailed descriptions will be 
provided in each experimental chapter.  
 
2.1 Study Population 
25 patients with active RA were enrolled to an open-label observational study which formed 
a pilot cohort for a Randomised, open labelled study in anti-TNFa inadequate responders to 
investigate the mechanisms for Response-Resistance to Rituximab versus Tocilizumab in RA 
(R4RA) trial which is led by Professor Pitzalis at Barts Health National Health Service Trust.  
One patient withdrew from the study. All patients had to be over 18 and meet the 1987 
American College of Rheumatology criteria for RA.  Patients were included if they were 
eligible to receive Rituximab therapy according to the National Institute of Clinical Excellence 
(NICE) Guidelines. All patients had failed traditional DMARD therapy. To be eligible for 
Rituximab therapy patients had to have active disease DAS-28³ 5.1, been deemed a non-
responder or have a contraindication to anti-TNF therapy.  Inclusion and exclusion criteria are 
fully described in table 2.1. 
 
As this was an observational study, patients had no restrictions on the use of methotrexate 
or other DMARDs.  Oral prednisolone was permitted at a dose of £10 mg per day provided 
this was stable for four weeks prior to any biopsy visits.  All patients underwent an ultrasound 
guided synovial biopsy of a clinically inflamed joint at baseline.  Optional repeat biopsies were 
performed at 16 weeks and at 52 weeks.  Patients were given 1g of paracetamol, 10 mg of 
chlorphenamine intravenously and intravenous methylprednisolone 100mg as pre-
medication.  Rituximab 1000mg was administered at day 0 and day 15.  The cycle was 
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repeated at physician’s discretion at flare.  The study received local ethical approval and all 
patients gave informed consent.  (REC 10/H1109/23). 
 
A flow-chart of patients that were available for each section of the analysis is described in 
figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Flow diagram of patients enrolled in the study 
 25 patients were enrolled, 1 patient withdrew before the start of the study, 2 patients withdrew prior to the 
end of the study.  Biopsies were deemed gradable if there was a presence of a clear lining layer in the tissue, 18 
paired samples were available for comparison.  20 samples had sufficient RNA available for Fluidigm gene 
analysis.  Only 14 patients had paired images available for analysis of ultrasound data, this was due to a change 
in ultrasound machines and storage during the study and due to patients who attended for the biopsy, but did 
not stay for US assessment. 
 
 
25 patients enrolled 
22 patients completed 
study with paired 
clinical data available 
at 16 weeks 
20 baseline biopsies 
available; 18 paired 
gradable biopsies 
available for 
histological analysis 
22 biopsies at 
baseline, 20 paired 
biopsies available for 
RNA analysis 
14 paired US 
timepoints available 
for analysis 
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Table 2.1 Inclusion and Exclusion criteria for the R4RA pilot study 
Inclusion Criteria Exclusion criteria 
Patients with 1987 ACR classification for a diagnosis 
of RA 
Women who are pregnant or breast-feeding 
Patients who have failed or have a contra-indication 
to anti TNF therapy  
History of current inflammatory joint disease or other 
autoimmune disease other than RA 
Eligible to receive Rituximab according to NICE 
guidelines 
Treatment with any investigational agent £ 4 weeks 
prior to baseline 
Over 18 years of age Intrarticular or parenteral corticosteroids £ 10mg 
prior to baseline 
Capable of giving informed consent and comply with 
study visits and procedures 
Active infection 
 Septic arthritis within a native joint in the last 12 
months 
Sepsis of a prosthetic joint within 12 months or 
indefinitely if joint in situ 
Known HIV of Hepatitis B/C infection 
Latent TB 
Malignancy (other than basal cell carcinoma in the 
last ten years) 
New York Heart Association grade 3 or 4  
Demyelinating disease 
Latex allergy or allergy to rituximab 
Presence of a transplanted organ 
Known recent substance abuse 
Poor tolerability of venepuncture of lack of adequate 
venous access for blood sampling 
Patients unable to tolerate synovial biopsy or on oral 
anticoagulants  
Patients recruited to other clinical trials  
Other severe acute or chronic medical or psychiatric 
condition which would impart excess risk 
(investigator’s judgement) 
Abbreviations: ACR = American College of Rheumatology, RA = rheumatoid arthritis, NICE = National Institute of 
Clinical Excellence  
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2.2 Clinical Assessments 
Patients were seen at baseline and then followed-up monthly for twelve months.  Clinical 
assessments included the number of tender joints, swollen joints, a patient visual analogue 
scale assessment, a patient’s pain score and a physician’s global activity of disease assessment 
score.  Health assessment questionnaires (HAQ) were performed at baseline, 3,6,9 and 12 
months.  The primary end point of the study was improvement in DAS-28(ESR) scores at 16 
weeks. 
 
2.3 Laboratory assessments 
At baseline, blood was sampled for erythrocyte sedimentation rate, c-reactive protein, Ig-M 
Rheumatoid Factor determined by nephelometry and ACPA determined by a second- 
generation enzyme-linked immunoassay. Immunoglobulin levels of IgA, IgM, and IgG and B 
and T- cell subsets were measured prior to Rituximab infusion. Full blood count, urea and 
electrolytes, liver function tests, ESR and CRP were performed monthly. Additionally, blood 
was sampled and stored for peripheral blood mononuclear cells isolation at weeks 0, 12, 16 
and 54.  
 
2.4 Radiographic assessments 
Plain x-rays of hands and feet were performed at baseline to assess the presence or absence 
of erosions. 
2.5 Ultrasound Assessments 
At baseline and at 16 weeks standard longitudinal images of the 1st to 5th 
metacarpophalangeal joints and radial, midline and ulnar views of both wrists were acquired 
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by myself and two other investigators using a GE logic 9 ultrasound machine with a 2-
dimensional M12L transducer (14MHz) at room temperature (20-22 degrees).  Images were 
assessed by myself and a blinded assessor (Ilias Lazarou) on a 0-3 scale for synovial thickening 
and power Doppler activity in accordance with EULAR-OMERACT synovitis scores [371], with 
excellent interobserver correlation coefficients.  Any differences were resolved by mutual 
agreement and by an independent assessor, Dr. Stephen Kelly.  Minimal probe pressure was 
applied in order to maintain at least 1 mm gel between the probe and skin.  A region of 
interest was selected using the power doppler colour box facility, with doppler settings 
adjusted to the lowest possible pulse repetition frequency.  Detailed description of scoring is 
seen in Figure 2.2. Briefly, for each patient baseline and 16 week scores were calculated by a 
0-3 scoring system to quantify synovial thickening (ST) and power doppler (PD) at the single 
joint level.  Addition of the total MCP score and mean score at the wrist, giving a total of 12 
joints with a minimum score of 0 and a maximum score of 36.  To summarise, settings were 
as follows: Grey scale frequency 14 Mhz, Power doppler frequency 7.5 MHz, gain 41, PRF 1.4 
kHz and wall filter 127 Hz.  Images were stored in a DICOM format and transferred to 
ImagePro, an imaging processing program.  
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Figure 2.2 Semi-quantitative US scoring methods using the recommended EULAR-OMERACT 
scoring methods from [371], with permission from BMJ publishing group 
(a) depicts scores of grey scale synovitis; G0 = no hypoechoic synovial thickening, G1 = minimal hypoechoic 
synovial thickening, G2 = Hypoechoic synovial thickening extending beyond the joint line but with upper surface 
convex or flat G3 = Hypoechoic synovial thickening extending beyond the joint line with upper surface convex, 
bulging over the periarticular bones 
(b) depicts scores of PDUS PD 0 = no flow in the synovium, PDUS 1 =  up to 3 single spots or 2 confluent spots, 
or 1 confluent and 2 single spots, PDUS 2 = Signals in less than 50% of the synovial area, PDUS 3 = signals in 
>50% of the synovial area 
 
2.6 Ultrasound guided synovial biopsy 
This procedure was performed as detailed [361] by trained operators: myself, Dr. Nora Ng, 
Dr. Frances Humby and Dr. Stephen Kelly.    Briefly, using a GE Logic 9 ultrasound machine 
with 2-dimensional M12L transducer , 1-3 mls of of local anaesthetic are injected into the soft 
tissues until the joint capsule under direct ultrasound guidance.  A further 2-5 ml of local 
anesthetic may be infiltrated into the joint, up to 15 mls may be used for large joints.  A Quick-
Coreâ Biopsy Needle (Cook medical, Limerick, Ireland) is then placed inside the joint under 
direct vision.  A minimum of 6 biopsy samples were retrieved and fixed in 4% formaldehyde.  
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A further 6 samples were placed in RNA-Later (Ambion) RNA stabilisation solution for 
subsequent RNA extraction [361], stored at -80°Celsius until ready for use. 
 
Figure 2.3 Ultrasound guided biopsy of the wrist joint 
 Inset shows the needle within the joint space above the scaphoid-lunate junction.   
Picture courtesy of Dr. Stephen Kelly. 
 
2.7 Sample fixation and staining 
The following methods are currently utilised within the experimental medicine and 
rheumatology laboratory and have been previously optimized for similar work. They make up 
part of the standard operating procedures (SOP) within the laboratory.  This part of the work 
was undertaken by Dr. Vidalba Rocher, Dr. Sudeh Riahi and Dr. Alessandra Nerviani. 
 
Following synovial biopsy, fresh tissue was fixed in 4% formaldehyde and kept at room 
temperature for 24 hours.  This tissue was then placed into embedding cassettes and the 
following protocol was used for processing: 70% ethanol (two changes, 1 hour each), 80% 
ethanol (two changes, 1 hour each),95% ethanol (two changes, 1 hour each), 100% ethanol 
(two changes, 1 hour each), Xylene, (three changes, 1 hour each). The tissue samples were 
then embedded in paraffin wax and left on a cold plate for approximately 20 minutes until 
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completely set.  Once embedded, samples were stored at room temperature in boxes until 
use.  
 
2.8 Sample cutting and sectioning 
Tissue samples were placed on ice to cool for two hours before being cut to 3 µm thick 
sections on a Leica microtome (Knowlhill, UK).  The sections were floated on a warm water 
bath at 40°C prior to being picked up on sequentially numbered Superfrost plus slides.  Excess 
water was permitted to drain off before being placed on a hot plate at 60°C for thirty minutes.  
These are then removed and stored at room temperature. 
 
Prior to any staining, tissue must be deparaffinised and rehydrated, allowing the tissue to 
become permeable again.  Slides were first immersed in xylene (2 changes, 10 minutes each) 
followed by 100% ethanol (2 changes, 5 minutes each). They were then rinsed with distilled 
water and placed in Tris buffer saline until used. 
 
2.9 Haemotoxylin and Eosin Staining 
Haemotoxylin and eosing (H&E) staining allows both the differentiation and visualization of 
nuclei and the cytoplasm of cells under light microscopy.   Haematoxylin stains chromatin 
found within the nuclei of cells a purple, whereas eosin stains cytoplasm and connective 
tissue pink.  Following rehydration, slides were immersed in Mayers haematoxylin for 4 
minutes, rinsed and placed in 1% alcohol for a few seconds to remove any excess 
haematoxylin.  Slides were then washed with distilled water and placed in eosin for 5 minutes.  
This was followed by washing in tap water, dehydrated with absolute ethanol (2 changes, 3 
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minutes each), followed by xylene (2 changes, 3 minutes each).  Any excess solvent was 
blotted.  The slides were then fixed using DPX mounting medium.  (Sigma, UK). 
 
2.10 Immunohistochemistry 
This technique relies on the binding of an unlabelled primary antibody to a target antigen in 
the tissue.  A further labelled secondary antibody reacts with the primary antibody and allows 
localization of the antigen of interest.  The secondary antibody can be 1) either directly linked 
to an enzyme or 2) conjugated to several biotinylated secondary antibodies that can recruit 
enzyme linked avidin complexes.  The latter requires a chromogen which results in light 
emission on reacting with the enzyme, resulting in colour precipitation at the antibody 
antigen binding site. Sequential sections underwent immunohistochemical staining and semi-
quantitative scoring (SQ) (0-4) for CD3+ T cells (F.7.328 Mouse, DAKO), CD68+ lining and 
sublining (sl) layer macrophages (KP1 mouse, DAKO), CD20 (L-26 mouse, DAKO) CD138+ 
plasma cells (M115 mouse, DAKO) and CD21+ follicular dendritic cells (1F8 mouse, DAKO) 
using our laboratory protocols.  
 
2.11 Scoring of synovial tissue 
Semi-quantitative (SQ) scores from 0-4 were performed using a standardised atlas by two 
observers (BH and VR) blinded to patient identification and any discrepancies in scores 
resolved by mutual agreement.  I also scored each sample independently. H&E samples were 
first scored according to the presence and/or size of lymphocytic aggregates as described by 
Manzo and colleagues [240].  Grade 1 (G1) display a radial cell number between 2 and 5, grade 
2 (G2) between 6 and 10 and grade 3 (G3) were defined as greater than 10 cells. Germinal 
centres were identified on IHC staining, characterised by the presence or absence of CD21+ 
 110 
FDC networks.  Sections stained for immune cell markers then underwent SQ scoring (0-4) for 
CD3, CD20, CD68L, CD68 SL and CD138.  A score of 0 represents minimal cellular expression 
and 4 high expression.  The total synovitis score was determined by the method described by 
Krenn [372].  Briefly, three features – the thickening of the lining cell layer, cellular density 
and cellular infiltration of leucocytes were graded on a 0-3 scale, from absent to strong.  
Summation of the three scores then provides a synovitis score from 0-9.  
 
Samples were further classified as ‘lymphoid’ based on large numbers of G2/G3 aggregates, 
‘myeloid’ based on the absence of aggregates but the abundance of macrophages and ‘pauci-
immune’ based upon the absence of aggregates and immune cell infiltrate. 
 
Samples were also further stratified into ‘B-cell poor’ (CD20 0-1) or ‘B-cell rich’ (CD20 2-4) 
following a new algorithm which was upon previous scoring methods [373]; detailed 
description of this will follow in the next chapter.  
 
2.12 RNA extraction  
This was done in accordance with our laboratory SOP by Dr. Vidalba Rocher.  Briefly, tissue 
samples were homogenized in TRIZOL reagent using a power homogenizer after shearing with 
a 26 guage needle.  Samples were centrifuged according to instruction at 20,000 rpm for 10 
minutes at 4°C.  The supernatant contained the RNA.  Chloroform was added and after 
shaking for 30 seconds, incubated on ice for 2 minutes and recentrifuged.  The sample further 
separated into a phenol-chloroform phase, interphase and an aqueous RNA containing phase.  
This was removed and added to isopropyl alcohol, incubated, recentrifuged for 40 minutes at 
4°C.  RNA precipitation was followed by a 70% ethanol wash which was then removed and 
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the RNA pellet left to dry.  This was then resuspended in Baxter water, quantified and stored 
at -80°C. 
All RNA samples were quantified using spectrophotometric analysis performed by a 
Nanodrop-1000 v. 3.2.I Spectrophotometer (Thermo Scientific). RNA integrity was 
determined by electrophoresis on tissue samples using the Agilent 2100 Bioanalyzer. (Agilent 
Technologies, California, USA).  
2.13 High throughput quantitative real-time polymerase chain reaction (PCR) 
High-throughput quantitative real-time PCR for 190 genes, pre-selected according to known 
role in RA/B cell biology (Appendix 1), was performed using the Fluidigm© platform (Fluidigm 
Corporation, South San Francisco, California, USA) as per manufacturer’s protocols, described 
further in Chapter 4.  PCR was carried out on the samples by the MedImmune laboratory. 
2.1 Statistical Analyses 
Statistical analysis is further described in each chapter in detail. Ordinal variables are 
described as median (interquartile range), continuous variables are expressed as means ± 
standard deviation.  Categorical variables are expressed as whole numbers and percentages.   
Analysis of clinical and histological data was performed using the Wilcoxon signed rank test, 
Spearman rank correlation coefficient, Fishers’ exact test and Mann-Whitney U-test as 
appropriate.  Analysis of gene expression data was performed using R programming language 
and is described in more detail in chapter 5. 
Unless stated, the cut-off for significance was P<0.05 for all tests. 
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Chapter 3: B-cell depletion: clinical, biochemical and 
synovial predictors of response 
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3.1 Introduction 
Despite a growing number of therapies available to treat RA, predicting response to 
treatment remains a clinical challenge.  Rituximab has been shown to be an effective and safe 
therapy for patients who have active RA and have not responded to or have contraindications 
to anti-TNF therapy, yet up to 40% of patients remain resistant to therapy [286].   Several 
studies have examined clinical predictors of response; however, data remains limited and 
clear clinical parameters at baseline, other than RF and ACPA positivity, are yet to be 
elucidated.  A key question that arises, however, is whether the presence of B-cells in the 
synovium in the absence of organized structures is of pathogenic relevance to the underlying 
disease process, and what score of infiltration suggests a ‘B-cell rich’ pathotype.   
 
As alluded to in the introductory chapter, B-cells play a critical role in the pathogenesis of RA 
through the production of autoantibodies, as antigen presenting cells and through the 
production of proinflammatory cytokines and chemokines which drive inflammation[242].  B-
cell infiltration in the synovium is heterogenous and can range from a complete absence of 
cells to tightly arranged aggregates which are present in 40% of patients with RA[369, 374].  
Furthermore, active germinal centres with CD21+ FDC networks can be seen in up to 25% of 
synovial biopsy samples [276].  ELS produce B-cell specific chemokines such as CXCL13, 
CXCL12 and CCL19 which are critical in promoting migration of B and T cells within the 
synovium and for continued immunological responses [240].  
 
Despite observations that rituximab, an anti-CD20 monoclonal antibody effectively depletes 
CD20+ B-cells in the peripheral blood majority of patients, clinical outcomes remain variable.  
The key questions here are whether a ‘B-cell rich pathoype’ can predict response to rituximab 
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and whether response correlates with the number of pre-treatment B-cells and the presence 
of ectopic lymphoid structures or with levels of depletion following therapy.  Studies exploring 
the role of B-cells in the synovium in response to therapy have thus far suggest that synovial 
depletion of B-cells is variable and may or may not correlate with clinical response. 
 
An early synovial biopsy-based study of 17 patients demonstrated a significant change in B-
cell depletion 4 weeks after the administration of rituximab.  Complete depletion was seen 
only in 3/13 patients who had pre-treatment synovial B-cells but no definite associations with 
response could be drawn due to the early end-point of this study [352].  In a longer study with 
biopsies taken at 16 weeks the authors reported that baseline B-cell numbers did not 
correlate with response, although there was an association with a reduction of plasma cells  
[347].  Kavanaugh and colleagues demonstrated a trend in  synovial B-cell depletion in 13 
patients with biopsies undertaken at baseline and 8 weeks after treatment [348], however 
this was not replicated in a further study of 25 patients where there was no difference in 
responses in patients who had complete versus incomplete synovial CD20 B-cell 
depletion[353].  The latter group did note, however, that high pre and post treatment 
expression of CD79a B-cells predicted non-responsiveness to rituximab and that ACPA IgM 
levels correlated with CD79a/ CD20- B-cells in the synovium, leading to the speculation that 
incomplete depletion of B-cell subsets or local plasmablasts may produce in-situ 
autoantibody production with continued synovial inflammation [354].  
 
The studies mentioned above are observational with limited sample sizes and varying 
timepoints, making interpretation and applicability to larger trials challenging. Given these 
conflicting results, there remains potential to use the synovium as an assessment or 
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prognostic tool to guide optimal treatment.  In addition, the application of minimally invasive 
US-guided techniques to sample synovium [361] offer significant benefits in terms of tissue 
accessibility and thus minimise recruitment bias to clinical trials whilst maximising 
opportunities to serial sample synovial tissue following therapeutic intervention [375], as a 
larger number of joints can be sampled and does not depend on those undergoing surgery as 
in previous studies.   Therefore, in order to address whether baseline synovial pathotype can 
predict response to rituximab therapy I evaluated clinical outcomes from a historical cohort 
of patients recruited for an observational non-blinded pilot study in which patients 
underwent an US guided synovial biopsy pre and post rituximab treatment. 
 
Before using the synovial biopsy as a stratification tool, however, it was critical to formulate 
and validate different scoring methods within the synovium, which I will describe herein.  
Synovial biopsy specimens have been utilised to investigate the underlying disease process in 
inflammatory arthritides for approximately five decades.  More recently, they have also been 
used in order to create molecular signatures of disease and assess response to both DMARD 
and biologic therapy. Several scoring systems have been described over this time period, 
developed in order to reliably compare both the degree of synovial organization and cellular 
infiltrates.  To the best of my knowledge, no study to date has defined a ‘B-cell rich’ 
pathotype.  Defining this was therefore formed the initial part of this work.   
 
The earliest scoring systems correlated macroscopic changes on arthroscopy with histological 
change.  Yates and Scott[376] provide the early descriptions of histopathological scoring on a 
0-4 scale in accordance with descriptions of surface fibrin deposition, synovial cell 
hyperplasia, subsynovial mononuclear cell infiltration, perivascular cellular infiltration and 
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perivascular oedema.  Additionally, they used three random high-power fields to grade the 
intensity of lymphocytic infiltration.  They found a significant correlation between the total 
histological score and total visible synovitis, as well as a correlation between the number of 
active villi and lymphocytic infiltrates but do not comment upon inflammatory cells 
individually.  The same six criteria were utilised to grade synovial biopsies on a 0-10 scale by 
Rooney[377], although the authors themselves comment that such a wide scale increases 
interobserver variability, making it difficult to score.  The Rooney score was further tested in 
a prospective study, where it did not associate with joint progression in established 
disease[378]. 
 
A Japanese pathology group led by Koizumi and colleagues[379] used a 0-3 scale  to grade RA 
synovium using  eight different domains: 1) proliferation of synovial cells; divided into 2) 
degree, 3) palisading and 4)the presence of giant cells, 5) proliferation of synovial stroma, 6) 
presence of synovial granulation tissue, 7) synovial fibrin and 8) synovial haemosiderosis.  This 
study, however used the scoring technique to confirm a histological diagnosis of RA rather 
than OA in synovial tissue samples, rather than to quantify histological severity of the disease.  
They group went on to find no correlation between clinical symptoms and the previous 
Rooney scoring system, although they did find an association with radiographic progression 
in a cross-sectional cohort [380].  The degree of variation and lack of agreement between the 
two scoring techniques proved problematic in terms of utility and application to large clinical 
trials. 
 
Tak and colleagues describe a five-point 0-4 scale according to the cellular infiltrate (0 being 
no inflammatory cells and 4 being significant infiltration) which they proved to be both 
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reproducible and sensitive to change [381-383] for a number of different 
immunohistochemical markers. Furthermore, SQ scoring was comparative to quantified 
analysis undertaken through manual counting (MC), although may not be as sensitive to small 
changes over time [384]. It is widely accepted that MC is both sensitive and accurate, but is 
onerous and time-consuming when the analysis of several samples is required[385]. The 
advent of digital image analysis provided a further quantitative option for researchers. DIA 
allows standard image acquisition and can provide quantification of the areas stained as well 
as the intensity, although the process itself is also dependent on the programs and expertise 
available, uniform staining and tissue quality. Kraan and colleagues demonstrated that the 
three methods were comparable with strong correlations for T-cells, subintimal and intimal 
macrophages with no discernible differences between SQ, DIA and MC except for the time 
taken to score samples [386]. 
 
Normal synovium consists of an intimal lining layer 1-2 cells thick and a synovial sublining.  It 
is thought to be relatively acellular with minimal infiltration of inflammatory cells, although 
variations have been described [365].  Studies focus mainly on the presence of adhesion 
molecules and perivascular lymphocytic infiltrates; little work has been done on the presence 
of B-cells in uninflamed synovium.  Smith and colleagues [366] took normal synovium from 
20 clinically and arthroscopically normal knees and scored the inflammatory infiltrate using a 
semi-quantitative 0-4 score and by digital image analysis.  With specific regards to B-cell and 
plasma cell infiltrate, they found the mean SQ score of 0.1, with a range of 0-1.  They did the 
same with cell count per mm2 using DIA which resulted in a score of 0.6, with a larger 
standard deviation of 1 and range of 0-4 cells per mm2 taken from six high power fields. 
Another study of 12 patients with normal knees undergoing needle-biopsy did not reveal any 
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L26+ B-cells [387].  An older study did show the occasional IgM positive staining lymphocytes 
but does not quantify how many samples or the quantity of circulating B-cells [388].  Post 
mortem studies prior to this are not reliable, given the limitation of available staining-
techniques. 
 
Arguably the presence of ELS, characterized by B and T-cell organization, follicular dendritic 
cell networks and high endothelial venules equates with B-cell rich pathology. A scoring 
system based upon the number of radial cells from a central blood vessel as grade 1 (G1) 
aggregates displaying 2-5 radial cells, grade 2 (G2) between 6-10 cells or grade 3 (G3) with 
>10 cells has been previously described [346, 389] and the same definitions have been used 
for the purpose of this study.  A key question that arises, however, is whether the presence 
of B-cells in the synovium in the absence of organized structures is of pathogenic relevance 
to the underlying disease process, and what score of infiltration suggests a ‘B-cell rich’ 
pathotype. 
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3.2 Hypothesis and Aims 
The hypothesis of this chapter is that a baseline or change in synovial B-cell signature can 
predict response to Rituximab therapy. In order to do this, it is important to elucidate and 
validate the presence of absence of a ‘B-cell rich’ pathotype.  I will then explore whether any 
clinical parameters and synovial pathotypes can be used to discriminate between responses 
to rituximab therapy in RA.   
 
The specific objectives were to: 
1. Ascertain whether B-cell SQ scoring was similar in this cohort to MC and DIA in 
order to validate scoring methods used for the remainder of this work 
2. To agree a ‘cut-off’ value for a B-cell rich pathotype through review of synovial 
samples and further expert opinion 
3. Determine any baseline clinical predictors of response to Rituximab therapy at 12 
and 16 weeks 
4. Describe the pathological characteristics of the synovium in an established RA 
cohort 
5. Determine whether different synovial pathotypes in this cohort correlate with 
clinical phenotypes  
6. Determine whether the presence or absence of B-cells in the synovium, and in 
particular germinal centres, correlates with clinical response to Rituximab therapy 
7. Describe pathological changes in the synovium after Rituximab treatment and 
explore correlations with response to therapy 
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3.3 Materials and Methods 
3.3.1 Study Population 
25 patients all fulfilling the revised 1987 criteria for RA were enrolled to the R4RA pilot study 
between 2009-2014 at Barts Health NHS Trust as described in the methods chapter.  One 
patient withdrew prior to baseline assessments, 2 patients withdrew prior to the study 
completing.  22 patients (18 females, 4 males) completed the study and had paired biopsies 
for analysis.  Of these 18 paired biopsies were available for comparison after excluding those 
where a clear lining layer was not visible, therefore deemed ungradeable. 
 
3.3.2 Patient Assessment 
Clinical parameters including number of swollen and tender joints, DAS-28 scores and c-
reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were recorded at baseline 
and then monthly for a total of 52 weeks.  A health activity questionnaire (HAQ) were 
undertaken at 0, 12, 24 and 52 weeks.  Clinical response to rituximab were assessed using the 
EULAR response criteria at 12 and 16 weeks.  Disease duration, previous number of DMARDs, 
prednisolone dosage and concomitant methotrexate dosage were all recorded at baseline. 
 
3.3.3 Laboratory assessments 
Levels of rheumatoid factor, ACPA, ESR, CRP, immunoglobulins and CD19 levels were 
recorded at baseline.  ESR and CRP were recorded monthly with the remaining variables 
repeated at 16 weeks.  Repeat CD19 levels were taken if a further cycle of Rituximab was 
planned. 
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3.3.4 US guided synovial biopsy 
Standard US images of 5 MCPs and wrists were acquired immediately prior to synovial biopsy.  
Synovial thickness (ST) and power Doppler (PD) scores for each joint were assessed on a 0-3 
scale by a blinded assessor.  The maximum score of 12 joints was determined for ST and PD.  
Synovial samples were taken using ultrasound guided synovial biopsy from all patients with a 
clinically involved joint at baseline.  The same joint was biopsied16 weeks using the technique 
described in the methods section.  A minimum of six synovial samples were retrieved and 
immediately immersed in paraformaldehyde for subsequent paraffin embedding as described 
in the methods chapter.   
 
3.3.5 Formulation of a B-cell Rich Score: comparison of imaging techniques 
The first aim of this chapter was to create and validate a cut-off for ‘B-cell rich vs B-cell poor 
samples.  SQ, MC and DIA techniques were used to score 22 baseline samples. 
Semi-quantitative analysis 
SQ analysis was performed by an independent observer (VR) and myself.  The expression of 
CD20+ cells was scored using a five-point scale as described by Tak and colleagues [381].  
Minor differences were resolved by mutual agreement.  A standardized scoring atlas for CD20 
staining present within the Experimental medicine and rheumatology laboratory at Queen 
Mary University is demonstrated in figure 3.1. 
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Figure 3.1 A semi-quantitative scoring atlas to grade CD20 
Score 0 = no staining, Score 1 = minimal CD20 staining, Score 2 = confluent areas but no aggregates, Score 3 = 
moderate staining beginning to resemble aggregates, Score 4 = dense CD20 staining with the formation of 
aggregates. 
Manual counting 
MC was performed on all sections containing both synovial lining and sublining layers.  Five 
high power fields at x20 magnification (Olympus light microscope) were selected as the most 
inflamed area of each specimen and the cells were counted by eye.  The final cell number 
recorded was the most extreme for each individual block and specimen.  
Digital Image Analysis  
In order to determine the area stained by DIA, I processed the images obtained using an 
Olympus microscope and Cellsens dimension software. Briefly, an overview of each tissue 
section at x20 magnification was constructed using the stage navigator function.  Five high 
power fields which contained both synovial lining and sublining layer were selected and a 
region of interest was drawn around the selected areas.  Using the ‘count and measure 
function’ colour threshold technique I calculated the fraction of synovial tissue stained in 
relation to the total area of tissue selected.  The final result was the mean score of the stained 
area. Ideally, the threshold should be the same across all samples and pre-determined to be 
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applicable to each sample.  Due to variances in tissue quality and staining intensity, I was 
unable to define a minimal colour threshold that could be reliably calibrated and used on all 
samples and therefore this had to be reset for each individual sample. 
 
Expert Opinion 
Based upon this pilot work, our group launched the Randomised, open labelled study in anti-
TNFa inadequate responders to investigate the mechanisms for Response-Resistance to 
Rituximab versus Tocilizumab in RA (R4RA) trial.  As part of this work 22 samples from the 
new study and the samples from this study were also regraded and analysed by an 
independent consultant histopathologist (HR) and the cut off for B-cells were discussed.  
Interobserver correlations were calculated and a threshold for ‘B-cell rich’ or ‘poor’ specimens 
was discussed. 
 
3.3.6 Statistical Analysis 
Continuous variables are expressed as mean ± standard deviations (sd) and ordinal variables 
as median (interquartile range). Spearman’s correlation coefficient was used to determine 
correlations between the three scoring methods.   Comparison of pre-treatment and post-
treatment clinical data and histological analysis was performed using the Wilcoxon signed 
rank test for paired data. For unpaired data, the Mann-Whitney U test was used to analyse 
for differences in median and rank. Associations were performed by deriving the Spearman 
rank correlation coefficient.  Fishers’ exact test of Chi-squared was used to test for 
associations between baseline synovial infiltrate scores and treatment EULAR treatment 
response.   
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All statistical analysis and graphs were derived using Prism (version 7, compatible for 
Macintosh systems).  The cut-off value for significance was <0.05 for all tests. 
 
3.4 Results 
3.4.1 SQ scoring significantly correlates with MC and with DIA 
 
Of the 22 samples analysed, 7 samples were identified as containing B-cells for manual 
counting.  Of these, three had easily identifiable germinal centres, whilst the remainder had 
a diffuse infiltration of B-cells. SQ scoring and DIA were compared to MC which was 
considered the gold standard.  Using manual counting as the gold standard there was a 
significant correlation between semiquantitative scoring and manual cell counts, r=0.95, 
p=0.01.  A similar observation was made when using the DIA method, r=0.8, p=0.03. 
 
 
 
 
Figure 3.2 SQ scoring correlates significantly with both manual counts and digital image 
analysis 
Spearman rank correlation plots of SQ scoring vs manual cell count (p=0.01) and DIA p=0.03, * represents p<0.05.    
Abbreviations: DIA = digital image analysis 
 
0 1 2 3 4
0
50
100
150
200
Semiquantitative Score
M
an
ua
l C
el
l C
ou
nt
Correlation of Manual Cell Count and 
Semiquantitative Scores
r= 0.95**
0 1 2 3 4
0.0
0.1
0.2
0.3
0.4
Semiquantitative Score
DI
A:
 st
ain
in
g 
/ μ
m
2
Correlation of Digital Image Analysis and 
Semiquantitative Scores
r=0.8*
 125 
3.4.2 Manual cell count does not significantly correlate with DIA 
In contrast to the SQ scoring method, I observed a trend towards correlation between the 
manual cell count and SQ scores (p=0.07) but this did not reach significance.   
 
 
Figure 3.3 There is a trend towards correlation between DIA and MC 
Spearman rank correlation plots of MC vs DIA, p = ns 
Abbreviations: MC = manual count, DIA = digital image analysis 
 
3.4.3 Expert opinion and grading in the NHS laboratory defined a B-cell rich pathotype as 
over 50 cells or the presence of aggregates  
An independent expert consultant histopathologist (Dr Hasan Rizvi) also graded 23 samples 
as described above (these were a combination of the pilot data and some samples from the 
R4RA study), with a strong interobserver correlation coefficient (kappa value of 0.87) for 
CD20.  Any differences were reviewed through mutual agreement.  The presence of over 50 
cells by manual counting, with or without the presence of aggregates, were deemed to be ‘B-
cell rich’, as it was concluded that it was unusual to find B-cells in normal uninflamed 
synovium. This was applied retrospectively to all of the samples within the pilot cohort – all 
had a SQ score of 2.  
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3.4.4. A Semi-quantitative B-cell score of 2 correlates with the presence of plasma cells 
I next utilised the CD138 marker to score the newly defined ‘B-cell rich’ group for plasma cells, 
summarised in table 3.1.  Plasma cells were seen in biopsies from five patients, indicative of 
B-cell driven immune infiltration. Furthermore, the presence of plasma cells was exclusive to 
the B-cell rich cohort, leading to the formulation of a new scoring procedure, illustrated in 
figure 3.4.    
 
 CD20 SQ score (0-4) CD138 SQ score (0-4) 
Sample 1 2 2 
Sample 2 2 3 
Sample 3 2 3 
Sample 4 3 3 
Sample 5 4 4 
Table 3.1 Concordance of SQ scoring of CD20 and CD138 scores 
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Figure 3.4 Formulation of a new Standard Operating Procedure (SOP) for grading 
Immunohistochemical samples 
used courtesy of  Dr. Rebecca Hands and the experimental medicine and rheumatology laboratory 
All samples must have a visible synovial lining layer for further CD20 staining to be valid.  If there is discordance 
with the presence of CD138 (plasma) cells then the tissue should be recut and re-stained for CD20.  In the 
absence of aggregates, a CD68 score of ³ 2 defines a myeloid pathotype.  The absence of immune cells but the 
presence of a visible lining layer correlates with a fibroid pathotype.  
 
 
Grading Analysis Requirements
Tissue must have a visible cell lining layer in order to be graded. The radial cell count is 
estimated by counting the number of cells from the centre of the aggregate not from the 
vessel as vessels are not always central to the aggregate. A vessel must be present either 
in or next to the lymphocytes (Perivascular). Mixed infiltrates have to be mainly 
lymphocytic and it must be noted if there is diffuse inflammatory infiltrate present in the 
tissue. Grading Categories: Uniflammed, Diffuse, Grade 1 (between 2-5 cell aggregate), 
Grade 2 (between 5-10 cells), Grade 3 (>10 cells), Ungradable (necrotic/adipose/muscle 
tissue)
H&E grading requirements 
Grading & IHC Scoring Flow 
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3.4.5 Clinical data: Patient Demographics 
The demographics and clinical characteristics of the 22 patients who completed the study and 
had paired synovial tissue available for analysis is shown in table 3.2.  82% (18/22) patients 
were female with a mean age of 52.3 years (SD 13.73).  77% (17/22) were positive for RF and 
86% (19/22) were positive for ACPA.  The median disease duration was 120 months, the 
median number of previous anti-TNF drugs was 1 (IQR 0-4).  32% (7/22) received rituximab as 
first line therapy following DMARDs due to contraindications, including prior malignancy or 
history of multiple sclerosis.  55% (12/22) were taking concomitant methotrexate, the median 
dose was 5 mg.  36% (8/22) were taking a single DMARD and 27% (6/22) were taking more 
than one DMARD at the time of enrolment.  36% (8/22) received Rituximab monotherapy.  
45% of patients (10/22) were taking oral steroids, with a median dose of 0 mg (0-8.75).   
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Table 3.2 Demographics and clinical characteristics of cohort at baseline  
 
  
Age (yrs) mean ± SD 52.4 ± 13.7 
Female, n, (%) 18 (82) 
Median disease duration months (IQR) 120 
RF positive, n, (%) 17 (77) 
ACPA positive, n, (%) 19 (86) 
RF and ACPA negative, n, (%) 2 (9) 
ESR mm/hr median, (IQR) 26 (9-58) 
CRP mg/l median, (IQR) 9 (0-19) 
DAS-28 mean ± sd 5.7±1.0 
SJ median (IQR) 6 (3-9) 
TJ median (IQR) 11 (7.7-22) 
VAS mean ± sd 65.67± 23.98 
HAQ mean ± sd 2.1 ± 0.72 
Erosive≥1 joint n, (%) 18 (82) 
ST median (IQR)  (n=21) 26 (23-30.5) 
PD median (IQR)   (n=21) 3 (2-5.5) 
Median number of previous anti-TNF drugs, 
IQR 
1 (0-2) 
No of patients receiving Rituximab as first 
line 
therapy, n (%) 
7 (32) 
No of patients on methotrexate n (%) 12 (55) 
Median methotrexate dose, mg (IQR) 5 (0-17.5) 
No of patients on prednisolone, n, (%) 9 (41) 
Median prednisolone dose, mg (IQR)  0 (0-8.75) 
 
Abbreviations 
RF=rheumatoid factor, ACPA= anti-citrullinated protein antibody, ESR = erythrocyte sedimentation 
rate, CRP = C-reactive protein, IQR=interquartile range DAS-28= 28 joint count disease activity score, 
HAQ = Health assessment questionnaire, SJ = swollen joints, TJ = tender joints, VAS = visual analogue 
score, ST = synovial thickening, PD = power Doppler, EULAR = European union league of action against 
rheumatism, TNF = tumour necrosis factor 
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3.4.6 Treatment with Rituximab results in a significant reduction in DAS-28 scores at 12 and 
16 weeks 
Data was available for 22 patients at 16 weeks.  1 patient withdrew from the study prior to 
the biopsy and 1 patient was lost to follow-up.  A significant decrease in mean DAS-28 scores 
was observed across the group at 12, 16, 24 and 52 weeks, shown in figure 3.5. The overall 
mean DAS-28 score at baseline was 5.73 (sd ± 1.55).  There was a significant reduction in DAS-
28 scores between baseline and 12 weeks (post-treatment mean DAS-28 4.93, mean D DAS-
28 0.81, p=0.0082) and at 16 weeks post treatment (post treatment mean DAS-28 5.01, mean 
D DAS-28 0.072, p=0.027). At 12 weeks 6/22 (27%) showed a ‘good’ EULAR response, 5/22 
(23%) showed a moderate response.  At 16 weeks this was 2/22 (9%) and 9/22(41%), 
respectively.  Treatment effects continued at week 24 and 52, although these figures are 
harder to interpret as rescue steroids and retreatment were permitted. 16/22 (73%) patients 
were retreated “at flare” during the 52-week follow up period and 14 (64%) patients 
remained on Rituximab therapy at 52 weeks.   
 
Next, I looked at specific components of the DAS-28 scores which improved at each timepoint.  
The number of tender joints did not significantly change from baseline, (median 11, IQR 7.7-
22) to 12 weeks, (median 9, IQR 5-20).  Similarly, there was no significant change at 16 weeks 
(median 7.5, IQR 3-16.25).  There was significant reduction in the number of swollen joints 
from week 0 (median 6, IQR 3-9) to week 12; (median 4, IQR 1.5-7), p=0.003 but this was not 
seen at week 16 (median 5.5, IQR 2-8).  Rituximab treatment resulted in a significant reduction 
in pre-treatment CRP (median 9, IQR 0 -19.3) at week 12 (median 0, IQR 0-11.75, p=0.002) 
and week 16 (median 0, IQR 0-8, p=0.016).  A significant reduction from pre-treatment ESR 
(median 25.5, IQR 9-58) was only seen at the 16 week timepoint (median 22, IQR 9-37), 
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p=0.03.  The VAS also reduced in both groups from baseline (mean 65.7 ± 23.98) to 12 weeks 
(mean 42.85 ± 20.61, p= 0.004) and to 16 weeks (mean 44.86 ± 28.35, p 0.01).  These values 
are summarised in Figures 3.5 and 3.6. 
 
 
 
 
Figure 3.5 Change in DAS-28 score following treatment with rituximab 
Bars represent mean score, error bars represent standard deviation. Wk corresponds to the number of weeks 
after first infusion of rituximab.  *p<0.05, **p<0.01, Wilcoxon matched paired signed rank test 
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Figure 3.6 Individual components of the DAS-28 score following treatment with rituximab 
Bars represent median, lines present interquartile range except *** where bar represents mean and standard 
deviation. Wk corresponds to the number of weeks after first infusion of rituximab.  Abbreviations: ESR =  
erythrocyte sedimentation rate; CRP =  c-reactive protein 
*p<0.05,  Wilcoxon matched paired signed rank test 
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3.4.7 Treatment with rituximab improves quality of life scores up to 52 weeks 
In line with a reduction in DAS-28, a significant reduction in both mean HAQ (pre-treatment 
mean 2.03 ± 0.73, post treatment mean 1.55 ± 0.82) and VAS (pre-treatment mean 63.8 ± 
24.3, post treatment mean 42.6 ± 20.61) were noted at 12 weeks.  This trend continued for 
patients who persisted on rituximab therapy at 52 weeks (post treatment mean 1.66 ±  0.95, 
p=0.02), illustrated in figure 3.7. 
 
 
Figure 3.7 Change in health assessment questionnaire scores following treatment with 
rituximab 
Bars represent mean score, error bars represent standard deviation. Wk corresponds to the number of weeks 
after the first infusion of rituximab.   
*p<0.05, **p<0.01, Wilcoxon matched paired signed rank test 
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3.4.8 There are no differences in clinical parameters at baseline between responders and 
non-responders at 16 weeks 
No clinical differences were found between responders and non-responders at baseline.  
Table 3.3 shows p-values comparing baseline variables between the two groups.  Although 
responders appear to have a higher mean level of rheumatoid factor and CCP at baseline, this 
was not significant.  Interestingly, 8/9 patients who responded to Rituximab had only had one 
anti-TNF prior to therapy, but there was also a high level of non-response in similar patients. 
No differences were observed in DAS-28 or HAQ at all timepoints between patients who 
received rituximab as monotherapy and those on concomitant methotrexate. Additionally, 
no significant correlations were noted between levels of baseline variables and D DAS-28 at 
16 weeks. 
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 Responders (n=9) 
 
Non-responders 
(n=13) 
 
p-value 
DAS-28, mean (sd) 5.82 (0.75) 5.67 (1.23) 0.832 
RF, median (IQR) 
 
215 (11.5-417) 66 (17-271) 0.459 
ACPA, median (IQR) 
 
354 (95-600) 66 (17-271) 0.240 
ESR, mm/hr median 
(IQR) 
 
16 (7.5-44) 38 (9-77) 0.194 
CRP mg/l, median 
(IQR) 
 
9 (0-17.5) 9 (0-45) 0.592 
IgG g/l, median (IQR) 
 
13 (9.3-14.3) 12.05 (9.73-14.9) 0.931 
CD19, median (IQR) 
 
211 (156-221) 205 (134-337) 0.669 
VAS, mean, sd 
 
70.33 (20.95) 62.6 (23.1) 0.544 
Previous anti TNF 
(<1) n, (%) 
 
8 (88) 9 (69) 0.606  
Concomitant 
Methotrexate,  
n, (%) 
5 (55) 11 (85) 0.607 
Methotrexate dose, 
mg, median (IQR) 
5 (0-13.75) 17.5 (0-18.75) 0.39 
Concomitant 
prednisolone, n (%) 
3 (33) 8 (62) 0.39 
Prednsiolone dose, 
mg, median (IQR) 
0 (0-8.75) 5 (0-10) 0.51 
Table 3.3 There are no differences in baseline variables between responders and non-
responders based on the EULAR response criteria 
Unless stated, all values are expressed as the median (IQR) or mean (sd) of each variable.  P-values calculate 
using Mann-Whitney test. 
Abbreviations: DAS-28 = disease activity score, RF = rheumatoid factor, ACPA = anti-citrullinated protein 
antibodies, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, IgG = immunoglobulin G, CD19=  
peripheral blood B cell marker, VAS visual analogue score, TJ = tender joints, SJ = swollen joints 
 136 
3.4.9 Synovial pathotype may be a predictor of response at 12 weeks, but this is dependent 
on the cutting level of tissue 
Initial analysis of this data revealed 5 patients that were deemed to be B-cell rich.  Analysis of 
these five patients resulted in a trend towards response in the B-cell rich group (p=0.09) at 12 
weeks using Fisher’s exact test.  Tissue samples noted to have plasma cells but no B-cells were 
then recut at further levels, resulting in a regrading of three samples, now deemed to be B-
cell rich, thus highlighting the importance of adequate tissue acquisition and cutting levels 
and the need for development of a clear scoring technique.  It should be noted that not all 
the tissues were recut at this point, which would have added further validity to the study. 
 
3.4.10 Synovial pathotype at baseline does not predict clinical phenotype or response to 
rituximab therapy at 16 weeks 
At week 0, 20/22 patients had synovial tissue suitable for histological analysis.   The sites of 
synovial biopsy are represented in figure 3.8.  Patients were divided into ‘B-cell rich’ or ‘B-cell 
poor’ groups as described.  Aggregates were scored from G1-G3 as described in the methods 
section and further scores as lymphoid, myeloid or pauci-immune, summarised table 3.4.   
11/20 (55%) patients were classified as myeloid, 4 were lymphoid (18%) and 5 samples were 
classified as diffuse or ‘pauci-immune’. There were no associations between synovial 
pathotype and response to rituximab therapy (p=0.46, Chi-squared).  8/20 (25%) of patients 
were classified as B-cell rich. Of the B-cell rich category 4/8 (50%) displayed features of G2/G3 
aggregates but none stained positively for CD21.  Out of these 4 patients, two patients did 
not have either RF antibodies or ACPA.  No differences were found in clinical parameters 
between B-cell rich and B-cell poor groups at baseline.  
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Of patients categorised as B-cell rich, 3/8 (37.5%) and 5/12 (42%) B-cell poor achieved a 
EULAR moderate / good response at 16 weeks. (p>0.99) Further classification of the B-cell 
rich group into those with and without aggregates also failed to show an association with 
response to therapy (p=0.76). Baseline histological classifications therefore did not predict 
response to rituximab therapy (table 3.3). 
 
 
Figure 3.8 Distribution of joints that underwent US-guided synovial biopsy 
Abbreviations: MCP = metacarpophalangeal joint 
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Synovial Pathotype 
EULAR response following Rituximab 
Responders, n, (% of 
subgroup) 
 Non-responders, n (% of 
subgroup) 
Lymphoid 3 (60) 2 (40) 
Myeloid 3 (27) 8 (73) 
Pauci-immune 2 (40) 3 (60) 
Table 3.4 Synovial pathotype does not predict response to Rituximab 
p = 0.46, Chi-squared, 2 degrees of freedom. 
 
Histological classification 
EULAR response following Rituximab 
Responders, n, (% of 
subgroup) 
Non-responders, n (% of 
subgroup) 
B-cell poor 5 (42) 7 (58) 
B-cell rich 1 (25) 3 (75) 
B-cell rich + aggregates 2 (50) 2 (50) 
 
Table 3.5 Histological B-cell classification does not predict response to rituximab 
B cell poor = semiquantitative score of 0-1; B-cell rich = semiquantitative score of 2-4, B-cell rich + aggregates = 
SQ score of 2-4 AND the presence of lymphoid follicles. p=0.76, Chi-squared, 2 degrees of freedom 
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3.4.11 B-cell rich patients have a significantly higher degree of synovial cellularity and are 
more likely to be on higher doses of methotrexate and prednisolone 
Next, I went on to examine whether the degree of synovial inflammation differed between 
the B cell rich and poor groups, displayed in Figure 3.9.  No differences were noted in median 
(IQR) semi-quantitative scores for CD68 lining layer macrophage number, B-cell rich 2.75 
(1.25-3) vs B-cell poor 2 (1-3).  There were significant differences in the median synovitis score 
(p=0.013) between the two groups with a higher synovitis score, median 5.5 (3.25-7.7) in the 
B cell rich patients compared with B-cell poor patients median 2.5 (2-3.75).  In addition, there 
were significantly higher numbers of CD3 T-cells, 1.5 (1-2) vs 0.75 (0-1); CD68 SL macrophages, 
2.75 (2-3) vs 1 (1-1.88) and most strikingly in CD138 plasma cells, 3 (2.25-3.75) vs 0 (0-1) in 
patients with a B-cell rich lymphoid pathotype, exhibited in figure 3.9.  This did not, however, 
correlate to clinical phenotype as no significant differences were found between the two 
groups except for the prednisolone dose which was slightly higher in the B-cell rich group, 
p=0.048 and interestingly, median methotrexate dose, p = 0.03 was also higher in the B-cell 
rich group, shown in table 3.6. 
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Figure 3.9 B-cell rich patients display a higher degree of cellularity in the synovium 
Bars represent the median and lines represent the interquartile range 
A Difference in synovitis score between B-cell rich and B-cell poor subgroups, *p<0.05 
B Difference in CD3 T-cells SQ scores between B-cell rich and B-cell poor subgroups, *p<0.05 
C Difference in CD68 sublining macrophages between B-cell rich and B-cell poor subgroups, *p<0.05 
D Difference in CD138 plasma cells between B-cell rich and B-cell poor subgroups  
***p<0.0001, Mann-Whitney test 
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 B-cell Rich B-cell poor p-values 
DAS-28 mean, sd 5.66, 0.57 5.99, 1.15  
RhF, median, IQR 27.5 (3.75-294) 165 (20.5-514.8) 0.33 
ACPA, median, IQR 315.5 (11-600) 116 (71-600) 0.98 
IgG, g/l median, IQR 11.9 (8.6-11.9) 13 (9.87-14.4) 0.79 
ESR mm/hr, median, IQR 31 (10.25-56.5) 30 (8.5-63.5) 0.97 
CRP mg/l, median, IQR 4.5 (0-16.75) 13 (0-32.75) 0.62 
TJ, median, IQR 12 (7.5-20.5) 12 (8.5-22.75) 0.72 
SJ, median, IQR 7 (3.75-8.75) 6.5 (3.75-9) 0.96 
VAS, mean, sd 66 (20.77) 68.35 (29.9) 0.74 
Median disease 
duration 
102 (39-120) 120 (27-120) 0.67 
Number of anti-TNF, 
median, IQR 
1 (0-1) 1 (0.25-2) 0.49 
Median methotrexate 
dose, IQR 
17.5 (8.13-19.38) 0 (0-6.88) 0.03* 
Median prednisolone 
dose, IQR 
7.5 (1.88-10.0) 0 (0-3.75) 0.049* 
Table 3.6 There are no differences in clinical variables between B-cell rich and B-cell poor groups except for 
methotrexate and prednisolone dose 
Unless stated, all values are expressed as the median (IQR) or mean (sd) of each variable.  P-values calculate 
using Mann-Whitney U-test, *p<0.05 
Abbreviations: DAS-28 = disease activity score, RF = rheumatoid factor, ACPA = anti-citrullinated protein 
antibodies, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, IgG = immunoglobulin G, CD19 =  
peripheral blood B cell marker, VAS visual analogue score, TJ = tender joints, SJ = swollen joints 
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3.4.12 The synovial cellular modulatory effects of Rituximab 
In order to determine the effects of rituximab on synovial immune cell infiltration I analysed 
differences in the synovitis score and changes in immune cell infiltration at baseline and 16 
weeks.  Paired data was available for 18 patients. I observed a significant reduction (reported 
as median, IQR) in pre and post CD20 score (pre 0.5, 0-2.25, post 0, 0-125), p = 0.031 and a 
strong trend for reduction in CD138 plasma cells (pre 1, 0-3, post 0.75, 0-2), p= 0.088).  There 
was also a significant reduction in sublining macrophages (pre, 1-3, post 1.25 (1-2), p= 0.039).  
There were non-significant reductions in the overall synovitis score, CD3 and CD68L 
macrophages.  Findings are summarised in figure 3.10. 
 
Next, patients were segregated into EULAR responders and non-responders in order to 
determine whether responders had differences in immune cell infiltration at baseline or a 
significant reduction in immune cell infiltration following treatment.  No differences were 
observed between the two groups, shown in figure 3.11. 
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Figure 3.10 Effect of rituximab on the histological characteristics of synovial tissue and 
distribution of cell populations in synovial biopsy samples obtained pre and post therapy 
A Immunohistological findings in representative synovial tissue samples obtained at week 0 and 16 weeks after 
rituximab therapy (original magnification x20) 
B Results of semiquantitative evaluation obtained in 18 paired samples (obtained at week 0 and week 16).  Each 
bar represents the median and lines denote the interquartile range. 
*p<0.05 using the Wilcoxon matched paired signed rank test. 
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Figure 3.11 There are no differences in cellular infiltrates at baseline between responders 
and non-responders  
Bars represent median and interquartile range.  No differences were observed in synovitis score, p=0.34, CD3 
score p=0.26, CD20 score p=0.61, CD 138 score p=0.18, CD 68(L) score p=0.71, CD68(SL) score p=0.86 between 
EULAR good/moderate responders and non-responders.  Abbreviations SQ = semi-quantitative 
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3.4.13 A trend towards a reduction in plasma cells correlates with D DAS-28 
In order to analyse whether a change in each specific synovial cellular marker correlated with 
a change in DAS-28 score I calculated Spearmans rank correlation co-efficients for each cell 
type and for the change in DAS-28 scores.  In the B-cell rich group, there was a trend towards 
a decrease in plasma CD138 cells and a decrease in DAS-28 (r 0.65, p=0.09).  When further 
analysed in only the moderate / good EULAR responder group no further associations were 
seen. 
 
 
Figure 3.12 A trend towards reduction of plasma cells correlated with a reduction in DAS-28 
scores 
Spearman’s rank correlation coefficient, p=ns 
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3.5 Discussion 
Ascertaining clinical and synovial biomarkers of response to rituximab therapy is challenging. 
RA synovium is a heterogenous entity.  Distinct histological subtypes (fibroid, myeloid and 
lymphoid) have been observed within the synovium but few studies have explored whether 
these can be used as a stratification tool to guide response to therapy. I have shown that at 
baseline, there were no clear clinical, laboratory or immunohistochemical parameters that 
associated with response to therapy in this cohort of patients. Treatment with rituximab does, 
however, lead to global changes in the cellular infiltrate although I did not show that this 
correlated with clinical outcomes.  The data presented here therefore adds to existing 
observational studies, showing that there are changes in cellular infiltration after Rituximab 
administration and that the modulatory effects of B-cell depletion extend beyond peripheral 
blood B-cell depletion.  
 
One of the main aims of this chapter was to validate the best method of scoring for the 
samples in this study in order to create a ‘B-cell rich’ or ‘B-cell poor’ classification.  Firstly, I 
validated the use of DIA and MC and have shown that these methods correlate significantly 
with SQ scoring.  It is however, important to consider significant limitations of these 
comparisons in synovial tissue analysis that would attract criticism.   
 
Firstly, there were only seven samples in total which had a significant number of B-cells to 
allow comparison.  The last ‘B-cell rich’ patient was not included as this sample was recut at 
the end of the study.  More samples would be needed to make this applicable to large scale 
studies, although others have previously demonstrated correlations between scoring 
methods [386]. Both manual counting and DIA became significantly more difficult when 
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determining the number of nuclei in samples with dense aggregates, particularly if only 
adhering to one magnification. I faced difficulty in utilising ‘pre-set’ thresholds for DIA of 
synovial tissue samples due to the fact that compared with arthroscopic samples, the tissue 
obtained is less in both size and sometimes quality, and therefore staining was often not 
uniform.  The maximal number of cells in all the sections visualised was taken as count 
number.  This inevitably leads to the discussion of whether the maximum number of cells 
obtained from different biopsy specimens and cutting levels is reflective of the diseased tissue 
status in 1) the biopsied joint and 2) the disease process as a whole.   This is further highlighted 
by the change in results when the tissue samples were recut.  Initial analysis suggested that a 
B-cell rich pathotype could predict response to therapy. This highlights the significant 
limitation of this sample size and whether synovial tissue should be cut at all possible levels 
to gain an accurate reflection of tissue staining.    
 
Previous studies have addressed the heterogeneity of immune cell marker expression in 
synovial biopsies.  Scire and colleagues [390] demonstrated that a cumulative area of 2.5 mm2 
from at least three biopsy specimens allows an estimate of cell number within 10% mean for 
the overall tissue. In this study, a minimum of six (maximum of twelve) ultrasound-guided 
biopsy specimens were obtained and cut at different levels prior to staining for CD20.  Rooney 
and colleagues also describe considerable immune cell homogeneity within one joint [377], 
as do Kirkham et al who also looked at variability in immune cell and cytokine expression 
within the knee joint[391].  The degree of T-cell infiltration within and between biopsy sites 
has also been explored, with the authors concluding that variation arises predominantly 
between different pieces of tissue and a reduction in variability could be attained by studying 
multiple slides[392]. Applying this method by calculating the mean number of cells per slide 
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to this work was challenging, as limited tissue meant some sections had little or no B-cells. 
This also proved to be testing when applied to the DIA method as often aggregate staining in 
a large tissue section resulted in a small area fraction as seen in Figure 3.3.   It was here where 
expert opinion from a consultant histopathologist guided the decision to take the maximal 
count following the notion that uninflamed synovium does not display a significant B-cell 
infiltration.  The positive correlations observed between SQ scoring which was based upon all 
tissue sections, MC and the DIA method as described lend support to this decision. 
 
Kraan and colleagues demonstrated in nine patients that synovial biopsies taken from an 
inflamed knee joint have similar histopathological changes to an uninflamed small joint at the 
same timepoint, demonstrating similar numbers of immune cell markers in each biopsy[393].  
Immune cell infiltration was also witnessed in tissues from clinically uninvolved joints [394] in 
patients with RA and in Rhesus monkeys induced with RA [395], suggestive that tissue from 
one joint is likely to be reflective of the disease process as a whole.  Furthermore, several 
studies have reported associations between histological features of inflammation and clinical 
paramaters disease activity [373, 396-398].  These observations have been extrapolated to 
this cohort to establish a subgroup of histologically ‘B-cell rich patients’. 
 
Finally, in order to further validate a SQ score of 2 I examined whether this subset of patients 
also had co-existing plasma cells within the synovium.  I found that all patients with a score 
of 2 had an equivalent or higher number of plasma cells present, indicating similar B-cell 
dependent processes within the joint lining, although it remains unclear if B-cell 
differentiation occurs in situ from autoreactive within the synovium[346, 399] or if similar  
trafficking processes leads to the co-existence of both cell lines. 
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In summary, I determined two subgroups within this cohort: ‘B-cell rich’, determined by a SQ 
³2 and a ‘B-cell poor’ pathotype determined by a SQ score of £1.   I have shown that SQ 
scoring correlates with both MC as the gold standard and the with DIA analysis – but is time-
effective, accurate and reproducible.  Expert opinion from a specialized histopathologist adds 
value to this study in that it allows us to cross medical disciplines, reflecting that synovial 
scoring techniques can be used in ‘real-world’ NHS settings. 
 
Next, I examined clinical responses to rituximab. In this cohort, rituximab was successful at 
ameliorating disease as evidenced by an improvement in DAS-28 scores pre and post 
treatment (p=0.027).  Compared with previous trials that reported EULAR good / moderate 
response rates of 89% at week 48 (MIRROR)[286] and 65% at week 24 (REFLEX) only 41% of 
patients were deemed to be moderate / good EULAR responders in this cohort.  The British 
Society of Rheumatology Biologics Registry report a 60% attrition rate in 1629 patients, of 
which 1371 had been exposed to a previous biologic DMARD, with RF positivity being 
associated with continued therapy [400].  In line with these findings, 16/22 patients (73%) of 
this cohort were retreated with a further cycle of Rituximab and 14/22 (63%) remained on 
Rituximab at 52 weeks.  This highlights the difficulties in the universal utility of clinical trial 
outcome data, as in this case treatment was led by physician and patients’ opinions of a 
‘partial response’ and knowledge that repeat cycles of rituximab may improve clinical 
outcome. The differences observed in EULAR response could potentially be explained by the 
population being reflective of a cohort with long-standing disease duration and high numbers 
of DMARD and TNF failures.  This finding also highlights the limitations of the DAS-28 itself, 
as high numbers of tender joints persisted in this cohort, which may in part be driven by an 
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upregulation in pain pathways and not ongoing inflammation itself.  In support of this, a 
recent systematic review showed that baseline characteristics of RA patients in observational 
studies differed significantly from those enrolled in RCT’s with regards to age, disease 
duration, DMARDs and DAS-28, leading to the conclusion that RCT data may not be reflective 
of efficacy in the ‘real-world’ setting[401].   
 
Another reason for the discrepancy in observed response rates may be the limited use of 
methotrexate, which was only 58% in this cohort.  6/22 (27%) of patients received Rituximab 
as monotherapy.  Early trials supported more favourable outcomes when Rituximab was 
given in conjunction with methotrexate, supported by a systematic Cochrane review[300]. 
Recently more observational data is emerging to suggest similar levels of efficacy in those not 
receiving concomitant methotrexate.  In a six-year study of 2484 patients on Rituximab 
therapy, 22.7% received the drug as monotherapy and achieved similar response rates to 
those on combined therapy [402]. This is further supported by similar findings [403, 404] in 
early disease, although higher levels of ACR response were noted in combination therapy. 
This once again highlights that this cohort is more reflective of registry than clinical trial data, 
including patients intolerant of cDMARD therapy. 
 
The improvement in DAS-28 was mirrored by an improvement in patient reported outcome 
measures. Amongst the multitude of patient reported outcomes available, the HAQ has 
strong predictors of economic outcomes including work disability, loss of income and finally 
as a predictor of mortality [405-407]. Estimates for the ability to detect change range between 
0.02-0.87, although 0.22 is widely accepted figure for meaningful change. [407]  There was a 
mean reduction in HAQ at 12 weeks which continued to 52 weeks in those patients who 
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stayed on Rituximab therapy.  This is in keeping with published registry data [408, 409], 
although no differences were observed between patients receiving rituximab monotherapy 
and those taking concomitant methotrexate. 
 
Despite the heterogeneity of synovial subtypes and associated molecular signatures, clinical 
phenotypes in RA remain similar.  B-cell rich or ‘lymphoid’ predominant with ELS have been 
observed in 44-58% of patients with up to 25% displaying CD21 positive germinal centres[276, 
410].  In this cohort 40% had a B-cell rich pathoype, with 20% showing evidence of aggregates, 
lower than previously reported, which may be due to the limited sample size.  Another 
important consideration here are studies that report reversal of ELS after the administration 
of TNF therapy [411, 412]. Given that the patients in this cohort had received varying numbers 
of cDMARDs and anti-TNF agents prior to Rituximab therapy, it is possible to speculate that 
this may have resulted in lower numbers of aggregates.  Finally, there has been debate over 
the relevance of ELS at different stages of RA. In early RA it has been postulated that they 
contribute to the initial break in tolerance, which can either resolve through clearance of the 
antigen over time or continue to perpetuate inflammation.  
In a prospective study, Van de Sande and colleagues observed that no differences in cellular 
lymphoid infiltration between patients with undifferentiated arthritis, psoriatic arthritis and 
established RA could be demonstrated, concluding that the presence of ELS was of limited 
diagnostic value. Furthermore, they noted that the patterns of infiltration were dynamic over 
time [413]. The patients in this cohort had a long disease duration with universally high levels 
of disease activity at baseline yet considerable variation of baseline B-cell infiltration. There 
were no discernible differences in clinical parameters at baseline between the B-cell rich and 
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B-cell poor groups, supporting the hypothesis that ELS may not play a crucial role in driving 
systemic inflammation in established disease.   
In keeping with previous observations [347, 411, 414] B-cell rich pathotypes were associated 
with a higher synovitis score and immune cell infiltrates of macrophages, T-cells and plasma 
cells. Studies have suggested that synovial lymphoid neogenesis has been associated with 
higher levels of CRP, ESR, TNF[411, 414] although this does not necessarily result in a more 
aggressive phenotype[414].  I did not demonstrate any significant association between the B-
cell rich pathotype and autoantibody status, laboratory markers of inflammation or disease 
activity.  One confounding factor for the lack of any observed associations is that the B-cell 
rich group were more likely to be on methotrexate and prednisolone, which may in itself be 
indicative of more aggressive disease.  Of interest, 2/4 patients that exhibited lymphoid 
aggregates in the synovium were seronegative, in line with previous studies suggesting that 
aggregates do not correlate to circulating levels of antibodies[412] and are seen in 
seronegative inflammatory diseases such as psoriatic arthritis[413, 415].  None of the samples 
in this study stained positively for CD21 and therefore I was unable to provide evidence at the 
histological level that these aggregates displayed any features of active germinal centres. 
In line with previous studies [347, 348, 353], I have shown that treatment with rituximab 
results in a significant decrease in B-cells in the synovium and a strong trend towards decrease 
in plasma cells but this does not always correlate with response. Interestingly, a decrease in 
plasma cells did show a trend for correlation with D DAS-29 (p=0.09). Sequencing studies have 
shown that clonally expanded B-cells / plasma cells reside within the RA synovium[416] and 
it is therefore possible that improvement in disease activity results from depletion of 
autoreactive B / plasma cells. I did not test specifically for correlations of changes in ACPA or 
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RF levels at 16 weeks, however previously a decrease in plasma cell numbers has been 
correlated with a reduction of ACPA levels, which may be again be due to the depletion of 
short-lived plasma cells, providing an alternative explanation for improvement [347].  
Rituximab results in B-cell depletion through antibody-dependent cytotoxicity, complement 
dependent cell death and B-cell apoptosis [280, 319], yet its precise mechanism of action in 
ameliorating clinical disease remains incompletely understood.  This work adds support to 
the observation that B-cell depletion therapy within the synovium is unlikely to be the most 
important mechanism in response and disproves the hypothesis that those with a lymphoid 
or ‘B-cell rich’ pathotype at baseline are more likely to respond to therapy. 
A reduction in CD68SL macrophages has previously been reported to as a biomarker of clinical 
response in the synovium [158, 160]. This change has been observed in response to several 
cDMARDs and bDMARDS, including prednisolone, gold, methotrexate, leflunomide and 
infliximab[159, 417, 418]. Whilst I observed a reduction in CD68SL in the group as a whole 
following Rituximab therapy, this change was not significantly different between responders 
and non-responders.  This may again be attributable to the small sample size and the limited 
number of responders at the 16-week timepoint.  The data does, however support the notion 
that the synovium is sensitive to changes induced by therapy and that subintimal 
macrophages may play a role in a common pathway that leads to disease progression or 
amelioration. 
This work is limited by the small sample size and numbers of paired synovial biopsies 
available.  It is reflective of ‘real-world’ data as patients had long-standing disease and had 
failed a number of different therapies.  The concomitant use of prednisolone may also have 
had an effect on the changes seen within the synovium.  It would have been interesting to 
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collect more data on reduction in rheumatoid factor and ACPA.  (Flow cytometry data has not 
been included in this work as it is forming part of a different thesis which is currently being 
undertaken by another student in our laboratory). 
Taken together however, this data illustrates salient findings, many of which support the 
current literature.  Despite marked B-cell depletion in the peripheral blood, synovial B-cells 
persist in most patients and indeed depletion is variable.  This may be due to local chemokines 
which remain active in the synovial compartment, promoting the formation of germinal 
centres and subsequent “resistance” to therapy. Decrease in other cell types suggests that B-
cells may be key players in mediating synovial inflammation and that somehow a reduction 
in circulating pathogenic B-cell results in a secondary reduction of macrophages and plasma 
cells. Additionally, the results presented here are in line with the other synovial- biopsy based 
studies, showing that minimally invasive ultrasound-guided synovial biopsies are able to 
reproduce comparable tissue and similar findings. In summary, these findings show that B-
cell repletion is variable and does not correlate with clinical response. These findings suggest 
that immunohistochemistry alone is not sensitive enough to act as a baseline biomarker for 
response to B-cell depletion.  
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Chapter 4 
Rituximab: Molecular effects on the synovium 
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4.1 Introduction 
 
The use of genomic and metabolomic technologies are creating new opportunities to allow 
more targeted treatment in RA.  The advent of high throughput technologies in 
transcriptomics, metabolomics and proteomics is both exciting and promising for both the 
understanding of RA pathogenesis and response to therapy. Currently, however, clear 
molecular markers of response have not been identified for utilisation in the clinical setting. 
Elucidating biomarkers of response to rituximab therapy remains a therapeutic challenge.  
Response to therapy is measured over an extended time period during which time there is 
continuation of disease activity and joint damage in those who fail to respond.  Additionally, 
there is a risk of exposure to unwanted side effects such as anaphylactic reactions, blood 
dyscrasias and a reduction of circulating immunoglobulins. Rapid recognition of molecular 
subtypes, akin to certain malignancies, that may predict response to different therapies 
would transform the RA landscape.  The first step towards this process relies on the 
identification of molecular markers, both in blood and synovium. 
 
Several studies have focused on the identification of response gene signatures in peripheral 
blood.  The first whole-genome microarray expression profiling study assessing B-cell 
depletion therapy was conducted in 2009 by Julia and colleagues [419] who took RNA from 
whole blood, B cells and CD4+ T-cells from 9 patients treated with Rituximab followed by 
validation with real-time PCR for identified genes.  They identified seven genes in whole blood 
which differed between responders and non-responders according to the relative 
improvement DAS score. Whole blood overexpression of ARG1, an important modulator of 
immune response through the nitric oxide pathway and subsequent downstream production 
 157 
of citrulline, was associated with non-response to Rituximab.  Overexpression of 
carboxypeptidase D that cleaves arginine residues was also associated with non-response.  
The authors also demonstrate a high TRAF1:ARG1 ratio in whole blood and overexpression of 
TLR4 in CD4+ T-cells correlate with response.   
 
To date, the type 1 interferon response signature is the most widely reported biomarker of 
response to Rituximab therapy in peripheral blood gene expression studies.  The expression 
of 3 IFN response genes was associated with a poor clinical response in 20 patients[420] and 
further validated in a genome-wide microarray study in 14 patients where a low level of IFN-
type 1 gene signatures associated with a good clinical response[421]. Furthermore, individual 
patients have differential regulation of type 1 interferon response following B-cell depletion 
therapy whereby an increased in IFN type 1 response gene confers better clinical 
outcomes[422].  This leads to two putative mechanisms of resistance to rituximab therapy; 
firstly that those with high interferon signatures have a disease regulated by pathways not 
controlled by B-cell activation and processes, or that high interferon activity associates with 
resistant pathogenic B-cell subsets that survive in niches in the bone marrow or synovium and 
continue to promote inflammation [421, 422]. Recently, a multi-parameter response model 
to Rituximab therapy has been described including eight interferon genes to form a baseline 
interferon score which has an AUC of 0.82, thus highlighting the potential for personalised 
medicine based upon gene expression data.[423]  
 
Sellam and colleagues identified a molecular signature of 143 genes which correctly classified 
89% of EULAR responders at 24 weeks.  They again found that down-regulation of the 
interferon pathway associated with response.  Upregulation of inflammatory genes including 
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IL33, STAT5A was noted in responders.  B-cell regulatory and functional genes were 
downregulated in the whole cohort but with no significant difference in clinical outcomes, 
reflective of CD19 depletion in peripheral blood not correlating with response to therapy 
[424]. 
In another study, downregulation of non-tissue specific regulatory genes MTOR, ULK1, p21, 
caspase 3m TNFa and IL-1b we associated with an improvement in clinical and laboratory 
outcomes after one cycle of Rituximab therapy[425]. Treatment with Rituximab induced a 
significant decrease in MTOR and MMP-9 levels. 
 
Studies assessing synovial gene and transcriptional profiles have also identified particular 
signatures or processes that associate with response.  Kavanaugh and colleagues used pre-
selected genes in 13 patients from the ARISE trial which demonstrated no change in synovial 
expression of TNFa, IL-6, or MMP1 but witnessed a change in IL-8 pre and post Rituximab 
treatment, although this change was noted more in non-responders.[348]   
 
Analysis of the synovial transcriptional profile in 20 patients using a GeneChip microarray 
revealed 549 differentially expressed genes before and after B-cell depletion therapy[426].  
Downregulated genes were enriched in immunoglobulin genes, immune responses and 
leucocyte activation, whereas genes which control developmental processes, wound healing 
and cell development were upregulated.  Of interest, this pattern of upregulation is similar to 
those seen in response to TNF inhibition with adalimumab and iL-6 inhibition with tocilizumab 
[427, 428] indicating that perhaps response to therapy is linked to the balance of active 
inflammation versus tissue repair and restoration.  The authors also found that a higher 
baseline synovial immunoglobulin gene profile and baseline IgG levels associated with 
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response to therapy, lending support to findings that patients with RF and ACPA positivity 
with B-cell driven immune responses have favourable outcomes. 
 
Finally, a study of synovial gene expression using high throughput quantitative real-time PCR 
in 20 RA patients showed two distinct pre-treatment populations characterised by different 
expression of immune response genes and remodelling / interferon a genes which associated 
with response[429].  The authors of this study used 16 genes which correlated most strongly 
to the three month change in DAS-28 to construct a composite baseline gene score which 
correlated with both early and late response to treatment, ESR, pain score and the histological 
thickness of the synovium lining layer.   Those who had higher baseline macrophage and T-
cell genes were more likely to respond, whereas those who had genes associated with 
remodelling and type I IFN had poorer outcomes.   Distinguishing a pre-treatment synovial 
gene profile in this case was able to discriminate between clinical outcomes based upon 
EULAR response criteria.   
 
The observation that there appear to be at least two patterns of synovial tissue gene 
expression; broadly, high inflammatory and low inflammatory, correlates to different 
patterns of synovitis that have been previously been described[430].  The high inflammatory 
group may be defined by genes related to the myeloid or lymphoid inflammatory 
compartments whereas the low inflammatory may reflect the ‘diffuse / pauci-immune’ 
group[369, 431].  
 
To date, there has been no study exploring specifically whether the presence of ELS or 
lymphoid associated genes affects outcomes in patients treated with B-cell depletion therapy.  
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Two studies have suggested that a synovial gene signature characterised by lymphoid 
inflammatory pathways did not associate with response to the anti-TNF agents infliximab or 
adalimumab [356, 428].  At the tissue level, however, there are conflicting reports on the 
presence of lymphoid gene signatures (including ELN) and response to therapy[411, 412].   
 
The functionality of ELS in the synovium has been demonstrated by our group by a series of 
elegant experiments described by Humby at al[346].   Activation-induced cytidine deaminase 
(AID), encoded by the AICDA gene is required for ongoing somatic hypermutation and class-
switch recombination (CSR) of immunoglobulin genes[432], as detailed in the introductory 
chapter. Humby and colleagues demonstrated that AID was only expressed in tissues with 
CD21 positive FDC networks and particularly in GC B-cells, confirmed by quantitative PCR. AID 
expression was also noted in the cytoplasm of large interfollicular B-cells.  Furthermore, AID 
was associated with CXCL13 and LTb expression and the presence of ACPA producing plasma 
cells around the periphery of GCs, suggesting a role for local cell differentiation within the 
synovium.  Finally, continued AID expression, B cell proliferation and production of human 
ACPA when GC positive synovial tissue was transplanted into severe combined 
immunodeficiency (SCID) mice provided further evidence that GCs are capable of sustaining 
chronic inflammation in the absence of peripheral B-cells.  Bugatti and colleagues, in 
conjunction with our laboratory, also demonstrate a correlation between CXCL13, LTb and 
AID expression.  They demonstrate an association between the presence of active follicles 
and abnormal bone remodelling, but did not find an association with clinical parameters[399]. 
Further evidence for functionality of ELS is evidenced by recombinant antibodies generated 
from B-cells within ACPA positive synovial ELS that can target citrullinated proteins and 
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recognise neutrophil extracellular traps from peripheral blood or synovial neutrophils, thus 
perpetuating the immune response within the synovium[433]. 
 
A study performed on peripheral blood showed significantly higher levels of AICDA expression 
in patients with RA with a positive correlation with serum RF, ACPA, IFNg and IL-17[434].  The 
same group also demonstrated AID in the synovium of patients with GCs in RA, but not in the 
synovium of patients with osteoarthritis.  The critical role of AID is further highlighted by the 
observation that overexpression in the BXD2 mouse model of arthritis resulted in increased 
germinal centre activity and the production of pathogenic autoantibodies, which could be 
blocked by inhibiting the CD28-CD86 interaction[435].  Inhibition of the functional activity of 
AID resulted in decreased GC formation and autoantibody production[436]. 
 
Conflicting with this data, Cantaert and colleagues report the presence of GCs occurring in 
similar frequencies in both seronegative and seropositive individuals and report similar ACPA 
levels in SF regardless of the inflammatory pathotype[437].  IgVh sequencing demonstrated 
multiple clonally related sequences, but of these only one sample was suggestive of antigen 
driven B-cell maturation and in situ somatic hypermutation, occurring independently of 
synovial lymphoneogenesis.  This is supported by a previous study which demonstrated that 
local plasma cells were not clonally related to intrafollicular B-cells related sequences despite 
the identification of similarly expanded clones within the CD20+ B-cell population[438]. This 
could lead to the conclusion that despite B-cell clonal expansion within the synovium, only a 
few cells take part in the GC reaction.  It is important to note, however that the latter study 
only used synovial tissue from one patient with RA.   
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Whether ELS in the synovium are related to the degree of inflammation or whether they act 
as fully functioning secondary lymphoid organs perpetuating the immune response remains 
unclear. I have demonstrated that in the present cohort, the histological presence of synovial 
B-cells or ELS did not discriminate between response and non-response to Rituximab therapy.  
This may be due to small sample size, variation in synovial sampling or that 
immunohistochemical analysis may not be a sensitive marker to change, which I have 
discussed in the previous chapter. In order to explore the molecular effects of Rituximab, and 
in particular the effects of ELS, the expression of AICDA and B-cell associated genes I examined 
whether differences in gene expression would provide a more sensitive marker of clinical 
outcome. 
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4.2 Hypothesis and aims 
The hypothesis of this experimental chapter was that patients with a ‘B-cell rich’ molecular 
signature, characterised by the expression of ELS associated genes, would aid stratification of 
response to therapy.   
The specific aims were to: 
1. Assess the global molecular effects of rituximab on the synovium by identifying 
significant changes in gene expression pre and post therapy 
2. Assess if there are any differences in gene expression in responders and non-
responders 
3. Create a ‘B-cell rich’ molecular signature based upon genes which are known to be 
involved in B-cell developmental processes and in the development of ELS 
4. Ascertain whether the expression of AICDA affects response to B-cell depletion 
therapy 
5. Utilise the findings to create a unique prediction model for response or non-
response to therapy 
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4.3 Methods 
4.3.1 Study Population 
A subset of 20 patients from the original cohort described in Chapter 3 who had paired 
biopsies with >1ug of RNA available were chosen for this analysis.   
 
4.3.2 RNA extraction 
Synovial samples were homogenised in TRIzol (Invitrogen, Carlsbad, California USA) using a 
power homogenizer following shearing with a 26 gauge needle.  Total RNA was isolated as 
described in the methods chapter and stored at -80°C.  All RNA samples were quantified using 
a spectrophotometric analysis performed by a Nanodrop-1000 v.3.2.1 Spectrophotometer 
(Thermo Scientific).  RNA integrity was determined by electrophoresis on tissue samples using 
the Agilent 2100 Bioanalyser.  (Agilent Technologies, California, USA.) 
 
4.3.3 High throughput quantitative real-time PCR 
High throughput quantitative real-time PCR for 190 genes, pre-selected according to known 
roles in RA / B cell biology was performed using the Fluidigmã platform (Fluidigm 
Corporation, South San Francisco, California, USA) as per manufacturer’s protocols.  Per 
sample Ct values were converted to DCT values for genes using GAPDH and UBC as controls.  
To normalise across all samples, DCT values were converted to DDCT values by subtracting 
the mean DCT of each gene across all samples and then to a negative DDCT.  Genes that fell 
under the lower 10% bracket of the variance range (cut-off d2=4.007) were then removed to 
reveal a uniform dataset. In total, 69 genes were removed.  A full list of genes is available in 
Appendix A. 
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4.3.4 Statistical analysis 
B-cell rich and poor populations were identified by histopathology scoring or by splitting the 
MS4A1 Fluidigm gene expression range in half, with the lower half being defined as MS4A1lo 
and MS4A1hi populations. Fishers’ exact test was used to compare molecular and histological 
classifications. For identifying markers of response to rituximab in 16 week EULAR responders 
versus non-responders, we fitted a linear model to the expression values at baseline, firstly 
comparing B-cell rich and B-cell poor using both histological and molecular parameters and 
subsequently responders and non-responders by changes in gene expression at 16 weeks.  
Statistical values were then adjusted using the empirical Bayes approach.  Genes which 
segregated with MS4A1 were identified as B-cell signature genes.  The baseline B-cell 
signature genes (p<0.05) were then used to conduct a regression and correlation analysis with 
16 week DDAS-28 as the dependent / response variable.  Spearman correlation coefficients 
and their associate p-values were used to determine B-cell signature genes that significantly 
correlated with response.  The signature was then extended to create a further model based 
upon the expression of AICDA, with samples segregated into tertiles as follows: MS4A1lo, 
MS4A1hiAICDAlo, and MS4A1hiAICDAhi according to levels of mean MS4A1 and AICDA 
expression across the whole cohort. 
 
All clustering and heatmap generation was performed using the heatmap.2 (gplots) function 
in R Programming Language (R), with either Euclidean or correlation distance and Ward’s 
linkage.  To define B-cell signatures at baseline, linear models were used using limma and 
ebayes. A likelihood ratio test was conducted to develop a signature at baseline for the three 
groupings based on the levels of expression of AICDA and MS4A1.  Correlation analysis was 
conducted using the cor.test function in R.  Also in R, linear modelling was performed using 
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the km function, with the linear fit plotted using ggplot2, comparing the actual versus 
predicted 16 week DDAS-28.  Unless stated, the cut off for significance was p<0.05 for all tests.  
This part of the analysis was conducted by Kevin Blighe, biostatistician at the William Harvey 
institute, Queen Mary University. 
 
4.4 Results 
4.4.1 Patient Demographics 
22 samples were used for baseline gene expression data, clinical characteristics of these 
patients are described in the previous chapter.  Clinical characteristics of 20 patients for 
whom paired biopsies were available with sufficient quality RNA are described in Table 4.1.  
As in chapter 3, there were no significant differences between responders and non-
responders at baseline.  Of these 20 patients with paired samples, 8/20 were EULAR good / 
moderate responders.   
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Table 4.1 Demographics and clinical characteristics of patients selected for molecular 
analysis 
  
Age (yrs) mean ± sd 52.4±14.36 
Female, n, (%) 16 (80) 
Median disease duration months (IQR) 99 (24 -120) 
RF positive, n, (%) 17 (85) 
ACPA positive, n, (%) 17 (85) 
ESR mm/hr median (IQR) 29 (9-59) 
CRP mg/l mean ± sd 9 (0-18.75) 
DAS-28 mean ± sd 5.64 (1) 
 
SJ median (IQR) 6 (3-8.75) 
TJ median (IQR) 11 (7.25-20.5) 
VAS mean ± sd 63.45 ±  23.88 
HAQ mean ± sd 2.07 ± 0.75 
Erosive≥1 joint n, (%) 16 (80) 
ST, median (IQR) 26 (23-30) 
PD, median (IQR) 3 (2-6) 
Median number of previous anti-TNF drugs, IQR 1 (0-4) 
No of patients receiving Rituximab as first line 
biologic 
therapy, n (%) 
6 (30) 
No of patients on methotrexate n (%) 11 (55) 
Methotrexate dose, median (IQR) 5 (0-17.5) 
No of patients on prednisolone, n 10 (50) 
Prednisolone dose, median (IQR) 2.5 (0-10) 
  
Abbreviations RF=rheumatoid factor, ACPA= anti-citrullinated protein antibody, ESR = erythrocyte 
sedimentation rate, CRP = c-reactive protein, DAS-28= 28 joint count disease activity score, HAQ = Health 
assessment questionnaire, SJ = swollen joints, TJ = tender joints, VAS = visual analogue score, ST = synovial 
thickening, PD = power Doppler, EULAR = European union league of action against rheumatism, TNF = tumour 
necrosis factor, IQR interquartile range 
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4.4.2 Principal component analysis 
Principal component analysis is used to explore large datasets by reducing dimensions to a 
few principal components that explain patterns[439].  Transcriptomic data is high 
dimensional, with a large number of genes in proportion to sample size, with only a few genes 
expected to correlate with the scientific question; PCA therefore reduces noise making the 
data more suitable for analysis[440].  The PCA plots in Figure 4.1 (A) show that there was little 
variation between samples – i.e. no outliers.  Figure 4.1 (B) also demonstrates little variance 
between genes, with no outliers identified. 
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                        A      B 
Figure 4.1 Principal components analysis of (A) samples and (B) genes.  No outliers were 
identified 
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4.4.3 The global molecular effects of rituximab 
Following treatment, there was a significant change in 14 genes pre and post rituximab 
therapy (p<0.05), summarised in tables 4.2 and 4.3.  Overall, there was significant 
downregulation of the B-cell associated gene FCGR1 as well as a significant number associated 
with macrophage and dendritic cell signalling and activation (CD163, CLEC4E, CD36).  IL-2RA, 
IL-15 and IL-1b were also downregulated.  Rituximab also significantly decreased expression 
of the T-cell associated chemokine CCR5 and CD96, a specific T cell receptor protein.  CXCL10 
expression, secreted in response to IFN-g was also reduced.  Decreased synovial expression 
of the angiogenesis related genes MMP9, VEGFC and CD36 was also noted post Rituximab 
treatment.  The fibroblast growth factor 1 gene, FGF1 was also significantly upregulated 
following treatment.  These results support previous observations documenting that 
rituximab downregulates genes involved in B and T cell immune responses and chemotaxis 
whilst inducing fibroblast genes involved in reparative processes[426, 429]. 
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Table 4.2 Downregulated genes following rituximab treatment 
 
Gene Chromosome p-value Function 
MMP9  20q 13.12 0.00365 Matrix metalloproteinase 
CD163 12p13.31 0.00422 Macrophage marker, inducer of local 
inflammation 
CCR5 3p21.31 0.00558 C-C chemokine receptor 5 
Expressed by T-cells and macrophages 
CD96 3q13.13-q13.2 
 
0.00558 Member of immunoglobulin superfamily 
Antigen presentation, T and NK immune 
responses 
CD11c 16p11.2 0.00831 Neutrophil and monocyte adherence, 
complement phagocytosis pathways 
 
CLEC4E 12p13.31 0.0121 Cell adhesion, cell signalling, glycoprotein 
turnover 
CD36 7q21.11 0.0136 Platelet surface receptor, cell adhesion 
IL-15 4q31.21 0.0136 Cytokine, T-cell and NK cell proliferation 
VEGFC 4q34.3 0.0327 Vascular endothelial growth factor 
CXCL10 4q21.1 0.0362 CXCR3 receptor ligand 
Stimulates monocytes, NK and T cell 
migration and modulation 
IL-1B 2q14.1 0.0262 Cytokine produced by activated 
macrophages 
FCGR1A 1q21.2 0.0399 Fc gamma receptor 
IL-2RA 10p15.1 0.0484 Subunit if IL-2 receptor 
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Table 4.3 Upregulated genes following rituximab treatment 
 
Gene Chromosome p-value Function 
FGF1 5q31.3 0.044 Fibroblast growth factor 1 
Cell survival and tissue repair 
 
 
4.4.4 Response is associated with a reduction in macrophage associated genes and 
upregulation of reparative genes 
 
Samples were then segregated into EULAR responders and non-responders at 16 weeks.  In 
the responder group there was a significant reduction in relative expression of CD163 and 
CCL4, macrophage associated genes.  There was a significant upregulation of FGF1, VEGFR3, 
PAD2 and RORgT in this group.  FGF1 and VEGFR3 are genes associated with angiogenesis and 
wound healing, and it may therefore be the latter properties that contribute to clinical 
improvement.  The relevance of PAD2 and RORgT are discussed later on in this chapter. 
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Table 4.4  Upregulated genes in responders following Rituximab treatment 
Gene Chromosome p-value Function 
FGF1 5q31.3 0.0078 Fibroblast growth factor 1 
Cell survival and tissue repair 
VEGFR3 5q35.3 0.016 Cell surface receptor tyrosine kinase 
associated with fibroblast growth factors 
PAD2 1p36.13 0.023 Post-translational citrullination of proteins 
RORgT 1q21.3 0.023 Important role in lymphoid organogenesis, 
Th17 differentiation 
 
 
Table 4.5 Downregulated genes in responders following Rituximab treatment 
Gene Chromosome p-value Function 
CD163  0.023 Fibroblast growth factor 1 
Cell survival and tissue repair 
CCL4  0.039  
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4.4.5 High baseline expression of genes regulating B-cell differentiation, T-cell and TH17 
responses and cell signalling significantly associate with a diminished delta DAS-28 
response. 
 
I went on to examine whether baseline synovial gene expression could identify subsequent 
EULAR responders vs non-responders at 16 weeks.  I searched for significant correlations 
between the genes examined at baseline and changes in DAS-28 between baseline and 16 
weeks.  Figure 4.2 displays the 11 genes identified at baseline with significant correlations 
with D DAS-28. 
 
High baseline expression of genes regulating B-cell differentiation (CD19, LTA, CXCR5, IL-15, 
PAX5, IL-21), T-cell and Th17 responses (TBX21, CD96, IL-23A, IL-21, IL-15) and cell signalling 
(CLEC4E, VEGFR3) were associated with a diminished D DAS-28 response. 
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Figure 4.2 Baseline predictors of response to rituximab  
High expression of 11 genes (CD19, CD96, CLEC4E, CXCR5, IL15, IL21, IL23A, LTA, PAX5, TBX21, VEGFR3) predicted 
16-week D DAS-28 response.  D DAS-28 scores are calculated as change from baseline; a fall in DAS-28 correlates 
with response to therapy.  Gene expression is calculated using the mean of the tissue and expressed as relative 
change from the mean.  P-values for each gene are derived using Spearman rank correlation, significance p<0.05. 
 
4.4.6 Histological B-cell rich classification correlates with MS4A1 expression 
To add further validity to the B-cell scoring methods described in the previous chapter, I 
investigated whether the histological CD20 classification correlated with MS4A1 expression 
at baseline.  MS4A1 expression was higher in the histological B-cell rich group than at 
baseline.  In the B-cell poor group, MS4A1 relative expression was 0, or the same as the 
average of all genes.  At 16 weeks, MS4A1 expression was similar in both B-cell rich and poor, 
and reduced overall from baseline (figure 4.3).   
 
Unexpectedly, the reduction of MS4A1 expression was reduced more in the B-cell poor group 
which may be in part explained by the greater variation observed in that group as a whole, or 
CD19 CD96 CLEC4E CXCR5 IL15 IL21 IL23A LTA PAX5 TBX21 VEGFR3
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the inference that synovial B-cell depletion is incomplete and that those with B-cells in 
germinal centres are resistant to depletion at the histological and molecular level.   
 
 
Figure 4.3 MS4A1 (CD20) expression pre and post rituximab therapy in samples classified as 
B-cell rich or poor by histology 
Solid black lines represent the median expression of MS4A1 in synovial tissue, boxes represent the upper and 
lower quartiles and lines represent the range.  *p<0.05 when comparing the mean MS4A1 expression in the 
histological B-cell rich group, *p<0.05 when comparing the change in MS4A1 expression from baseline. ° 
represents outliers. 
 
 
 
 
 
 
* * 
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4.4.7 There is a high level of concordance between histological staining and CD20 gene 
expression 
There was a significant association between the molecular and histological grading (p=0.0003, 
Fishers’ exact test).  Eight patients were deemed to be B-cell rich according to the CD20 
histological score.  All of these samples were categorised into tertiles and had high or 
intermediate levels of MS4A1 expression.   Only one patient sample was deemed to be 
MS4A1hi but had been graded as B cell poor on histology.  For the last sample that was graded 
as B-cell rich as per molecular classification the RNA was of adequate quality but the fixed 
synovial tissue was ungradable for IHC staining and therefore no comparison could be made.  
The high level of concordance between molecular CD20 expression and that seen on histology 
suggests that tissue collected via US guided biopsies is reflective of molecular processes. 
 
4.4.8 Genes involved in B-cell maturation, signalling and ELS formation are differentially 
expressed between MS4A1hi and MS4A1lo groups 
 
Patients were first stratified according to the mean tissue expression of the CD20 molecular 
marker MS4A1, into MS4A1hi or MS4A1lo groups and significant differences in gene expression 
between the two groups examined.  18 genes were identified (table 4.7) as being significantly 
differentially expressed between the MS4A1hi and Ms4A1lo groups. A significant proportion of 
these genes (Benjamini P=0.0000034) were directly involved in ectopic lymphoid structure 
formation, B-cell maturation and signalling. Figure 4.4 illustrates the differential expression 
of the top 8 genes in each group, figure 4.5 demonstrates the classification via a heatmap, 
illustrating expression between the MS4A1hi and MS4A1lo groups.  
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Figure 4.4 Differential expression of genes between histological and molecular B-cell rich 
groups 
 
A The top 8 genes segregating with CD20 (MS4A1) expression in the ‘B-cell rich’ group based on histological 
CD20 score.  Solid black lines represent the median with boxes indicate the upper and lower quartiles, lines 
represent the range; °signifies outliers 
 
B The top 8 genes segregating with CD20 (MS4A1) expression in the ‘B-cell rich’ group based on the molecular 
CD20 score.  Solid black lines represent the median with boxes indicate the upper and lower quartiles, lines 
represent the range; °signifies outliers 
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Figure 4.5 Heatmap of significant baseline genes associated with MS4A1 expression, 
classifying patients into MS4A1hi and MS4A1lo  
18 genes were significantly associated with MS4A1 expression at baseline through a linear model fig using a p-
value cut-off of 0.05 for clustering and heatmap generation. 
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Figure 3 Determination of a B-cell molecular signature and genes associated with response to therapy
3a Heatmap of significant baseline genes associated with MS4A1 expression, classifying patients into 
MS4A1hi and MS4A1lo. 18 genes were significantly associated with MS4A1 expression at baseline through a 
linear model fit using a P-value cutoff of 0.05 for clustering and heatmap.  
3b Heatmap showing the top six significant baseline genes associated with EULAR response (P-value cutoff 
0.02) in the focused MS4A1hi group: MS4A1, CXCR5, AICDA, IL21, IL23A, VEGFR3 
3c Baseline predictors of response to therapy in the focused MS4A1hi group
High expression of 8 genes involved in B-cell maturation and ELS formation (AICDA, BLK, CXCR5, IL21, 
IL23A, MS4A1, VEGFR3, WNT104) is associated with non-response at 16-weeks in the MS4A1hi subgroup.  
ΔDAS-28 scores are calculated as change from baseline; a fall in DAS-28 correlates with response to therapy.  
Gene expression is calculated using the mean of the tissue and expressed as relative change from the mean. 
P-values for each gene are derived using Spearman rank correlation.
3A 3B
3C
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Table 4.6 18 genes segregate with MS4A1 expression in the molecular B-cell rich group 
Location and function of genes that segregate by MS4A1 expression 
Gene Chromosome p-value Function 
PAX5 9p13.2 0.00073 B-cell specific activator protein 
FCRL5 1q23.1 0.0013 Fc receptor like protein, involved in B-cell development 
and differentiation 
FGF1 5q31.3 0.0013 Fibroblast growth factor 1 
Cell survival and tissue repair 
IL7R 5p13.2 0.0039 Receptor for IL-7, involved in lymphopoeisis 
SLAMF7 1q23.3 0.0063 Th1 specific transcription factor that regulates IFNg 
production 
IL21R 16p12.1 0.0082 Receptor for IL-21 
CSFR1R 1q.32 0.0084 Macrophage and monocyte specific growth factor 
CCR7 17q21.2 0.0098 Homing of T-cells in peripheral lymphoid organs 
IGKC 2p11.2 0.015 Immunoglobulin kappa constant, encodes the constant 
domain for kappa light chains 
TNFRSF17 16p13.13 0.015 B-cell maturation factor 
FOXP3 Xp11.23 0.026 Development and function of Tregs and expressed by 
some Bregs 
IGH1 14q32.33 0.031 IgG heavy chain locus 
ICAM1 19p13.2 0.036 Inducible glycloprotein of immunoglobulin family 
CD8A 2p11.2 0.037 T-cell antigen 
LTb 6p21.33 0.038 Produced by lymphocytes, involved in cell priming and 
ELS formation 
IL22 12q15 0.044 Activates signal transduction molecules in immune 
processes 
TSLP 5q22.1 0.007 Activates maturation of dendritic cells and T-cell 
cytokines 
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4.4.9 In the MS4A1hi group, genes involved in ELS formation are associated with a 
diminished response to rituximab 
I then focused only on the MS4A1hi group and determined whether any genes were 
significantly associated with clinical response to Rituximab.  Figure 4.6 demonstrates a 
heatmap of the top 6 genes (p<0.02) (MS4A1, CXCR5, AIDCA, IL21, IL23A, VEGFR3) which 
segregate between EULAR responders and non-responders. A p-value of 0.02 was chosen in 
this case to demonstrate the most strongly correlated genes. Figure 4.7 shows the top 8 genes 
(p<0.05) and the correlation of D DAS-28; higher expression of these genes (AICDA, BLK, 
CXCR5, IL21, MS4A1, VEGFR3, WNT10AI) results in a diminished response to Rituximab 
therapy. 
 
 
 
Figure 4.6 Heatmap demonstrating the top six significant baseline genes associated with 
EULAR response (p=value cutoff 0.02) in the focused MS4A1hi group: MS4A1. CXCR5, AICDA, IL21, IL23A, 
VEGFR3 
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Figure 3 Determination of a B-cell molecular signature and genes associated with response to therapy
3a Heatmap of significant baseline genes associated with MS4A1 expression, classifying patients into 
MS4A1hi and MS4A1lo. 18 genes were significantly associated with MS4A1 expression at baseline through a 
linear model fit using a P-value cutoff of 0.05 for clustering and heatmap.  
3b Heatmap showing the top six significant baseline genes associated with EULAR response (P-value cutoff 
0.02) in the focused MS4A1hi group: MS4A1, CXCR5, AICDA, IL21, IL23A, VEGFR3 
3c Baseline predictors of response to therapy in the focused MS4A1hi group
High expression of 8 genes involved in B-cell maturation and ELS formation (AICDA, BLK, CXCR5, IL21, 
IL23A, MS4A1, VEGFR3, WNT104) is associated with non-response at 16-weeks in the MS4A1hi subgroup.  
ΔDAS-28 scores are calculated as change from baseline; a fall in DAS-28 correlates with response to therapy.  
Gene expression is calculated using the mean of the tissue and expressed as relative change from the mean. 
P-values for each gene are derived using Spearman rank correlation.
3A 3B
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Figure 4.7 Baseline predictors of response to therapy in the MS4A1hi group 
High expression of 8 genes involved in B-cell maturation and ELS formation (AICDA, BLK, CXCR5, IL21, IL23A 
MS4A1, VEGFR3, WNT104) is associated with non-response to rituximab at 16 weeks in the MS4A1hi subgroup.  
D DAS-28 scores are calculated as change from baseline; a fall in DAS-28 correlates with response to therapy.  
Gene expression is calculated using the mean of the tissue and expressed as a relative change from the mean.  
P-values for each gene are derived using Spearman rank correlation. 
 
4.4.10 A baseline MS4AhiAICDAhi synovial gene signature predicts non-response to 
rituximab therapy 
 
Given previous data identifying AID as a critical mediator of synovial B cell aggregate 
functionality and furthermore the significant association of AICDA with non-response to 
rituximab identified in this cohort I went on to investigate whether synovial baseline 
expression of AICDA could be applied to discriminate responders vs non responders to 
rituximab.  Patients were divided at baseline into three groups: 1) MS4A1hiAICDAhi, 2) 
MS4A1hiAICDAlo and MS4A1lo (figure 4.8). We then identified significantly differentially 
expressed genes between these 3 groups and found that this provided a natural separation 
through clustering.  For each group, correlating their baseline expression against their 
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respective 16 week D DAS-28 and taking significant correlates, it was possible to segregate 
16-week responders and non-responders through groups, although this was not possible for 
the MS4A1lo group. 
 
The MS4A1hiAICDAhi correlated signature genes were then applied to the whole cohort of 
patients at baseline, irrespective of grade or level of expression of any gene.  A ROC analysis 
of clinical response at 16 weeks based on this signature achieved an AUC of 0.86 suggesting 
that response to rituximab therapy can also be segregated by the MS4A1hiAICDAhi gene 
signature across the whole cohort. 
 
Figure 4.8 Segregation of cohort into MS4A1hiAICDAhi, MS4A1hiAICDAlo and MS4A1lo groups 
Scatter plots with box plot overlays (median with upper and lower quartiles) showing the segregation of groups 
by MS4A1 / AICDA expression ***p<0.001 
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Figure 4.9 Clustering and heatmap showing the natural segregation of groups into three, 
with the top 16 genes by likelihood ratio test segregating each group.   
Heatmap colour key: red indicates high gene expression when compared to the overall mean of the tissue; green 
correlates with decreased expression from mean score 
 
4.4.11 A prediction model can be constructed using a MS4A1hiAICDAhi gene signature 
Finally, we created a linear model predicting 16 week D DAS-28 and found that using the 
MS4A1hiAICDAhi gene signature it is possible to predict response at 16 weeks (adjusted R 
0.865). 
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Figure 4.10 Receiver operating characteristic analysis to predict EULAR response.   
Using a subset of genes(MS4A1, SLAMF7, IL-2RB, FGF1, PAX5, FCRL5, IGKV1, TRAF1, IL-17R, IL-21R, MMP9 and 
CD8A) that segregated MS4A1 / AICDA grouping through clustering an AUC of 86.5 (62.7-92.3) was achieved. 
 
 
Figure 4.11 Prediction model of D DAS-28  
Only genes that were significant baseline correlates of D DAS-28 from the MSA41hiAICDAhi/lo group were chosen.  
The final model achieved R2 0.798 and included CD96, FCER2, IL1B, MMP25, CCL22, CD29.  The final predictive 
model of D DAS-28 was tested for auto-correlated errors using the Durbin Watson test using durbinWatsonTest 
(car package), and also non-linearity, skewness, kurtosis, and heteroscedasticity using gvmodel (gvlma) 
package).  Model outliers were detected using outlierTest (car package).  Finally, robustness of the model was 
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tested by shrinking r2 through 10-fold cross validation (CV) using crossval (bootstrap package) and comparing 
the fitted vesus predicted coefficients after each CV cycle. 
 
4.5 Discussion 
In the previous chapter I reported that the degree of baseline B cell infiltration does not 
predict subsequent response to therapy. Gene expression data shows rituximab differentially 
down regulates a number of genes involved in B and T cell activation and differentially 
upregulates fibroblast genes involved in reparative processes.  Through this work I provide 
novel insights into mechanisms of resistance to rituximab identifying that high baseline 
expression of genes regulating B cell differentiation, T-cell and Th17 responses and cell 
signalling significantly associate with a diminished delta-DAS 28 response. Finally, I also 
identified a baseline B-cell signature that in this cohort reliably predicts clinical response to 
rituximab.  
This data supports the notion that molecular analysis maybe a more sensitive biomarker of 
response [355, 356, 397, 441, 442]. Consistent with previous gene expression studies, there 
was a significant decrease in expression of the CD20 gene MS4A1 following rituximab therapy 
although this did not vary between responders and non-responders. Surprisingly, the level of 
B-cell depletion appeared to be higher in the B-cell poor group both by histology and 
molecular analysis, suggesting that organised cellular infiltrates are somehow resistant to 
depletion. 
 
There was significant modulation of T cell associated pathways following treatment with 
Rituximab.   Firstly, there was a global reduction in the expression of T-cell associated 
chemokine receptor CCR5 in responders. CCR5 is a functional receptor for several pro-
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inflammatory cytokines, including CCL4 (macrophage inflammatory protein-1b), which was 
also downregulated in responders.  Its other ligands include CCL3 (macrophage inflammatory 
protein 1a) and CCL5 (RANTES ‘regulated upon activation, normal T cell expressed and 
secreted’)[443, 444]. The role of CCR5 in inflammation has been highlighted through the 
identification of a potentially ‘protective’ polymorphism [445], although results from varying 
populations were conflicting.  Furthermore, CCR5 blockade results in amelioration in mouse 
models of disease[446].  Downregulation of this gene and its ligand provides further in vivo 
evidence that this chemokine has a key role in RA and propagation of synovial inflammation. 
 
Modulation of T-cell pathways was further evidenced by a global reduction in IL-2A and CD96 
expression. One study has previously reported higher levels of IL-2A in patients who 
responded to Rituximab therapy [447].  Low serum levels of IL-2 have also been suggested as 
a prognostic marker of remission through a systematic review [448].  CD96 is a receptor 
expressed on both T-cells and natural killer cells and is involved in cell adhesion pathways 
[449].  Its exact role in RA remains undefined, however it is likely to aid cell migration after 
exposure to a selected antigen. 
 
Rituximab has previously been shown to deplete T-cells, mainly of the CD4+ subtype [277].  
Thurlings and colleagues also demonstrated a reduction in T-cells in the synovium follow B-
cell depletion therapy [347].  There may be several mechanisms underpinning these 
observations.  Some circulating T-cells express CD20 and therefore it is plausible that 
Rituximab may have a direct effect on depletion of these cells.  Arguably however, the small 
proportion of these cells in peripheral blood, found by one study to be 3.2% [319], means that 
translation into a significant clinical response is unlikely.  B-cells are known to stimulate CD4+ 
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cells in the presence of activated dendritic cells [242, 450, 451] and Rituximab may indirectly 
result in the alteration of downstream T-cell signalling pathways.  Furthermore, B-cells 
significantly contribute to the inflammatory cytokine milieu which could result in an alteration 
in T-cell activation and differentiation.  Lastly, a reduction in T-cells may be expected as a 
response to disease amelioration and reduction of chronic inflammation which may not be 
directly related to the synovium. 
 
Downregulation of CD163, CLEC4E and CD36 lends support to previous findings that B-cell 
depletion also plays a role in the modulation of macrophage activation and correlates with 
the histological findings described in the previous chapter. CD163 is a cell surface marker of 
M2 macrophages.  CLEC4E (MINCLE) is a transmembrane protein expressed mainly on 
macrophages in the innate immune response and can induce the production of TNFa, IL-6 
and other proinflammatory cytokines through the Syk signalling cascade[452].   CD36, found 
on macrophages and dendritic cells, is less well studied and appears to have a range of 
biological functions, including negative regulation of angiogenesis and fatty acid 
oxidation[453] making its role here more difficult to define.  The observation that a reduction 
in sublining macrophages correlates with response regardless of the DMARD used suggests a 
common end macrophage mediated pathway of inflammation.   Lower numbers of circulating 
autoantibody producing B-cells and immune complexes could result in reduced activation of 
macrophages which carry both Fcg receptors and C5a receptors for complement mediated 
activation[454].  In vitro, human monocyte derived macrophages showed decreased TNFa 
production after B-cell depletion therapy and increased expression of BAFF and IL-10mRNA 
further suggesting that Rituximab is able to modulate macrophage function[455]. 
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Only one gene was significantly upregulated following the administration of Rituximab.  FGF-
1 is a heparin binding growth factor that stimulates proliferation and migration of cells and is 
abundantly expressed in the inflamed synovium. FGF-1 has been associated with repair and 
cell proliferation in hepatocytes and renal tubular cells, however its role in the synovium is 
thought to be pro-inflammatory[456].  FGF-1 and 2 have previously been shown to be present 
in the synovium of patients with high levels of inflammation and promote angiogenesis[456, 
457], with the latter being more potent.  What is not clear, however, is whether FGF-1 is 
produced in an attempt to heal the inflamed synovium or whether it forms an inherent, 
destructive part of the inflammatory process leading to joint damage. If the former part of 
the statement is true, then upregulation of this gene following rituximab may be reflective of 
its role in cell repair and regeneration, triggered by a decrease in inflammatory cytokines. The 
witnessed downregulation of other angiogenic (VEGFC, CD36) and matrix metalloproteinase- 
9 genes would support an overall reparative role of Rituximab in synovial healing. 
 
I have commented briefly on the cytokine producing role of B-cells.  In this cohort, there was 
a reduction in the expression of IL-15, IL-1b and IL-2RA.  Reduced levels of serum and surface 
Il-15 were seen in conjunction with changes in T-cell populations in the peripheral blood of 
33 patients who received Rituximab therapy [458].  Additionally, IL-15 induces growth and 
proliferation of B-cells [459, 460] and therefore downregulation of the gene could correlate 
with decreased circulating numbers. Furthermore, IL-15 levels are linked to IL-17 production 
and Treg numbers and are critical to memory CD8 T cell proliferation and production[461, 
462].  The reduction in IL-15 could therefore be linked to Rituximab induced alteration of T-
cell subsets, with a positive feedback loop, or directly due to B-cell depletion and the reduced 
need for ongoing proliferation.  IL-1 is produced by a multitude of cells, including synovial 
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macrophages and dendritic cells.  IL-1b is capable of inducing both IL-6 and TNF which act 
synergistically to promote inflammation and joint damage[463].  Downregulation of 
expression following Rituximab therapy may be related to the reduction or alteration of 
macrophage function.  Finally, downregulation of the IL2R following treatment may be related 
directly to receptor depletion by Rituximab, as it acts to proliferate both growth and 
differentiation of B-cells[464].   
 
The increased modulation of macrophage associated genes witnessed in the responder 
subset indicates that this may be one of the predominant mechanisms of clinical response.  
CCL4 is heavily involved in the recruitment of macrophages [393, 465] and a reduction of 
synovial macrophages has been shown to correlate with response to therapy[159, 160].  FGF1 
and VEGFR3 are involved in reparative processes in tissue, however within the synovium 
result in neoangiogenesis, pannus formation and correlate with disease activity [466, 467].  
PAD2 is key to citrullination of proteins[468] within the synovium whereas RORgT is a key 
regulator of Th17 differentiation[469].  Upregulation of these four genes in the responder 
group may result in response to synovial depletion of proteins; or may simply correlate to a 
group of patients in which antibody production and lymphoneogenesis play a more pivotal 
role in the disease process, perhaps resulting in a group that are more likely to response to 
CD20 depletion therapy. 
 
Critically, I have reported on novel synovial pathways identified as mediating resistance to 
rituximab. Firstly, I demonstrated that differential upregulation of the TH17 associated genes: 
TBX21, CD96, IL-23A, IL-21 and IL-15 at baseline were associated with a diminished response 
to therapy.  If we consider the function of each of these genes, it is possible to understand 
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how a subset of patients have disease that is predominantly driven by the Th17 pathway and 
therefore do not respond to depletion by Rituximab therapy. Modulation of the TH17 
response by rituximab therapy has been shown to correlate with a decrease of local IL-17 
production in the synovium, for which the presence of B-cells is required, resulting in 
amelioration of symptoms [278]. 
 
 TBX21 (Tbet) is a critical T cell transcription factor that controls Th1 cell differentiation and 
the production of IFN-γ, a known predictor of non-response[420].  It also is a negative 
regulator of commitment to the Th17 cell lineage. T-cells co-express both IL-17 and IFN- γ and 
the balance between IFN-γ and IL-17 produced by Th1 and Th17 cells plays a pivotal role in 
inflammation, particularly through the activation of fibroblast like synoviocytes[470]. High 
expression of IL21 drives towards the production of IL-17, whereas TBX 21 favours IFN-γ 
production[471].  The observation that high expression of both IL21 and TBX 21 correlates 
with worse outcomes is of importance, suggesting that the original  IFN-γ+ TH17 cell associated 
cytokines and transcription factors play a pivotal role in this subtype of disease, regardless of 
the downstream mechanism of inflammation. 
 
Reduction of IL-15 following treatment with rituximab therapy has been shown to correlate 
with both TH17 depletion and improvement in clinical response [458]. A similar phenomenon 
is seen in Sjögren’s syndrome, where treatment with rituximab results in a reduced glandular 
IL-17 expression. [472]   High expression of IL-15 can be taken as a surrogate marker of Th17 
and IL17 expression. I have already discussed the role of IL-21 in the differentiation of T cells 
to the Th17 subtype.  Il-21 also promotes the migration of cells towards GC and aids in situ B-
cell growth, differentiation to plasma cells and class switching[473-476], lending further 
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evidence to the hypothesis that GC’s are functionally active and may continue to propagate 
inflammation despite peripheral blood B-cell depletion. Finally, IL-23 induces Th17 cells and 
is necessary for maintained pathogenicity in this lineage[477, 478].  The IL23R is found on 
memory T-cells and is an important stimulator of IL-17 production.   
 
High levels of TH17 related genes may be associated with a reduced response to Rituximab 
therapy through a multitude of mechanisms.  Following antigen presentation, these cells may 
play a key role in orchestrating immune infiltration and therefore ‘one hit’ or depletion of B-
cells may not be able to ameliorate disease. Taken together, these results suggest that 
disruption of the Th17 response at a certain threshold, which resets the Th17/Treg ratio, is 
necessary to obtain a clinical response in individuals expressing this molecular pattern. 
Furthermore, we know that Th17 and IL-21 are also key orchestrators of ELS formation, 
highlighted in a recent study by Kelvey and colleagues who describe subtypes of RA synovia 
which can be segregated according to IL-17A and CD21L (the long isoform of CD21) gene 
expression, which are associated with tertiary lymphoid formation and B-lymphocyte 
pathways[479]. 
 
Stratifying patients according to MS4A1 expression demonstrated that genes involved in B-
cell regulation and functioning segregate with CD20 expression.  The high level of 
concordance between the molecular MS4A1 and histological B-cell score provides both 
validity to the scoring methods from the first chapter and further evidence for the presence 
of a ‘B-cell rich’ molecular signature.  IGKC, FCRL5, LTb, CSF1R and FGF1 were present in both 
the histological and molecular group. IGKC, or immunoglobulin kappa constant was identified 
to be a key gene differentially expressed between OA and RA samples [480], and was 
 193 
identified as a key gene in a microarray based study defining a plasma cell signature[481].  
The human Fc receptor-like 5 (FCRL5) is an IgG receptor expressed on B-cells which regulates 
the cellular response to antigens.  A recent study has identified cell lines which co-express 
FCRL5 and CD21, resulting in enhanced B-cell activity capable of responding to immune 
complexes[482].  Furthermore, FCRL5(+) tissue-like memory B cells in peripheral blood are 
more likely to accumulate somatic mutations[483] and are found in greater numbers in 
autoimmune disease.  Extrapolating these findings to synovial tissue, it is possible to 
speculate that the high co-expression of FCRL5 in the molecular B-cell rich group is suggestive 
of ongoing antigen presentation and B-cell activation.  LTb has been extensively studied for 
its pivotal role in lymphoid follicle development [276] and production of pro-inflammatory 
cytokines, matrix metalloproteinases and cell adhesion molecules[484]. Other pivotal genes 
expressed in the molecular B-cell rich group include PAX5, FOXP3, CCR7 and the IL-7R, all 
involved in B-cell maturation and priming. 
 
In this cohort, high expression of genes specifically involved in B-cell activation and the 
formation of ectopic lymphoid structures (LTA, CXCR5, IL15, PAX5) significantly associated 
with a diminished response to rituximab therapy. This observation was seen in the group as 
a whole, but also in the MS4A1hi group at baseline, where high expression of CXCR5, MS4A1, 
AICDA, BLK, and WNT107 enriched for non-response. AID is essential for somatic 
hypermutation and class switch DNA recombination and may result in in situ autoantibody 
production.  Activated B-cell CD40 signalling induces AID expression, enhanced by interleukin 
4 and toll like receptors [485].  CXCR5 is a chemokine which enhances trafficking of Tfh to 
germinal centres,  binding to its ligand CXCL13, a chemoattractant for B-cells[486]. BLK or B-
lymphoid kinase is crucial for B and T cell interactions, B cell receptor development and 
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certain haplotypes have been shown to confer risk of developing autoimmune diseases such 
as RA and SLE[487]. The Finally, the WNT family has been associated with synoviocyte like 
fibroblasts[488] which promote plasma cell survival and retention in ELS[489].  High 
expression of all five of these genes suggest that despite peripheral blood B-cell depletion, 
predominant overexpression of ELS genes within the synovium confers resistance to therapy. 
 
Reclassifying individuals by AICDA expression revealed three distinct groups: those with little 
or no B-cell gene expression, those with high expression but no active germinal centres and 
finally those with high MS4A1 and active germinal centres, characterised by expression of 
AICDA.  The latter group was least likely to respond to therapy.  This may seem somewhat 
counterintuitive; but supports previous work suggesting that synovial lymphoid aggregates 
may act as reservoirs for autoreactive B cells[346, 490]. Thus, specifically targeting the 
generation of these autoreactive B-cells or administering repeat cycles of rituximab in a bid 
to disrupt B-cell trafficking and subsequent maturation and organization into ELS may result 
in a more favourable response in this subset of patients. 
 
Finally, I then created a prediction algorithm based upon MS4A1/AICDA expression, 
demonstrating an AUC of 86.5%. Furthermore, by modelling the MS4A1hiAICDAhi group’s 
baseline gene expression to delta DAS28, ten genes were identified whose expression could 
be modelled for response in all patients at baseline to successfully predict the delta DAS-28 
for the group as a whole, irrespective of histology and clinical parameters at baseline. This 
needs to be confirmed using more samples but appears promising based upon the 
functionally linked activities of the genes described. Further changes in gene expression and 
response after one cycle of rituximab would also enhance a prediction model and may be able 
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to segregate those who require further cycles of Rituximab to disrupt T/B cell interaction from 
those in whom Th17 / IL23 pathways appear to be the major driver and are unlikely to 
respond. 
 
In summary, it is possible to create a predictive algorithm based on individual synovial gene 
expression pre and post Rituximab. B-cell depletion is necessary but may not necessarily 
predict response to therapy, particularly at the synovial level.  The biology of the genes within 
the response signature suggests that disruption of B-cell trafficking genes / ELS may be the 
key to response.  Additionally, Th17 pathways may contribute substantially to the 
inflammatory process; disruption of these, either through repeated B-cell depletion or 
alternate therapy may be the key to tailoring response in targeted individuals.  These findings 
need to be validated in a larger cohort of patients, but provide a step towards stratification 
based on molecular heterogeneity. 
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Chapter 5: 
Imaging predictors of response to Rituximab therapy 
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Arguably the most important clinical outcome in the efficacious treatment of RA is to halt or 
reduce progression of joint damage.  Several studies have confirmed through the use of plain 
radiographs or magnetic resonance imaging that Rituximab effectively prevents and slows 
down erosion progression[288, 289, 291, 298, 491-493] either as monotherapy or in 
combination with methotrexate.   To date, few studies have focused on established RA 
imaging and tissue responses to biological therapy, particularly in the context of B-cell 
depletion. 
 
Musculoskeletal US is a widely utilised tool used by rheumatologists in the diagnosis and 
assessment of RA.  The pathogenesis of RA involves neovascularity and vasodilation in 
synovial tissue; angiogenesis plays a crucial role in both the development and perpetuation 
of inflammation within the joint[494].  US detects both synovial thickening and 
vascularisation of tissue, measured through grey scale synovial thickening (ST) and power 
doppler signal (PD). Ultrasound has been shown to be more accurate than clinical 
examination in the evaluation of joint synovitis[61, 495, 496] and correlates with changes at 
the tissue level but does not yet feature in treatment or prognostic algorithms.  
 
Valor and colleagues undertook a study to explore whether the presence of B-cells in 
peripheral blood may influence subclinical synovitis[497].  All of the patients in this study had 
received two or more cycles of Rituximab and only two were classed as having active disease 
(DAS-28 >5.1).  Interestingly, all of the patients had US synovial thickening and 41% had PD 
signal after treatment. The group found no correlation between US indices, DAS-28, SDAI or 
last Rituximab cycle and the amount of circulating peripheral blood B-cells. 
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Another study followed up patients who were deemed to need retreatment at 6-9 months 
after the first cycle of Rituximab and a second group of patients where a further cycle was not 
felt necessary based upon clinical disease activity[498].  They utilised a grey scale US score 
and also formulated a novel US7 score based upon the most commonly affected joints: wrist, 
MCP and PIP 2 and 3, and MTP 2 and 5.  There was a significant reduction in GSUS, US7 and 
PD scores following treatment with Rituximab, with correlations noted between a reduction 
in tender joints, DAS-28 and GSUS.  Additionally, the group observed a reduction in the size 
and number of erosions following Rituximab therapy.  Patients requiring retreatment showed 
an increase in PD score in the months leading to therapy, indicating that this is a sensitive 
measure even in those with established disease. 
 
Only a few studies have explored the relationship between US and synovial pathology and 
therefore direct evidence linking PD signals to active inflammation remains limited.  
Furthermore, to my knowledge, no studies have examined the modulatory effects of 
rituximab on synovial histopathology and its relationship to ultrasonographic outcomes.  
Results from other synovial based studies have so far been conflicting, although there is more 
consistent reporting of an association of PD with histological inflammation.  
 
A recent study of 26 knee biopsies from a range of inflammatory conditions, including crystal 
arthropathies, found strong correlations between US synovitis grade and histological synovitis 
scores, US doppler grade and vascularity, with a moderate correlation with CD68 
macrophages[499].  Andersen and colleagues conducted a study where synovial explants 
were removed from patients about to initiate biological therapy.  Explants were cultured in 
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vitro and production of IL-6, monocyte chemoattractant protein 1 (MCP-1) and macrophage 
inflammatory protein 1-beta were measured using a multiplex assay. The authors report that 
colour doppler US in vivo were correlated with IL-6 production in vitro[500].  They did not, 
however, directly measure correlations with histological synovitis.  The same group had 
conducted an earlier study in 81 arthroscopic needle biopsies where they demonstrated PD 
correlations with the synovitis score, CD68, CD3, Ki67 and von Willebrand factor[501].  Similar 
findings were demonstrated by Takase et al in biopsies obtained prior to knee arthroplasty in 
patients with long-standing disease  where PDUS and GSUS correlated with histological grade 
of synovitis[502].  Conversely, an older study by Koski and colleagues in which synovial tissue 
samples obtained from a range of large and small joints, bursae and tendon sheaths using the 
US guided biopsy technique showed no correlation with synovial thickening or power doppler 
scores, although there was an association between absence or presence of PD signal[503].   
Interpretation of all of these studies is complicated, however, by different scoring methods 
and varying techniques of tissue acquisition. 
 
There are multiple lines of evidence to suggest that B-cells play a role in bone damage, leading 
to the hallmark erosions seen in RA.  Rituximab therapy inhibits the formation of erosions by 
altering the ratio of bone resorption and formation, inducing changes in the RANKL / 
osteoprotegrin ratio[491, 504, 505].  B-cell rich lymphoid aggregates are present at the 
junction of synovium and subchondral bone, with the ability to recruit osteoclast progenitor 
cells resulting in an increased number of osteoclasts and bone erosion[274]. The antibody 
producing role of B-cells may also be involved in the formation of erosions as CCP positive 
synovitis is associated with more infiltrating cells, cartilage degradation and bone 
destruction[186, 187, 506].  Furthermore, memory B-cells are capable of producing RANK-L 
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both in vivo and in vitro[507]. Despite ample evidence that B-cells are inherently involved in 
destructive processes in RA, how much they contribute to the initial processes of 
neovascularisation and synovial thickening remains to be elucidated. 
 
Angiogenic factors and pro-inflammatory cytokines play a key role in the formation of new 
vessels within the synovium.   In normal joints, there is a modest correlation between vascular 
endothelial growth factor (VEGF) and PDUS score, p=0.045 [508].  An ultrasound guided 
biopsy study of 12 patients with early arthritis showed significant correlations of PDUS with 
expression of angiogenic factors VEGF-A, angiopoetin-2 and Tie-2, with further correlations 
between US synovitis and VEGF-C and VEGF-R3.  This study also demonstrated a correlation 
between PDUS and sublining macrophage infiltrates[509]. A previous study also identified 
high levels of angiogenesis associated gene expression within the synovial tissue and fluid of 
8 RA patients with established disease who had a mean disease duration of 16.3 years[510], 
indicating that upregulation of proliferative growth factors can be witnessed at all stages of 
the disease. 
 
Further studies exploring gene expression associated with angioneogenesis in humans are 
lacking in the literature.  Increased mRNA expression of VEGF receptors, hepatocyte growth 
factor and insulin-like growth factor-1 and angiopoietin-1 has been observed in the collagen 
induced arthritis (CIA) mouse model of RA[511].  In further support of these findings, the use 
of an anti angiogenic and antiproliferative compound delayed disease onset, reduced severity 
and resulted in suppression of gene expression of bFGF and VEGF in the synovium with an 
overall reduction of synovial blood vessel formation[512].  Further animal studies have 
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proposed mechanisms to halt or reduce neoangiogenesis [513, 514] but are yet to be 
replicated in large human studies. 
 
The studies described above raise a number of issues which lead to the hypothesis and aims 
of this chapter.  Firstly, there is paucity of data regarding synovial cell infiltration and US 
scoring in established or longstanding RA. Indeed, it remains unclear whether findings from 
early RA can be extrapolated to a cohort of patients with long disease duration who have 
failed multiple therapies.  Although there are studies assessing changes following bDMARD 
therapy with anti-TNF, only two studies were found that specifically assess ultrasound 
changes before and after B-cell depletion therapy.  One of the studies hypothesised a 
correlation with peripheral blood B-cells, but did not address whether there may be a pro-
inflammatory role for B-cells or lymphoid aggregates within the synovium.  Finally, previous 
gene expression studies exploring changes before and after Rituximab therapy have not 
commented specifically on changes in expression of growth factors and genes involved in 
neoangiogenesis.  All of these factors play an important role in assessing whether US imaging 
can potentially serve as a biomarker of response after B-cell depletion therapy, which forms 
the experimental objective of this chapter. 
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5.2 Hypothesis and Aims 
The main hypothesis of this work was that B-cell rich patients will display higher levels of 
synovial thickening and ultrasound PD and that this can serve as a biomarker to guide 
response to therapy.  The specific aims were  to: 
1. Ascertain if clinical parameters and histology correlate with US and PD at baseline 
2. Determine if those with a B-cell rich pathotype have higher grades of ST and PDUS 
3. Determine the modulatory effects of Rituximab of US imaging and whether this 
correlates with changes in histological infiltration 
4. Explore whether higher levels of genes associated with angiogenesis associate 
significantly with ST and PD at baseline and at 16 weeks 
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5.3 Methods 
5.3.1  Study Population 
22 patients (18 males and 4 females) all fulfilling the revised 1987 criteria for RA enrolled as 
part of the R4RA pilot study at Barts Health NHS Trust were studied as described in the 
methods chapter. 21 patients had ultrasound data available at baseline, paired ultrasound 
data was only available for 14 patients. 
 
5.3.2 Patient Assessment 
Clinical parameters including number of swollen and tender joints, health assessment 
questionnaires, c-reactive protein and erythrocyte sedimentation rate were recorded at 
baseline and at 12 weeks follow up. Clinical response to rituximab were assessed using the 
EULAR response criteria.   
 
5.3.3 US Assessment 
US images were acquired by myself and two other researchers trained in musculoskeletal 
ultrasound, Nora Ng and Maria DiCicco.  We used a GE Logic 9 ultrasound machine with a 14 
MHz two dimensional M12 transducer.  Longitudinal images of MCP joints 1-5 and three 
(midline, radial and ulnar) views of both wrists were acquired to form a 12 joint synovitis 
score.  Additionally, details were recorded of the biopsied joint.  Scans were performed at 
room temperature and images which conform to recommended standards of acquisition with 
at least 1mm of gel between the probe and overlying skin were obtained.  Settings are as 
described in the methods chapter. 
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5.3.4 US guided biopsy 
Synovial samples were taken using ultrasound guided synovial biopsy from all patients with a 
clinically involved joint at baseline and at 16 weeks.  A minimum of 6 synovial samples were 
also retrieved and immediately immersed in RNALater (AMBION life technologies, UK) for 
subsequent RNA extraction as previously described. 
5.4.4 High throughput quantitative real-time PCR 
High throughput quantitative real-time PCR for 190 genes, pre-selected according to known 
roles in RA / B cell biology was performed using the Fluidigmã platform (Fluidigm 
Corporation, South San Francisco, California, USA) as described in the methods in chapter 4.   
5.5.5 Statistical Analysis 
Continuous variables are expressed as mean ± standard deviations.  Comparison of pre-
treatment and post-treatment clinical data, histological and US analysis was performed using 
the Wilcoxon signed rank test for paired data. For unpaired data, the Mann-Whitney U test 
was used to analyse for differences in median and rank. Associations were performed by 
deriving the Spearman rank correlation coefficient.   
Gene correlations with clinical variables and synovial thickening and power doppler signals 
were calculated using Spearman rank correlation coefficients with p<0.05 deemed to be 
significant.  
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All statistical analysis and graphs were derived using Prism (version 7, compatible for 
Macintosh systems) or R Programming Language (R) The cut-off value for significance was 
<0.05 for all tests. 
 
5.4 Results 
5.4.1 Study population 
US data was available for 21 patients at baseline and 14 patients at the 16-week timepoint 
due to loss of follow-up or an incomplete dataset.   
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Table 5.1 Demographics and clinical characteristics of patients with data available at 
baseline for analysis of ultrasound scores 
  
Age (yrs) mean ± sd 53±13.78 
Female, n, (%) 17 (81) 
Median disease duration months (IQR) 99 (24 -120) 
RF positive, n, (%) 16 (76) 
ACPA positive, n, (%) 19 (90) 
ESR mm/hr median (IQR) 22 (9-55) 
CRP mg/l median (IQR) 9 (0-19.5) 
DAS-28 mean ± (sd) 5.73 ± (1.07) 
 
SJ median (IQR) 6 (3-8.5) 
TJ median (IQR) 11 (7.5-19) 
VAS mean ± sd 65.33 ±24.49 
HAQ mean ± sd 2.08 ± 0.73 
Erosive≥1 joint n, (%) 17 (81) 
ST, median (IQR) 26 (23-30.5) 
PD, median (IQR) 3 (2-5.5) 
Median number of previous anti-TNF drugs, IQR 1 (0-1.5) 
No of patients receiving Rituximab as first line 
biologic 
therapy, n (%) 
6 (29) 
No of patients on methotrexate n (%) 12 (57) 
Methotrexate dose, median (IQR) 5 (0-17.5) 
No of patients on prednisolone, n 10 (48) 
Prednisolone dose, median (IQR) 0 (0-8.75) 
  
Abbreviations 
RF=rheumatoid factor, ACPA= anti-citrullinated protein antibody, ESR = erythrocyte sedimentation rate, CRP = 
c-reactive protein, DAS-28= 28 joint count disease activity score, HAQ = Health assessment questionnaire, SJ = 
swollen joints, TJ = tender joints, VAS = visual analogue score, ST = synovial thickening, PD = power Doppler, 
EULAR = European union 
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5.4.2 Treatment with rituximab did not result in a change in ST and PD US scores 
There was no significant change in ST before and after Rituximab treatment in this cohort as 
a whole, despite the observation that there was a significant improvement in DAS-28.  The 
median pre-treatment was 26  (21.74-31.25) and post treatment 25.5 (21.75-29.75), p=0.72. 
I then divided the groups into responders and non-responders, and witnessed no significant 
decrease (p=0.99, p=0.59, respectively) in ST or PD in these groups regardless of differences 
in clinical outcomes.  Although there was a reduction in median power doppler score pre and 
post Rituximab treatment, pre 3 (1.75-6.25), post 2 (1-4.5) this reduction was not significant 
(p=0.29).  Furthermore, no differences were detected pre and post treatment between 
responders and non-responders (p=0.99, p=0.13, respectively). At 16 weeks there were no 
differences in ST (p=0.47) and PD scores (p= 0.88) between responders and non-responders.  
I then redid the analysis with single joint scores, with no significant differences found within 
the groups.  This was due to two reasons -  the algorithm used to choose the affected joint to 
biopsy means that all samples had a ST score of at least 2; the second reason was because 
many of the joints biopsied were knees or elbows, which were not included in the overall joint 
score and therefore individual values had not been recorded.  
 
 208 
 
Figure 5.1 No differences were observed between synovial thickening (ST) and power 
doppler (PD) scores before and after treatment with Rituximab  
Bars represent median, lines represent interquartile ranges.  No values were significant using Wilcoxon ranked 
pairs test.  Abbreviation ST = synovial thickening, PD = power dopppler 
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Figure 5.2 At 16 weeks there was no difference in synovial thickening (ST) or power doppler 
scores between responders and non-responders 
Bars represent median, lines represent interquartile range 
Abbreviations ST = synovial thickening, PD = power doppler 
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5.4.3 There is a significant correlation between US ST and PD at baseline 
At baseline, there is a significant correlation between US ST scores and PD scores (p=0.02).  
This is lost at 16 weeks, although there a trend towards correlation remains (p=0.06). 
 
Figure 5.3 There was significant correlation between synovial thickening and power doppler 
at baseline but not at 16 weeks 
Spearman’s rank correlation coefficient. Abbreviations ST = synovial thickening, PD = power doppler, wk = week 
*p<0.05, Spearman’s correlation co-efficient 
 
5.4.4 Serum levels of IgM with US ST baseline 
Next, I went on to explore whether US ST and PD correlated with any clinical variables at 
baseline and at 16 weeks.  At baseline, the only significant clinical or laboratory correlations 
found were serum levels of IgM (g/l) and ST (r = 0.56, p=0.010). The significance of this 
association is unclear and will be discussed further.  At the 16-week timepoint, no associations 
were detected with clinical parameters, including the number of tender and swollen joints. 
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Figure 5.4 There is a positive correlation between serum IgM levels, g/l and synovial 
thickness scores 
 
5.4.5 Patients in Imaging remission have a lower CRP and SJC 
Next, I took patients in “imaging remission”, with a PDUS <1 at 16 weeks and conducted 
analyses to ascertain whether there were differences between the two groups. Of the 14 
samples where US data was available at the 16 week timepoint, 6/14 (42.9%) patients had a 
PD score of £1.  3/6 (50%) had a moderate or good EULAR response to Rituximab therapy.  A 
similar proportion, 3/8 (37.5%) in the group with active synovitis defined by US criteria, 
however, displayed a good DAS-28 response and were deemed to be responders.  CRP was 
the only discriminatory laboratory variable amongst those in PD remission and those with 
active synovitis on US (p=0.05).  There was a trend towards a lower swollen joint count in 
those patients in US remission (p=0.09) but this did not reach significance.  For all other clinical 
variables, no significant differences were found between the groups.   
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Figure 5.5 There is no difference in clinical variables between patients in PD remission 
compared with those with active PD on ultrasound 
PD remission is defined as a score £1.  There were no significant differences between groups 
using the Mann-Whitney test. 
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5.4.6 B-cell rich patients do not have higher ST and PD US scores 
Contrary to the proposed hypothesis, I found that in this cohort of patients, B-cell poor 
patients had more ST at baseline than B-cell rich patients; median B-cell rich 23 (21-26) vs 
median B-cell poor, 26 (22-27.5), p=0.02. No significant differences were seen in PD signal 
between B-cell rich and poor patients.  Unexpectedly, negative correlations were found 
between CD20 (r=-0.5, p = 0.031), CD68SL (r=-0.46, p = 0.049) and CD138 (r=-0.49, p = 0.035) 
and ST.  No significant correlations were found between PD and synovial cell infiltrate. 
 
 
 
Figure 5.6 A B-cell poor synovial pathotype correlates with higher US synovial thickening at 
baseline 
Solid lines represent the mean, boxes represent the standard deviation and lines represent the range, * p<0.05 
using Mann Whitney test. 
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Figure 5.7 Correlation plots of A) ST and baseline SQ CD20 score, B) ST and SQ CD138 score, 
C ST and SQ CD68 sublining macrophage scores 
Significant negative correlations were observed with ST scores, CD20, CD138 and CD68 (SL) infiltrations using 
Spearman’s rank correlation coefficient. 
Abbreviations SQ = semi-quantitative score, ST = synovial thickening 
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5.4.7 Genes involved in T-cell effector responses correlate with ST and PD scores 
Using the Fluidigm data, I explored the function of genes with significant correlation with US 
synovial thickening, PD scores and erosions at baseline. The top ten genes which correlated 
with each variable are listed in table 4.2.  CD163, CD206 and MS4A4A showed negative 
correlations with ST, the latter two genes also associated with PD signal. CD163 is a 
macrophage specific protein; high levels of expression are characteristic of tissues responding 
to inflammation [515].  CD206 is a receptor expressed by macrophages and dendritic cells, 
with a role in collagen internalisation and degradation[516]. MS4A4A is a member of the 
membrane spanning, four domain family which includes CD20, FcRb and HTm4 and has been 
demonstrated in immature dendritic cells, M2 macrophages and plasma cells[517]. These 
findings support the results of the histological analysis which showed an unexpected negative 
correlation with B-cells, macrophages and plasma cells. 
 
Positive correlations were seen between  synovial thickening, power doppler and IL-17A  and 
IL-17F, members of the IL-17 family which share 50% homology[518].  TNFRSF4 (TNF receptor 
superfamily, member 4), also known as CD134 or OX40, which plays a role in the activation of 
TH2 cells and subsequent cytokine production[519], also positively correlated with ST and PD.  
OSM, or oncostatin-M, a gp-130 signalling cytokine found in RA synovium was present in both 
groups.  Of importance, IL18R and the IL18RAP (Il-18 receptor associated protein) which bind 
to IL-18, a key mediator in leucocyte extravasation and subsequent pro-angiogenic cytoking 
production[520], were found to have significant associations with US PD scores. 
 
The expression of 34 genes correlated with the presence or absence of erosions in this cohort.  
IL17F, IL17A, Il18RAP, IL18R1, TNFRSF4 and OSM expression also appeared in this group.  
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Again, there was a negative correlations of the genes CD206, CD163 and MS4A4A with the 
presence of erosions.  
 
At 16 weeks, levels of ICOSLG, CTGF, CXCR6 and IL18R1 correlated with both ST and PD. 
 
Genes correlating with ST at  
baseline 
Genes correlating with ST at  
16 weeks post Rituximab treatment 
Gene r  p Gene r  p 
IL17F 0.65 1.7774E-05 CTGF 0.71 0.00045 
TNFRSF4 0.62 5.3298E-05 ICOSLG 0.62 0.0033 
PDCD1 0.61 7.9428E-05 CXCR6 0.52 0.020 
CD206 -0.61 8.0163E-05 FCER1A 0.51 0.023 
MSA4A4A -0.61 8.0532E-05 IL18R1 0.45 0.044 
FCRL4 0.61 9.6196E-05  
SMAD7 -0.59 0.00014 
CD163 -0.59 0.00015 
IL17A 0.58 0.00021 
OSM 0.58 0.00023 
Table 5.2 Genes correlating with ST at baseline and at 16 weeks post rituximab treatment 
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Genes correlating with PD at  
baseline 
Genes correlating with PD at 16 weeks 
post Rituximab treatment 
Gene r  p Gene r  p 
CD206 -0.68 5.4814E-06 ICOSLG 0.84 4.3686E-06 
IL18RAP 0.62 5.7255E-05 CTGF 0.69 0.00085 
MSA4A4A -0.58 0.00020 MAF 0.62 0.0034 
TNFSF3 -0.58 0.00024 FCER2 0.57 0.0083 
IL13RA2 -0.57 0.00026 IL18R1 0.56 0.0096 
IL17F 0.56 0.00037 PAD2 0.56 0.011 
LYVE1 -0.56 0.00041 CXCR6 0.55 0.013 
OSM 0.55 0.00045 TNFRSF17 0.54 0.014 
TNFRSF4 0.54 0.00059 LTA 0.54 0.014 
IL18R1 0.54 0.00062 VEGFR3 0.53 0.017 
Table 5.3 Genes correlating with PD at baseline and at 16 weeks post rituximab treatment 
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5.5 Discussion 
 
Musculoskeletal ultrasound is a widely used by rheumatologists in the diagnosis, 
management and detection of relapse in RA.    The ultimate goal of RA treatment is to prevent 
structural, long-lasting joint damage by inducing remission.  The definition of remission, 
however, remains unclear.  Moreover, whether changes in US ST and PD accurately reflect 
underlying inflammation at the tissue level has not been fully elucidated, particularly in 
longstanding disease.   
 
The aim of this chapter was to ascertain whether treatment with Rituximab therapy resulted 
in changes in ST and PD signal and if this correlated with the presence of synovial infiltrates, 
in particular B-cells, and associated gene expression.  The results differed from the original 
hypothesis, as I was unable to demonstrate significant changes in ST and PD following B-cell 
depletion.  Secondly and unexpectedly, contrary to previous studies, I found a negative 
association between histological synovitis and ST of PD grading which also manifest itself at 
the gene expression level.  Finally, despite a recognised role for B-cell biology in the formation 
of erosions, genes associated with ST and PD were largely had T-cell associated function.   
 
In patients with established RA, disparities have been reported between the clinical 
assessment of tender and swollen joints and the presence of PD signal.  Despite a significant 
reduction in DAS-28, the patients in this cohort did not undergo a significant reduction in ST 
and PD signal.  There was also no association with tender or swollen joints. US data was 
available for six patients with moderate or good EULAR responses – 50% of these still had 
synovitis on ultrasound. This is in keeping with findings by Valor and colleagues [497], 
 219 
although conflicts with reported findings from Reiche et al[498]. The main explanations for 
these findings come from investigating differences in patients with early RA and those with 
long standing RA, which all show varying levels of persisting GSUS and PD signals.  A study 
designed to compare early and longstanding cohorts showed that 65.2% of patients with 
longstanding disease had grey scale thickening, or ‘inactive synovitis’, and at 12 months only 
17.2% showed evidence of US remission[521].  Brown and colleagues recruited a cohort of 
patients who had a median disease duration of 7 years and found that despite being clinical 
remission, 87% had evidence of GSUS thickening and 63% had power doppler signal; 92% had 
synovitis on MRI which correlated with structural damage progression[522].   A further study 
showed that disease duration correlated with grey scale synovitis (p=0.011) and 
approximately 20% displayed PD signal in the absence of any tender or swollen joints[523].  
This study also highlights limitations of the DAS-28 as a scoring system for active inflammatory 
disease, influenced by the weighting of the different components and the need to evaluate 
the utility of imaging in longstanding disease[524]. 
 
These findings lend support to the observation that in this cohort there was ongoing synovitis 
despite improvements in clinical parameters. It is known that patients with established RA 
have chronic inflammatory changes and at the simplest level, the absence of changes in ST 
scores may be due to the detection of chronic fibrous tissue rather than active inflammation 
or that the 16 week time point is too early for meaningful change. This notion is conflicted by 
a recent study suggesting that GS synovial hypertrophy without active PD is also sensitive to 
change, independent of the grade and duration of disease[525].  Changes in the synovial 
vascular bed, neoangiogenesis and capillary blood flow, however, have not yet clearly been 
described in patients with longstanding RA, although certainly studies with other biologic 
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therapies and long disease duration would suggest that it is possible to achieve a significant 
reduction in PD scores[102, 498, 526-529].   
 
I demonstrate in this cohort that low PD activity correlates with low CRP levels and that there 
is a trend towards a lower swollen joint count which suggests that in a proportion of patients, 
PD is a sensitive marker of response to Rituximab therapy.  Significant correlations were also 
seen between serum IgM levels and ST.  Since I did not specifically test for RF IgM it is difficult 
to draw any sound scientific conclusions from this association, although it would be 
interesting to explore if specific RF fractions coupled with greater degrees of synovitis. 
 
 
Further disparities between current ultrasound studies and my findings may also be explained 
by the “Treat to Target” or “Window of opportunity” approach that has been adopted by 
physicians, particularly in the last decade.  This tight, targeted approach to therapy is 
temporally related to the rise in musculoskeletal ultrasound-based studies in the literature. 
This raises the possibility that plasticity of the synovium is greater in early disease, with tight 
control reflecting changes in ST and PD more accurately than in this cohort with longstanding 
disease activity.  In the context of this study, several bDMARDs have been licensed after the 
onset of RA, inferring that physicians treating early in the disease had restricted therapeutic 
options to ‘treat to target’, resulting in high levels of ST and PD at baseline.   
 
Another critical area of research highlighted by these findings is the need to define “true” 
remission and response in RA. Clinical remission does not invariably halt progression of 
structural damage and therefore whether true remission should be characterised by the 
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absence of PD signal is a question which remains to be answered. Despite improvements in 
DAS-28, none of the patients in this cohort achieved clinical (DAS-28 <2.6) or ultrasound 
remission (PD score of 0), yet did show response to therapy.  The coordinators of the recent 
ARCTIC and TASER trials conclude that the use of ultrasound may lead to overtreatment and 
inefficient use of resources, as no significant differences in outcome were seen in the US tight 
control arm vs the conventional tight control arm[65, 66].  The answer may ultimately rest 
with the availability of resources and the ease at which US can be used as an adjunct to guide 
treatment. 
 
Given previous work showing that B-cells may have a multifactorial role in the development 
of erosions and that ELS are associated with higher grades of synovitis, I was expecting to 
demonstrate that B-cell rich patients displayed more ST and PD.  Surprisingly, patients who 
did not have large numbers of inflammatory cells within the synovium displayed higher 
degrees of imaging synovitis, with negative correlations of CD20, CD138 and CD168(SL) cells.  
One explanation for this may be that synovial proliferation is driven by activated synovial 
fibroblasts, which I did not test for within this work.  Proliferation of synovial fibroblasts is a 
key feature of the diseased synovium, resulting in the production of matrix 
metalloproteinases and pro-inflammatory cytokines[530].  The subsequent creation of an 
inflammatory environment results in an increase in leucocyte infiltration which is coupled 
with neovascularisation through tissue hypoxia and the subsequent production of pro-
angiogenic factors[531].  Another possibility is that the majority of the patients in this cohort 
displayed a ‘low-inflammatory’ or ‘pauci-immune’ subtype[369] or had predominantly fibroid 
driven disease.  These are distinct molecular subsets of synovitis recently described by Dennis 
et al [356], which, despite molecular heterogeneity display similar clinical phenotypes to 
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lymphoid or macrophage rich disease.  It is also worth questioning whether synovial cellularity 
is truly reflective of different disease processes or whether it presents a continuum of the 
same disease, leading to the speculation that the processes which lead to the initiation of 
synovial proliferation are not predominantly B-cell driven.  Finally, it is important to note the 
therapeutic heterogeneity of this sample, as I have not explored the effects of concomitant 
prednisolone, methotrexate, varying number of cDMARDS and prior anti-TNF therapy on the 
synovium. 
 
Analysis of gene expression profiles associated with synovial thickening and power doppler 
signal also revealed some novel and interesting findings.  In keeping with the histological data, 
levels of macrophage and B-cell associated genes MS4A4A, CD163 and CD206 negatively 
correlated with ST and PD.  In this cohort of patients, ST and PD appear to be more dependent 
on T-cell associated genes.   
 
IL-17 plays a key role in RA pathogenesis.  Most studies have focused on IL-17A, which shares 
50% homology with IL17F suggesting overlapping biological roles.  In keeping with my 
findings, serum IL-17 levels have previously been shown to correlate with US ST and PD, with 
significantly higher PD signals in patients with detectable levels of IL-17 [532].  Another study 
found that the percentage of IL-17 positive T-cells in synovial fluid correlated with PDUS, 
active disease and both in and ex vivo levels of VEGFA[533].  Additionally, IL-17 has been 
identified as part of a synovial cytokine expression profile associated with joint damage 
progression[378].   Several in vitro and mouse model experiments demonstrate a key role for 
IL-17 in angiogenesis. In vitro,  IL-17 stimulates fibroblast like synoviocytes to secrete 
VEGF[534] and also results in an increased production of matrix metalloproteinases in 
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synovial tissue explants through the actions of TNF and OSM[535].  In this cohort, OSM 
expression was also upregulated in patients with higher PD and ST at baseline, suggesting that 
these genes may be acting synergistically to drive synovial proliferation.  IL-17 can also 
promote osteoclastogenesis by directly stimulating osteoclast differentiation in vitro and 
through the production of RANK-L[536, 537].  Furthermore, several mouse models of arthritis 
demonstrated IL-17 mediated cartilage and bone erosion with amelioration of these findings 
after IL-17 blockade[206, 538, 539]. 
 
I also found that expression of both IL-18 and IL-18 RAP significantly correlated with ST and 
PD, suggesting a pivotal role for IL-18 in joint swelling.  IL18 is significantly elevated in the 
joints and sera of patients with RA[540, 541] and is produced by a multitude of cells, including 
macrophages and synovial fibroblasts, the latter mediated by a TNFa dependent 
pathway[520, 542].  In vitro, synovial fibroblasts stimulated by IL-18 produce a number of 
adhesion molecules and angiogenic factors, including intercellular adhesion molecule 1 
(ICAM-1) vascular cell adhesion molecular 1 (VCAM-1), VEGF, stromal derived factor as well 
as a number of leucocyte chemotactic factors[543, 544]. Murine models also demonstrate a 
pathogenic role of IL-18; administration of this cytokine worsens the severity of CIA, whereas 
blockade ameliorates disease[545-548].  Chew and colleagues[549] used IL-18 as marker of 
synovial inflammation in a study designed to utilise MRI findings to identify subclinical 
inflammation.  mRNA levels of IL-18, however were undetectable in several patients, perhaps 
due to the sensitivity of the assay, and therefore no firm associations between imaging and 
cytokine levels were made.  To my knowledge, no previous studies have assessed the 
relationship of IL-18 or its associated receptor or protein with US ST and PD, making this an 
important and novel finding, highlighting it as a potential biomarker of angiogenesis. 
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Analysis of genes associated with the presence or absence of erosions had marked similarity 
to those associated with ST and PD signal.  The lack of B-cell associated genes in this subgroup 
suggests that similar mechanisms contribute to erosions as the end product of synovial 
inflammation, which in this cohort appear to be driven predominantly by cytokines derived 
from T-cells, macrophages and synovial fibroblasts. 
 
Drawing findings from genes correlated with PD and ST at 16 weeks post Rituximab therapy 
is more challenging.   I have therefore concentrated on the functions of genes appearing in 
both groups.  Upregulation of the IL18R remains present in both groups at 16 weeks, 
indicating that despite B-cell depletion, the cytokine and its receptor may be associated with 
ongoing inflammation.  The other two genes of note that appear to correlate with both ST 
and PD at ICOS-L and CTGF.  Inducible costimulator (ICOS) and its ligand (ICOSL) regulate 
adaptive B and T cell processes by providing costimulatory signals following antigen 
exposure[550].  ICOS is associated with an increase in the suppressive activity of Tregs, which 
have been shown to have a higher frequency in inactive RA and negatively correlated with 
DAS-28 scores[551].  Although largely speculative, the restoration of Treg: TH17 ratios could 
explain the absence of IL17A and IL17F at the 16-week time point, mirrored by an increase in 
ICOS and its ligand.  
 
CTGF, or connective tissue growth factor, is a heparin binding protein involved in 
inflammation, angiogenesis, wound healing, fibrosis and tumorigenesis[552] and has recently 
been identified as a potential biomarker of RA[553]. Without functional studies it is difficult 
to ascertain whether the witnessed association is due to the angiogenic or fibrosis inducing 
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properties of the protein. It may be possible that synovial reparative processes are 
upregulated following B-cell depletion resulting in resolution of inflammation and increased 
fibrosis which would correlate to a GSUS score.  The association with power doppler, 
however, would suggest an alternate mechanism whereby the angiogenic properties of the 
growth factor play a more important role.    
 
The work presented in this chapter raises several findings which differ from the original 
hypothesis but highlight critical pathways in the processes of synovial proliferation and joint 
swelling.  The data described here does, however, have several limitations.  Firstly, the small 
sample size inherently reduces the reliability and validity of any significant results.  The semi-
quantitative analysis of both synovial histology and US scores, although straightforward for 
the scoring physician, has limited sensitivity to detect real changes, and would have been 
improved by quantitative scoring methods.  The results could also be influenced by the 
composite score rather than that of just the biopsied joint, although this in itself would be 
biased based upon the minimal ST score of 2 when selecting a joint to biopsy. Assessing US 
data at later timepoints such as six months or 12 months may also have yielded different 
results.  Furthermore, formal scoring of erosions was not assessed within this work and would 
have provided a more reliable measure of structural change.  Finally, correlation does not 
imply causality and therefore much of this discussion remains speculative based upon known 
biological pathways.  Most of this data is observational but could form the starting point of 
several in vitro or vivo studies which would lend support to causality.   
 
Nevertheless, this chapter presents some novel ideas and posing questions.  I have 
demonstrated that ST and PD scores may not be as sensitive to change in long standing 
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disease and appear to remain unchanged at 16 weeks after Rituximab therapy.  Despite 
previous data suggesting that synovial histology correlates with ST and PD scores, this data 
suggests that this correlation may be lost in long standing disease and that further studies 
should be undertaken in larger numbers of patients at different stages of the disease process.  
Finally, I have demonstrated that Th17 related pathways and IL-18 may play a key role in 
synovial neovascularisation and proliferation and that these may be altered by Rituximab 
therapy.   
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Chapter 6: General Discussion 
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RA is heterogenous disease with variation at clinical, biological and molecular levels.  
Rheumatologists now have a wealth of treatment options to treat RA, yet a sizeable 
proportion of patients remain resistant to certain therapies.  Ideally, treatment in RA should 
be personalised in order to minimise disease progression and optimise quality of life, with 
utopian goals of disease remission, minimal side effects and a good quality of life.  Current 
biomarkers are not sensitive enough to predict response to therapy.  The synovium remains 
the key site of insult and injury in RA, yet the order of events leading from an initial break in 
tolerance to disease perpetuation remains unclear.  The main focus of this thesis was to 
evaluate whether heterogeneity at the synovial level, particularly in the context of B-cell rich 
enriched tissue, could predict imaging and clinical response to rituximab, a drug that is already 
widely used in the treatment of RA.   
I have examined a cohort of 24 patients with established RA who had failed or had a 
contraindication to anti-TNF therapy and assessed whether histological and molecular 
signatures in the synovium correlated with outcomes and imaging.  I have reported a number 
of novel observations: 
• Despite a reduction in CD20 cells and CD68SL macrophages after rituximab therapy, 
synovial histology did not correlate with clinical phenotypes and EULAR response 
• High baseline expression of genes regulating ELN and Th17 responses are associated 
with a diminished DAS-28 response to rituximab, indicating that the synovial tissue may be 
resistant to B-cell depletion therapy, potentially through the production of autoantibodies 
and short-lived plasma cells 
• Histological CD20 staining correlates with MS4A1 expression, indicating that tissue 
collected through US guided synovial biopsies is reflective of molecular processes 
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• A MS4A1hiAICDAhi signature can predict non-response to the first cycle of rituximab, 
with an AUC of 0.86 
• Upregulation of Th17 associated pathways is associated with non-response to 
Rituximab therapy 
• Expression of genes involved in T-cell effector responses, in particular Th17 and 
expression of IL-18 correlate with US ST and PD scores, leading to the speculation that T-cells 
and fibroblasts may also play a key role in the expansion of the synovial cell layer 
• Overarching findings suggest that modulation of Th17 pathways by Rituximab therapy 
may play a role in treatment stratification and response 
• Finally, this work supports a role for further exploration of synovial tissue as a 
potential biomarker of response to therapies.   
Currently, arthroscopy remains the gold standard of synovial tissue acquisition but remains 
an invasive procedure within a highly specialised setting.  Minimally-invasive ultrasound 
guided biopsies are tolerable and safe and provide a good yield of synovial tissue[361].  
Furthermore, they allow sampling of both large and small joints, the latter of which are not 
amenable to arthroscopy.  Validation of US guided biopsies has been performed and been 
shown to comparable to arthoscopy[390] and forms part of the OMERACT research 
agenda[554].  More recently, the technique has been shown to yield a higher proportion of 
gradable synovial tissue than blind needle biopsies and comparable tissue for RNA extraction 
to surgical and portal and forceps techniques[364].  I have demonstrated herein that 
ultrasound guided synovial biopsies can be utilised to unravel and provide novel insights into 
disease pathogenesis and response to therapy.  It also lends plausibility to the idea that in the 
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future, akin to several oncology models, molecular tissue markers may be integrated with 
clinical decision making to guide therapeutic choices. 
The notion that biomarkers can aid prediction of response to therapies has been explored in 
several different studies.  Alluded to previously, seropositivity for RF and ACPA has been 
shown to enhance response to Rituximab [313, 336, 555].  Despite these observations, a 
significant variability in response is seen within seropositive patients, indicating that alternate 
immune and pain pathways may mediate disease. Additionally, the type I interferon signature 
has been identified as a marker of non-response[420] but has not been validated in further 
large independent cohorts.   The pursuit for alternate markers in the peripheral blood has so 
far lacked sensitivity or specificity for predicting response to biologic therapies and has 
therefore driven the search for biomarkers within synovial tissue.   
Studies exploring synovial tissue and response however have to date provided conflicting 
data, highlighting the difficulty in extrapolating findings to larger cohorts due to 
methodological differences.  In the context of anti-TNF therapy, one group demonstrated that 
synovial lymphoneogenesis was a negative predictor of response to therapy[411], whereas 
another group reported that aggregates were associated with a positive outcome [412].   In 
Rituximab based studies, a reduction of B-cells, immunoglobulin synthesis and plasma cells 
have been reported as predictors of response to therapy [347, 348] suggesting that 
modulation of B-cell associated pathways in the synovium play a role in response to therapy. 
Applying this data to larger cohorts remains problematic due to limited sample sizes and 
heterogeneity in treatment.  The effect of previous DMARDs on the synovium and the optimal 
time to perform a biopsy following treatment to detect meaningful changes remains 
unknown, leading to study designs that are largely based upon times (usually 12 or 16 weeks) 
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in which physicians determine response to therapy in the clinical setting.  I have 
demonstrated that in this cohort, although Rituximab resulted in a decrease in CD20 B-cells, 
plasma cells and synovial macrophages, this did not correlate with clinical response.  I was 
also unable to demonstrate a direct relationship between ectopic lymphoid structures 
identified on histology and clinical outcome.   
Molecular analysis of the synovium, however has demonstrated novel findings of significant 
biological importance. First and foremost, upregulation of genes involved in the formation of 
ELS were associated with non-response to therapy.  It has previously been shown that the 
presence of plasma cell precursors, presumed to originate from solid tissue, in the peripheral 
blood is associated with poor response to therapy[320]. Autoreactive dominant B-cell and 
plasma cell clones have been identified in the diseased synovium in multiple joints of the 
same individual[351, 416], along with the presence of potentially pathogenic memory B-cells. 
Moreover, these clones were not identified in the peripheral blood. Increased frequency of 
the IGHV4-34, which is associated with autoreactivity in SLE, was also found within the RA 
synovium. B-cells from tissues which did not have lymphoid aggregates showed little 
intraclonal variability[351], in keeping with findings in animal models that fewer somatic 
mutations in the absence of germinal centres[556].  Further evidence for ongoing somatic 
hypermutation and class-switching within the synovium has been described by our group in 
an elegant SCID mouse model[346].  Taken together, this is suggestive that inflamed joint 
tissue forms a niche for autoreactive, dominant B-cells which act as antigenic targets and are 
capable of perpetuating inflammation both independently and through the migration or 
antigen dependent generation of plasmablasts.  My findings that non-response is associated 
with genes that promote B-cell migration and ELS formation in the synovium adds further 
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evidence to the functional role of germinal centres.  The lack of response to Rituximab may 
be due to two factors – 1) that peripheral blood B-cell depletion does not effectively target 
the synovial compartment in these patients or that 2) upregulation of these genes identifies 
a subset of patients who would benefit from further cycles of Rituximab in a bid to disrupt 
ELS formation. 
The second key finding I have presented is the modulation of Th17 related genes following 
Rituximab therapy.  The discovery of IL-17 producing CD4 T-cells, that required co-stimulation 
by CD28 and ICOS, in 2005 led to increased interest in the role of T-cells in RA 
pathogenesis[557, 558]. Several lines of evidence in RA patients and mouse models of arthritis 
implicate Th17 and their effector molecules in the pathogenesis of RA mainly through the 
production of the pleiotropic cytokine IL-17A [559].  This includes the activation of fibroblast-
like synoviocytes, oscteoclast maturation and macrophage activation and function[560].  
Th17 cells display a degree of plasticity and have also been shown to have a regulatory 
function, associated with IL-10 production[561].  It is therefore plausible that clinical response 
is dependent on the ratio of pathogenic and regulatory T cells.   
The observation that a subset of patients display high IL-17A and CD21L expression in the 
synovium[479] is of particular importance in the context of my findings. FDCs, characterised 
by the CD21L expression, have been identified as key orchestrators in the development of 
ELS[562]. In line with my findings, McKelvey and colleagues found low numbers of histological 
GC+ELS within the synovium of 54 patients with RA, suggesting that expression of CD21L is 
reflective of an environment capable of producing ELS.  It is therefore possible to speculate 
that in this cohort of patients, the expression of AID in the absence of histologically identified 
germinal centres mirrors a similar microenvironment which is proficient in the production of 
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lymphoid neogenesis, somatic hypermutation and ongoing antibody production.  Th17 cells 
have been found adjacent to ELS[563] and therefore play a potential role in the induction and 
maintenance of these structures.  This group found that patients with IL17+/CD21L+ had 
larger CD20 containing aggregates but did not observe increased numbers of ELS.  Data from 
mouse models identify IL-17A are necessary to maintain lymphoid aggregate structure and 
function [564] which suggests that IL-17 may be involved in the stability of germinal centres 
and that this is linked to IL-23 expression[565].  As mentioned previously, whether germinal 
centres are representative of a specific synovial pathotype or whether are temporally related 
to stages of inflammation remains unknown.  High expression of IL-17 may therefore be 
indicative of a distinct synovial pathotype with unique drivers of inflammation, or may simply 
vary at different timepoints in disease.  The witnessed resistance to Rituximab therapy may 
therefore be due to several mechanisms:  1) in this subgroup of patients, it may be the Th17 
pathway which drives inflammation and therefore B-cell depletion is of limited clinical 
benefit; 2) that the presence of IL-17 supports ongoing ELS formation which is not sufficiently 
disrupted by Rituximab therapy and supports the production of pathogenic B-cell 
autoantibodies in the synovium; and finally  3) that it is the ratio of Tregs to Th17 cells which 
is of critical importance in this subgroup and the manipulation of key regulatory cytokines 
may result in disease amelioration in this subset.  Although Rituximab therapy has been 
shown to modulate T-cell function, in these patients this may not be enough to switch off 
inflammation. 
Incorporating imaging as a clinical predictor of response is important, particularly in the 
context of early RA.  MRI has been used as a predictive tool in undifferentiated arthritis[566] 
but remains a relatively expensive and time consuming modality.  By contrast, US can be 
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performed quickly, cheaply and often in real-time in the setting of rheumatology clinics.  
Again, incorporating US in the assessment of early RA appears to increase the sensitivity of 
previous prediction models[567] but further data in routine use has not conferred any 
benefits over clinical assessment[65].  I have shown through this work that in established RA, 
synovial pathotype does not appear to correlate with ST and PD findings.  Additionally, the 
absence or presence of synovitis on US did not correlate with EULAR response outcomes 
which questions our understanding of true remission in established disease.  I unexpectedly 
found a negative correlation with CD20, CD138 and CD68 cells at both the histological and 
molecular level but did find a correlation between IL-17 associated genes.  Again, this and 
previous findings confirming that IL-17 is associated with US changes, highlights the 
importance of Th17 cells and their associated cytokines in the pathogenesis of RA. It also 
suggests fibroblasts may play a crucial role in the processes contributing to synovial 
thickening and that Rituximab therapy does not result in an alteration of these pathways. 
Finally, upregulation of the ICOS ligand following rituximab therapy lends support to the 
notion of increased activity of Tregs resulting in resolution of inflammation.   
The original hypothesis of this work was formulated on B-cell biology and associated 
pathways.  I was expecting to demonstrate that B-cell rich patients had an enriched response 
to rituximab therapy and that the presence of associated B-cell gene signatures would predict 
response to therapy.  I did not find any histological, clinical or ultrasound markers of response, 
but successfully demonstrated that the presence of an ELS / IL-17 rich molecular signature 
confers non-response to the first cycle Rituximab therapy and thus can be incorporated into 
a prediction model. I have also shown that in addition to B-cell depletion, rituximab 
modulates T-cell pathways which highlights the need for further understanding of changes 
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which occur secondary to B-cell depletion. US changes did not correlate with synovial 
histology in this cohort, which may in part be due to longstanding disease, or again due to the 
upregulation of alternate pathways.  Additionally, there is no consensus on how many or 
which joints should be incorporated to formulate an US score which is truly reflective of 
disease activity – which adds a level of difficulty to the interpretation of US-based studies.   
Finally, I have shown that the US guided synovial biopsy can be used as a tool to aid our 
understanding of pathogenesis and treatment response, providing sufficient tissue for both 
histological analysis and RNA extraction. 
The strengths of this work were that the tissue sampling and histological analysis methods 
were robust.  Scoring was based on previously described methods, and the formation of the 
B-cell rich score was made in conjunction with expert opinion from a pathologist. Analysis 
using the Fluidigmã platform meant that a large number expression of a large number of 
genes could be explored, and only samples with good quality RNA were analysed.  Conversely 
there are also several limitations to this data.  The sample size was relatively small, but still 
comparable with previous studies.  Patients enrolled in this pilot trial had longstanding 
disease and there were no stringent criteria on the number of previous conventional or 
biological DMARDs.  Furthermore, the permissible use of steroid therapy may have resulted 
in changes which cannot be wholly attributed to modulation by Rituximab therapy. Fibroblast 
staining was not undertaken during the histological analysis – and could have been explored 
further to delineate the low-inflammatory or pauci-immune group. One could also argue that 
the genes in this dataset were pre-selected - although using known biological pathways 
reduces genetic noise and allow us to draw more robust conclusions.  A larger sample size 
with further US and biopsy timepoints may have resulted in different results.  Also, this is a 
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single-centre study and further work would be required across sites. Lastly, this was a non-
blinded observational study with several investigators involved, which could theoretically 
result in bias and inconsistencies. 
Nevertheless, this work leads to a number of critical unanswered questions and ideas for 
further work.  Firstly, this data adds to the field of interest in the structure and function of 
ELS. Although conflicting results have arisen from TNF blockade, presence of germinal centres 
appears to confer resistance to Rituximab therapy indicating a role in disease pathogenesis.  
A question that remains unanswered in my work is whether disruption of these follicles would 
result in disease suppression and could be further explored by sequential biopsies in larger 
numbers of patients, with molecular analysis after second or third cycles.  The increased use 
of next generation sequencing and sequential biopsies would allow us to answer whether the 
synovium provides a niche for pathogenic clones which are resistant to B-cell depletion 
therapy or whether repopulation occurs from autoreactive cells arising from other sources 
such a lymph nodes or bone marrow.  This could enhance our understanding of Rituximab 
therapy and crucially explain both relapse and variations in response.  Another key criticism 
of this work is that I have not incorporated any FACS data as this is currently forming part of 
another thesis, currently in progress.  The ideal study would compare different B-cell 
subpopulations in the peripheral blood and synovium at different timepoints, with paired 
RNA analysis from each compartment in order to elucidate differences at the level of synovial 
tissue. 
The imaging data presented here challenges our definitions of true remission and the 
relevance of subclinical synovitis in long-standing disease.  More longitudinal studies are 
needed on radiographic progression in such patients.  I have also highlighted the 
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controversies surrounding the true definition of remission in a ‘treat to target’ era, as data in 
the clinical setting remains conflicting.  The utility of integrating US into a clinical prediction 
model is well described in early RA, but more studies are needed in patients with established 
disease with more robust clinical data sets. 
Lastly, Th17 cells and their associated cytokines have recently been placed under the 
spotlight.   Clinical trials with IL-17A blockade only resulted in modest clinical improvements 
in comparison to anti-TNF agents, IL-6 blockade and T-cell co-stimulation[568-570] in patients 
with RA and failed to reach primary endpoints.  Longer term data, however, suggests that in 
those who did respond, clinical responses were sustained at one year[571].  A recent meta-
analysis of IL-17 trials suggested that blockade was effective in achieving ACR20 and ACR 50 
compared to placebo[572] but comment that the heterogeneity and short duration of the 
studies included make extrapolation of results difficult. Initial results have led to no further 
large trials but the observation that a subset of patients respond of critical importance.  Large, 
randomised, double-blinded studies with adequate power to detect differences remain the 
gold standard of clinical trials.  The data that I have presented and the trials described above 
pose the question of whether these results are truly applicable to a heterogenous disease.  
Using the synovial biopsy as a stratification tool, it is possible to divide patients into specific 
molecular subgroups – and perhaps blockade of the most upregulated pathways at the 
individual level would result in more promising results.  
 In an era of personalised medicine, it may be therefore be time to rethink scientific tradition.  
This is currently being addressed by our group through two biopsy based clinical trials: 1. 
‘R4RA’ trial which is an Randomised open label study in anti-TNFa non-responders to 
investigate mechanisms for response – resistance to rituximab versus Tocilizumab in RA and 
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2. STRAP: Stratification of biologic therapies for Rheumatoid Arthritis by Pathobiology.  Both 
trials have currently completed recruitment and therefore results are imminent. 
In summary, this present thesis provides novel insights into both pathogenesis of disease and 
the complex role of alternative inflammatory pathways that result in resistance to Rituximab 
therapy.  For both patients and clinicians, the landscape of RA is changing. The advent of 
biosimilars has resulted in choices that are less driven by economic responsibility. With a 
growing armamentarium of drugs, physicians should be compelled to think about therapeutic 
options based upon specific biological pathways.  Current biomarkers are based upon clinical 
and laboratory parameters and do not sensitively discriminate those who will respond to 
treatment. In an era of advanced genomic and proteomic analysis, synovial pathobiology has 
the potential to unlock the future of personalised healthcare in RA through the utilisation of 
individual molecular signatures to guide clinical decision-making – leading to the right drug 
for the right patient at the right time. 
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Appendix A: Genes selected for Fluidigm © analysis 
 
 
 
 
 IL20 CCL18 GSMB CD19 
CD40 CCL21 IL17RA ICOSLG TBX21 
ID1 IGKV1-5 FOXP3 CLEC9A IL15 
IL15RA TNFRSF4 LTA FASLG CXCR6 
IL7 CD1C TNFSF3 FCGRIIA VEGFR3 
CLEC6A CD80 CCL17 KDR FCGR1A 
FCER2 IL6 CXCL9 TNFRSF17 ICAM1 
HLADRB1 MMP3 FCGR2B TRAF4 TRAF1 
PAD2 AICDA FLT1 VEGFC MMP9 
TIE2 CD274 IL18RAP CCL3 CXCL8 
CSFR1R IL33 SLAMF7 IL1B CD8A 
CXCR3 LTB TSLP MAF ST2 
CD40LG NOS2 BMP4 MMP25 IL2RB 
CXCL11 BMP6 CD209 ANGPT2 CCL20 
CXCL13 CCL13 DKK1 IL12A CCR4 
CXCR5 CD3E IGHA1 CCR7 PAX5 
FGF1 FCRL5 IGJ CD11C TLR6 
IGKC IGH1 PAD4 IL2RA CCR5 
CCL4 RSAD2 IL23A RORGT CLEC4E 
IL21R TNF IL7R WNT10A MS4A1 
RANKL BLK THEMIS CCL22 FCGR1B 
CD83 IL10 BMP5 CD11A CD96 
IL1A IL22 CXCL10 CD163  
CD36 APO-C1 CCR 2 IL21  
 
 
Houskeeping Genes: GAPDH 
UBC 
 
 
